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ABSTRACT 
 
 
 HIV-1 integrase (IN) is essential for viral replication and offers a promising target 
for the development of anti-retroviral drugs. Two decades of extensive research has lead 
to the recent approval of raltegravir as the first IN inhibitor. Advancement of drug 
candidate elvitegravir, which is currently in Phase III clinical trial, has furthermore 
accelerated efforts against this potential target for combating HIV. However, the 
emergence of resistance against raltegravir and elvitegravir demands exploration of novel 
chemical scaffolds that could circumvent resistance against currently used HIV-1 IN 
inhibitors. With the goal of discovering new agents targeting HIV, a novel structural class 
of HIV-IN inhibitors have been designed and synthesized. Substantial computational 
studies were also performed that could aid the design and development of potent HIV IN 
inhibitors. 
 
 A part of this dissertation research, covered in Chapter 3, details the design, 
synthesis, and biological evaluation of 3-keto salicylic acid chalcones as novel HIV-1 IN 
inhibitors. In the chalcone series, the most active compound, 5-bromo-2-hydroxy-3-[3-
(2,3,6-trichloro-phenyl)-acryloyl]-2-hydroxybenzoic acid (96) was selectively active 
against IN strand transfer (ST) with IC50 of 3.7 ?M. While most of the compounds 
exhibit ST selectivity, a few were nonselective, such as 5-bromo-3-[3-(4-bromo-phenyl)-
acryloyl]-2-hydroxybenzoic acid (86), which was active against both 3?-processing (3?-P) 
and ST with IC50 values of 11 ± 4 and 5 ± 2 μM, respectively. The compounds also 
inhibited HIV-1 replication with potencies comparable to their integrase inhibitory 
activities. Thus, compounds 96 and 86 inhibited HIV-1 replication with EC50 values of 
7.3 and 8.7 μM, respectively. Chapter 4 describes the synthesis of structurally related 
amide derivatives which were designed by modification of the chalcone moiety. In the 
amide series, the most active compound, 5-bromo-3-[(3-chloro-2,4-difluoro benzyl)- 
carbamoyl]-2-hydroxy- benzoic acid (151), inhibited ST with an IC50 of 4 ?M. Chapter 5 
discloses the synthesis, and biological studies of halogenated phenanthrene ?-diketo acids 
as novel HIV-1 IN inhibitors. The two most active compounds of the series, 4-(8-
chlorophenanthren-3-yl)-2,4-dioxobutanoic acid (179) and 4-(6-chlorophenanthren-2-yl)-
2,4-dioxobutanoic acid (177) had ST IC50 values of  1.2 and 1.3 μM, respectively, and 
corresponding 3?-P values of 11.0 and 5.0 μM. 
 
 In the last section of the dissertation detailed in Chapter 6, computational studies 
were conducted with the aim of exploring the possible binding modes of potent IN 
inhibitors and evaluating the structural requirements for IN inhibition. To determine the 
physicochemical parameters important for ligand binding, in the first part of this chapter, 
a PHASE pharmacophore hypothesis was developed and used for molecular alignments 
in the initial comparative molecular field analysis (CoMFA) and comparative molecular 
similarity analysis (CoMSIA) 3D-quantitative structure activity relationship (3D-QSAR) 
modeling of the chalcone derivatives. A recent breakthrough in the field of anti-HIV 
research was achieved with the crystallization and 3D structure determination of a 
complete foamy virus IN-DNA complex. To take advantage of the power of structure-
based drug design, in the second part of the computational studies, homology models of 
 vi 
HIV-1 IN-DNA were constructed based on the foamy virus IN-DNA complex X-ray 
crystal structure as template through collaboration with the Oak Ridge National 
Laboratory. The binding modes of raltegravir and elvitegravir in our homology models 
were in accordance with their binding modes in their complexes with the foamy virus 
structure. The homology model was then used for docking and 3D-QSAR studies on our 
synthesized inhibitors and other integrase inhibitors including the clinically available 
raltegravir and elvitegravir. Free energy calculations using Molecular Mechanics-
Generalized Born Surface Area (MM-GBSA) methods were carried out to rescore and 
validate the binding modes of HIV-1 integrase inhibitors.  3D-QSAR models derived 
from this study provided detailed insights into the structural requirements for IN 
inhibition and established predictive tools to guide further inhibitor design. Linear 
interaction energy (LIE) calculations were also performed to derive energy parameters 
contributing to the binding free energies of the IN inhibitors in the data set. These energy 
parameters were also analyzed to gain insight into the binding modes of raltegravir and 
elvitegravir as well as to validate the conformations of our synthesized chalcone and 
amide derivatives. The energy terms were then used as descriptors to develop a linear 
interaction approximation (LIA) activity model for the inhibition of integration catalytic 
step. In the next section of the chapter, lead optimization was attempted using structure- 
and ligand-based drug design tools. RACHEL, a drug optimization software, was used to 
design an inhibitor with desired binding interactions with the IN active site residues. The 
hit obtained from RACHEL was used to design a structurally related compound (157), 
the synthesis and activity testing of which has been described in Chapter 4. Docking 
studies were also performed on the phenanthrene derivatives synthesized in Chapter 5. 
The docking studies predominantly revealed two binding poses that were distinct from 
the possible binding modes of clinically used raltegravir and advanced IN inhibitor 
elvitegravir and, moreover, do not interact significantly with some of the key amino acids 
(Q148 and N155) implicated in viral resistance. Therefore, this series of compounds can 
further be investigated as IN inhibitors to circumvent resistance associated with current 
clinically used HIV-1 IN inhibitors. 
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CHAPTER 1.   INTRODUCTION 
 
 
HIV/AIDS 
 
Acquired Immunodeficiency syndrome (AIDS) is one of the most devastating 
infections in human history.1 Since the first report of this syndrome in 1981, about 30 
million people have died from the AIDS-related diseases.2 The Human 
Immunodeficiency virus (HIV) was first identified as the causative agent of AIDS in 
1983.3-8 The number of people infected with HIV has increased from 8 million in 1990 to 
33 million today, with an addition of 2.6 million new HIV infections each year; making it 
a major pandemic of the 21st century.9,10 
 
 There is still neither a cure nor a vaccine available for AIDS and it remains a 
serious challenge to the scientific and healthcare community.11 Two decades of 
tremendous effort has however led to major breakthroughs in combating this dreadful 
menace.12-15  Before the discovery of its causative agent most patients died within 2 years 
of infection. Today, the average longevity has exceeded 22 years due to the current 
antiretroviral therapy and early diagnosis of patients with AIDS.16,17 Since the 
identification of zidovudine (AZT) as the first drug against HIV, remarkable success has 
been achieved.18-20 This is reflected by the fact that the number of clinically approved 
drugs against HIV exceeds the number of drugs for all other viral infection, taken 
together.21 Despite this unprecedented achievement, the issues of drug toxicity,22-27 
compliance,28-30 and more importantly the emergence of drug resistance due to viral 
mutations have rendered the current therapy ineffective.31-36 It is thus highly imperative to 
stay ahead of the virus and develop drugs with novel scaffolds and different mechanisms 
of action for achieving an effective and sustained success against AIDS/HIV. 
 
 
The HIV-1 Life Cycle 
 
HIV-1 belongs to the genus lentivirus and is a member of retroviridae, a family of 
RNA viruses that use an intermediate DNA for replication.37 The life cycle of HIV 
(shown in Figure 1-1) begins with the attachment of the virus to the host cell 
membrane.38 This process involves specific interactions of the viral envelope 
glycoprotein gp120 with CD4 receptors on the host cell surface. This interaction results 
in conformational changes that expose the chemokine co-receptors CXCR4 or CCR5 to 
the viral gp120. The gp120 protein binds to the co-receptors and further leads to 
conformational changes that expose viral fusion protein gp41 which then fuses with the 
host cell surface. After fusion and entry of the viral particle into the host cell, the virion is 
decapsidated to release the viral RNA genetic material and core proteins in a 
nucleoprotein complex. Viral enzyme reverse transcriptase (RT) then transcribes viral 
single-stranded RNA to viral double-stranded DNA. Viral integrase (IN) thereafter 
catalyzes the integration of the viral DNA into the host genome. The process of 
integration occurs via two catalytic steps viz., the 3?-processing (3?-P) and the strand 
transfer (ST) which involves integration of the viral DNA into the host genome. The   
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Figure 1-1. Life cycle of HIV-1 
 
(Reproduced with permission from Nature Publishing Group: Pomerantz, R. J.; Horn, D. 
L. Twenty years of therapy for HIV-1 infection. Nat. Med. 2003, 9, 867-873.)17 
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integrated viral DNA uses the host’s cellular machinery to transcribe viral RNA, which 
then undergoes translation to give viral proteins.39 The viral genetic material and the gag 
and gag-pol polyproteins are assembled together in the cytoplasm and the viral particle is 
budded off from the cell. Finally, during assembly, the viral protease (PR) cleaves the 
gag-pol polyprotein to generate a mature and functional virion capable of infecting 
another host cell. 
 
 
Current Therapy 
 
There are currently 25 drugs approved for anti-HIV therapy. These drugs (shown 
in Table 1-1) belong to seven different classes which include:  
 
1) Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
 
2) Nucleotide Reverse Transcriptase Inhibitors (NtRTIs) 
 
3) Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
 
4) Protease Inhibitors (PIs) 
 
5) Co-receptor Inhibitors (CRIs) 
 
6) Fusion Inhibitors (FIs) 
 
7) Integrase Inhibitors (INs) 
 
 
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
  
 Zidovudine (AZT, 1), a nucleoside analog, was the first anti-HIV drug approved 
by the FDA.40 There are currently 7 NRTIs clinically available and 4 more are in 
advanced Phase II/III clinical trials (Table 1-2). NRTIs, shown in Figure 1-2, exert their 
anti-HIV effect by inhibiting the viral enzyme RT. These drugs are deoxyribonucleoside 
mimic without the 3?-OH group. They require in vivo phosphorylation to be transformed 
to their active triphosphate form, which then acts as an alternate substrate and gets 
incorporated into the growing DNA, resulting in chain termination.41 
 
 
Nucleotide Reverse Transcriptase Inhibitors (NtRTIs)  
 
 Tenofovir (8) is currently the only NtRTI (Figure 1-3) approved for the treatment 
of HIV.42 It also inhibits the enzyme RT. However, it has a phosphonate group 
incorporated into its structure and hence requires only two phosphorylations to be 
converted to its active triphosphate form.  
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Table 1-1. FDA-approved anti-HIV drugs 
 
Class Generic name Brand name Approval year 
NRTIs Zidovudine Retrovir 1987 
 Didanosine Videx 1991 
 Zalcitabine Hivid 1992 
 Stavudine Zerit 1994 
 Lamivudine Epivir 1995 
 Abacavir Ziagen 1998 
 Emtricitabine Emtriva 2003 
NtRTI Tenofovir disoproxil Viread 2001 
NNRTIs Nevirapine Viramune 1996 
 Delavirdine Rescriptor 1997 
 Efavirenz Sustiva 1998 
 Etravirine Intelence 2008 
PIs Saquinavir mesylate Invirase 1995 
 Indinavir Crixivan 1996 
 Ritonavir Norvir 1996 
 Saquinavir Fortovase 1997 
 Nelfinavir Viracept 1997 
 Amprenavir Agenerase 1999 
 Lopinavir+Ritonavir Kaletra 2000 
 Fosamprenavir Lexiva 2003 
 Atazanavir Reyataz 2003 
 Tipranavir Aptivus 2005 
 Darunavir Prezista 2006 
Fusion 
inhibitors 
Entry 
inhibitors 
INIs 
Enfuvirtide 
 
Maraviroc 
 
Raltegravir 
Fuzeon 
 
Selzentry 
 
Isentress 
2003 
 
2007 
 
2007 
 
(Adapted with permission from Nature Publishing Group: Pommier, Y.; Johnson, A. A.; 
Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 2005, 4, 
236-248.)96  
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Table 1-2. Clinically advanced anti-HIV agents 
 
Class Drug Clinical trials (Phases) 
NRTIs Apricitabine III 
NRTIs Amdoxovir II 
NRTIs Elvucitabine II 
NRTIs Racivir II 
NNRTIs BILR 355 BS II 
NNRTIs (+)-Calanolide A II 
NNRTIs IDX899 I/II 
NNRTIs MIV-150 II 
NNRTIs RDEA806 II 
NNRTIs Rilpivirine II 
CRIs AK-602 III 
CRIs AMD070 II 
CRIs HGS004 II 
CRIs Ibalizumab (TNX-355) II 
CRIs PF-232798 II 
CRIs VCH-286 II 
CRIs Vicriviroc III 
FIs PRO 140 II 
EIs SP01A III 
INIs Elvitegravir III 
INIs Dolutegravir II 
 
(Adapted with permission from American Chemical Society Publisher Ltd.: Mehellou, 
Y.; De Clercq, E. Twenty-six years of anti-HIV drug discovery: where do we stand and 
where do we go? J. Med. Chem. 2010, 53, 521-538.)21 
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Figure 1-2. Structures of nucleoside reverse transcriptase inhibitors 
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Figure 1-3. Structure of Tenofovir 
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Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)  
 
 Nevirapine (9) was the first NNRTI approved in 1996. In contrast to the above 
two classes, these are non-substrate analogs that bind to an adjacent allosteric site and 
inhibit RT by a non-competitive mechanism. Three more NNRTIs including Delavirdine, 
Efavirenz, and Etravirine (Figure 1-4) are approved as anti-HIV agents.43,44 In addition, 
there are six NNRTIs that are currently under clinical development (see Table 1-2). 
 
 
Protease Inhibitors (PIs)  
 
HIV PR acts at a later stage of viral replication cycle and cleaves the gag and gag-
pol precursor polypetides to structural and functional proteins resulting in mature and 
infectious virions. These drugs act by inhibiting HIV protease and thereby preventing the 
formation of a mature and infectious viral particle. Protease inhibitors constitute the 
largest class of HIV/AIDS drugs with 10 approved for anti-HIV therapy.45,46 The first 
protease inhibitor approved was saquinavir mesylate (13) shown in Figure 1-5. Most of 
these drugs are peptidomimetic transition state analogs and possess a hydroxyethylene 
moiety as a non-scissile peptide bond isostere. 
 
 
Co-Receptor Inhibitors (CRIs) 
 
 The first step in viral replication involves interactions of the viral glycoprotein 
gp120 with chemokine receptors on the host cell membrane. Co-receptor inhibitors 
prevent this interaction and inhibit the entry of virus into the cell.47 Although a large 
number of small molecules antagonist have been discovered, maraviroc (Figure 1-6) is 
currently the only approved CCR5 antagonist. 
 
 
Fusion Inhibitors (FIs) 
 
Synthetic peptides were derived from gp41and targeted as HIV fusion inhibitors. 
A synthetic peptide, enfuvirtide, is the only fusion inhibitor currently approved. It 
prevents the fusion of the viral fusogenic peptide gp41 to the host cell membrane thereby 
preventing viral entry.48 
 
 
Integrase Inhibitors (INIs) 
 
HIV IN is an important enzyme involved in viral replication. It catalyzes the 
insertion of the viral DNA into the host genome. Since IN has no homologue in human 
cells, it offers a promising strategy for anti-retroviral drug development. ?-Diketo acids 
and isosteres are the most advanced class to have shown promising HIV-1 IN inhibitory 
activity.49 S-1360 (Figure 1-7) was the first IN inhibitor to enter clinical trials.50 Over the 
last two decades, promising IN inhibitors were designed to incorporate bioisosteres of 
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Figure 1-4. Structures of non-nucleotide reverse transcriptase inhibitors 
     
 
 
 
 
 
Figure 1-5. Structure of Saquinavir 
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Figure 1-6. Structure of Maraviroc 
 
 
 
 
 
 
Figure 1-7. Structure of S-1360 
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diketo acid functionality. Raltegravir (16) shown in Figure 1-8 is currently the only IN 
inhibitor approved by the FDA51 and 2 inhibitors elvitegravir and dolutegravir are in 
Phase III and II clinical trials, respectively. 
 
Resistance to anti-retroviral drugs results due to the high mutational rate of HIV 
which in turn is caused by a low genetic barrier and a high turnover of the virus. To 
circumvent viral resistance, the currently available anti-HIV regimens include a cocktails 
of drugs from two or more classes. FDA-approved anti-HIV drug combinations are listed 
in Table 1-3. The combination therapy called Highly Active Antiretroviral Therapy 
(HAART), comprises of two NRTIs and one NNRTI and/or a PI. HAART though highly 
successful in reducing morbidity and mortality, has failed to fully eradicate the virus.52-55 
The emergence of multi-drug resistant viral stains demands development of drugs with 
novel mechanisms of action. Towards this end, IN has emerged as a promising target 
with the introduction of raltegravir for the clinical management of AIDS. 
 
 
HIV Integrase: Structure and Function 
 
 
Structure of HIV-1 IN 
 
 HIV-1 integrase, encoded by the pol gene, is an important enzyme in HIV 
replication. IN is a 288 amino acid 32 kDa protein composed of three distinct domains 
viz., the N-terminal domain (NTD), the central core domain (CCD), and the C-terminal 
domain (CTD) (Figure 1-9), all of which are required for catalytic activity. The NTD 
(1-50 amino acids) has a His-His-Cys-Cys (HHCC) zinc-finger motif, which is highly 
conserved in the IN of retroviruses and retrotransposases. Coordination of this motif with 
a Zn2+ ion stabilizes protein folding and multimerization, which in turn, is required for 
normal enzymatic activity. The CCD (aa 51-212) contains a catalytic triad of acidic 
amino acids that are conserved among the members of the super family of 
polynucleotidyl transferases. The catalytic triad consists of residues D64, D116 and E152 
which are involved in chelation with metal ions in the IN active site. Any mutation in any 
of these residues and/or disruption of this coordination renders the enzyme inactive. It is 
believed that two divalent ions, Mg2+ in vivo and Mg2+ or Mn2+ in vitro, are required for 
catalysis. While D64 and D116 coordinate one Mg2+ ion, the second Mg2+ ion binds 
residues D64 and E152. The CTD (aa 213-288) is the least conserved, and bears some 
structural homology with SH3 DNA binding domains. This lysine-rich positively charged 
domain has nonspecific but strong DNA binding function. All the three domains, 
connected by flexible linkers, are prone to homodimerization. Recombinant IN exists in 
dynamic equilibrium between monomers, dimmers, and tetramers in solution.56 Earlier 
in vitro studies have reported that while the monomeric form of IN is inactive in vitro, the 
isolated NTD, CCD, and CTD all exist as dimers. In the dimeric form, the IN is capable 
of catalyzing 3?-P and integration of one viral DNA end. In further studies, IN has been 
isolated as a tetramer from human cells expressing HIV-1 IN. Electron microscopy, 
single-particle image reconstruction studies and atomic force microscopy of intact 
IN-DNA complex have also revealed that IN acts as a tetramer.57,58 Structural modeling  
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Figure 1-8. Structure of Raltegravir 
 
 
 
Table 1-3. FDA-approved anti-HIV combination therapies 
 
Combination Components FDA approval year 
Combivir Zidovudine (300 mg), Lamivudine (150mg) 1997 
Trizivir Abacavir (300 mg), Zidovudine (300 mg), 
Lamivudine (150mg) 
2000 
Epzicom Abacavir (600 mg), Lamivudine (300mg)  2004 
Truvada Tenofovir disoproxil fumarate (TDF) (300 
mg), Emtricitabine (200 mg) 
2004 
Atripla TDF (300 mg), Emtricitabine (200mg), 
Efavirenz (600 mg) 
2006 
 
(Adapted with permission from American Chemical Society Publisher Ltd.: Mehellou, 
Y.; De Clercq, E. Twenty-six years of anti-HIV drug discovery: where do we stand and 
where do we go? J. Med. Chem. 2010, 53, 521-538.)21 
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Figure 1-9. Structure of HIV-1 integrase 
 
(Adapted with permission from Nature Publishing Group: Pommier, Y.; Johnson, A. A.; 
Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 2005, 4, 
236-248.)96 
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further supports that the tetrameric form of IN catalyzes the insertion of two viral DNA 
ends into the target DNA. It should be noted that because of the staggered cut, which 
occurs 5 base pairs apart in a target helical B-form of DNA, the site of integration should 
be separated by a corresponding distance of 15-18 Å. Thus the active site in a functional 
integrase should also be separated by a similar distance. However, in the crystal structure 
of the dimeric CCD, the active sites are found 35 Å apart. It was therefore concluded that 
in order to maintain a distance of 35 Å at least one tetramer of IN is required to fulfill the 
complete concerted ‘two-ended’ ST integration step.59 Moreover, studies on IN isolated 
from a nuclear extract and its complex with lens epithelium-derived growth factor 
(LEDGF) has further indicated that IN exists as a tetramer.60 
 
 3D structures of individual domains of recombinant HIV-1 IN have been reported 
by either NMR or X-ray crystallography.61-80 Because of the poor solubility, full-length 
wild type HIV-1 IN has yet not been crystallized. The F185K Mutation resulted in 
substantial improvement in solubility and led to the first crystallization of the CCD. The 
CCD has five-stranded mixed ?-sheet flanked by ?- helices. The crystal structures of 
HIV-1 CCD have been solved for its apo form as well as with different metal-complexes. 
The available structures however contain only single metal ion and no structure with two 
metals have yet been reported. A crystal structure of a CCD-inhibitor (5-CITEP) complex 
has also been reported. The inhibitor showed only indirect, water mediated, contact with 
the active site Mg2+ and no interactions with either Asp64 or Asp116 were observed. 
Later, it was confirmed that binding mode of 5-CITEP was affected by crystal 
packing.81,82 Most of the structures of a CCD have partially resolved flexible loop region 
(residues Gly140-Gln148). Only two crystal structures (chain B of 1BIS and chain C of 
1BL3) have a completely resolved flexible loop, however, the conformations of the active 
site residues in these structures were different. Although no X-ray crystal structures of the 
CTD and NTD are available, the structures of these domains have been solved by 
solution NMR spectroscopy. The solution structure of NTD of HIV-1 revealed that the 
NTD exists as a homodimer, each monomer of which consists of 4 helices. The NMR 
resolved structure of CTD also showed the presence of dimeric molecules in which each 
monomer comprises 5 ?-strands, arranged in an antiparallel manner in a ?-barrel. 
Interdomain (CCD-CTD or CCD-NTD) structures of HIV-1 IN have also been 
crystallized. Table 1-4 summarizes the reported 3D structures of HIV-1 IN solved by 
NMR and X-ray crystallography. One of the major limitations of the available structures 
is that they have only partially resolved inter-domain linker conformations. Furthermore, 
the absence of two metals in the IN active site and of a full-length HIV IN-DNA complex 
make the structural information available limited and far from reality. Several studies 
have been directed to exploring the binding interactions of IN with the viral DNA.83-88 
HIV-1 IN-DNA models were constructed based on the solved two domain (CCD-
NTD/CCD-CTD) structures. Although IN is not very selective for the target DNA, it does 
recognize viral DNA sequence-specifically. The terminal conserved CA dinucleotide is 
shown to be important for IN binding and catalyzing 3?-P and ST reactions. In addition, 
in vitro mutational studies revealed a region centered 12 bases from the 3?-terminus to be 
essential in DNA binding in the presence of magnesium cofactor.89,90 Specific  
photocrosslinking studies have identified Lys156 and Lys159 as important CCD residues 
involved in interaction with the viral DNA.91 
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Table 1-4. Crystal structures of HIV-1 IN 
 
Protein PDB code Method Resolution (Å) Year Ref. 
NTD 1WJA, 
1WJB 
NMR N/Aa 1997 62 
NTD 1WJC, 
1WJD 
NMR N/A 1997 62 
NTD 1WJE, 1WJF NMR N/A 1998 64 
CCD 1ITG X-ray 2.30 1994 63 
CCD 2ITG X-ray 2.60 1996 61 
CCD 1BHL X-ray 2.20 1998 66 
CCD 1BI4 X-ray 2.50 1998 66 
CCD 1BL3 X-ray 2.00 1998 66 
CCD 1BIS X-ray 1.95 1998 67 
CCD 1BIU X-ray 2.50 1998 67 
CCD 1BIZ X-ray 1.95 1998 67 
CCD 1B92 X-ray 2.02 1999 68 
CCD 1B9D X-ray 1.70 1999 68 
CCD 1B9F X-ray 1.70 1999 68 
CCD 1QS4 X-ray 2.10 1999 69 
CCD 1EXQ X-ray 1.60 2000 70 
CCD 1HYV X-ray 1.70 2001 71 
CCD 1HYZ X-ray 2.30 2001 71 
CTD 1IHV NMR N/A 1995 72 
CTD 1QMC NMR N/A 1999 73 
NTD-CCD 1K6Y X-ray 2.40 2001 74 
CCD-CTD 1EX4 X-ray 2.80 2000 70 
CCD+LEDGF 
CCD 
CCD 
CCD 
CCD 
CCD 
CCD 
CCD 
2B4J 
3LPT 
3LPU 
3L3U 
3L3V 
3NF6, 3NF8 
3NF7 
3NF9, 3NFA 
X-ray 
X-ray 
X-ray 
X-ray 
X-ray 
X-ray 
X-ray 
X-ray 
2.02 
2.00 
1.95 
1.40 
2.00 
1.90 
1.85 
1.95 
2005 
2010 
2010 
2010 
2010 
2011 
2011 
2011 
76 
77 
77 
78 
78 
79 
79 
79 
 
a N/A = not available. 
 
(Adapted with permission from John Wiley and Sons: Jaskolski, M.; Alexandratos, J. N.; 
Bujacz, G.; Wlodawer, A. Piecing together the structure of retroviral integrase, an 
important target in AIDS therapy. FEBS J. 2009, 276, 2926-2946.)80 
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Since IN inhibitors target a DNA- IN complex and not a free protein, tremendous 
efforts are underway to solve a complete HIV IN-DNA complex structure which would 
accelerate the structure-based design of new HIV-IN inhibitors. In a recent breakthrough, 
crystal structures of  full-length IN from prototype foamy virus in complex with the 
viral/host DNA (Figure 1-10) have been determined.92-94 Crystal structures of the foamy 
virus IN-DNA-inhibitor (raltegravir or elvitegravir) complexes have also been 
published.92 The structure revealed the retroviral IN as a tetramer tightly bound to the 
viral DNA. This minimal IN-DNA complex within the pre integration complex (PIC) 
capable of carrying 3?-P and ST is referred to as intasome. Foamy virus and HIV both 
belong to the family of retroviruses and super family of polynucleotidyl transferases. 
They share a conserved triad of acidic residues in the active site and use two divalent 
metals (Mg2+) for nucleophilic SN2 catalytic mechanism. A high level of sequence 
identity in the active sites of the foamy virus and HIV provides a rationale for using the 
foamy structure as a surrogate for HIV. This structure was used as template and sequence 
aligned with the secondary structure of HIV-1 to build a model for HIV-1 intasome.95 
The modeled intasome consisted of a pair of IN dimer (forming a tetramer) tightly bound 
to a molecule of viral DNA. The outer CCDs of the two dimers serve an accessory role to 
the complex; while the CCDs of the inner subunits of each dimer forms a pair of 
functional active site which is involved in all protein-protein and protein- DNA 
interactions. Residues of the active site loop (Gln140-Gln148) and ?4 helix are involved 
in CCD-DNA contacts. Most of the contacts were observed with the backbone of the 
nontransferred DNA strand, however few specific contacts with the bases are also 
observed. Apart from the residues previously implicated in DNA binding, Arg20 and 
Lys266 were identified as new residues which have role in DNA binding and 
integration.95 Another crystal structure of the foamy virus intasome shows (Figure 1-11) 
viral DNA-IN in association with the target DNA.94 Within the intasome, target DNA is 
placed in a cleft between the two symmetric dimers of the IN. Severe bending of the 
target DNA makes it possible to position its scissile phosphodiester into the intasome 
active site, separated by a distance of ~ 27Å. While there are only few direct contacts 
between target DNA and IN, the phosphodiester backbone is involved in 8 hydrogen-
bonds with the main chain amides of IN.94 
 
 
Function and Putative Mechanism of IN 
 
HIV-1 IN is one of the three enymes essential for viral replication, the other two 
being HIV-1 reverse transcriptase and HIV-1 protease. It catalyzes the integration96 of the 
viral DNA into the host genome by two catalytic steps, 3?-P and ST (Figure 1-12).97 In 
the 3?-P reaction, which occurs in the cytoplasm of an infected cell within a pre-
integration complex (PIC), a site specific endonucleolytic activity removes a GT 
dinucleotide from the long terminal repeat region (LTR) of the viral genome. The 
terminal nucleotides removed are adjacent to the highly conserved CA dinucleotide at 
each of the 3?-end of the proviral DNA. Chemically, the reaction involves the 
nucleophilic activation of a water molecule by the Mg2+ ion (coordinated with Glu152 
and Asp64); the activated water molecule then subsequently attacks the phosphodiester 
bond of the viral DNA to generate free 3?-OH ends.   
 17 
 
 
 
Figure 1-10. Crystal structure of foamy virus integrase-viral DNA complex 
 
The inner subunits of the IN tetramer, engaged with viral DNA, are blue and green; outer 
IN chains are yellow. The reactive and non-transferred DNA strands are magenta and 
orange, respectively. Side chains of Asp128, Asp185 and Glu221 active-site residues are 
red sticks; Zn atoms are grey spheres. 
 
(Reproduced with permission from Nature Publishing Group: Hare, S.; Gupta, S. S.; 
Valkov, E.; Engelman, A.; Cherepanov, P. Retroviral intasome assembly and inhibition 
of DNA strand transfer. Nature 2010, 464, 232-236.)93 
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Figure 1-11. Crystal structure of foamy virus IN, viral and target DNA strand 
transfer complex 
 
Representations of the STC crystal structure, viewed along or perpendicular to the 
crystallographic two-fold axis, respectively. IN active site carboxylates are shown in red.  
 
(Reproduced with permission from Nature Publishing Group: Maertens, G. N.; Hare, S.; 
Cherepanov, P. The mechanism of retroviral integration from X-ray structures of its key 
intermediates. Nature 2010, 468, 326-329.)94 
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Figure 1-12. Mechanism of integration 
 
(I) Donor DNA; (II) integrase-catalyzed 3?- processing; (III) integrase-catalyzed strand 
transfer; (IV) product of strand transfer; (V) DNA repair by cellular enzymes. 
 
(Open Access: Savarino, A. In-Silico docking of HIV-1 integrase inhibitors reveals a 
novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology 2007, 4, 
21.)97 
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The primed viral DNA in association with the viral protein, in a pre-integration 
complex, then translocates into the nucleus of the host cell. Within the nucleus, viral IN 
catalyzes the next step of integration, ST. In the process of ST, IN introduces a staggered 
cut in the target DNA at sites separated by 5 base pairs resulting in overhangs with 5? 
phosphorylated ends. IN then performs strand transfer, also called as the 3? -end joining 
reaction wherein the primed 3?-ends of the viral DNA are joined to the 5?-ends of the 
host/target DNA. Chemically, this involves a second nucleophilic attack, this time by the 
3? OH groups at the phosphodiester bond of the host DNA. Finally, host enzymes remove 
the two mismatched nucleotides at each 5? end of viral DNA, fill in the single stranded 
gaps and ligate the remaining ends. 
 
A putative mechanism for inhibition of integration has been proposed based on 
the recently reported foamy virus crystal structures. For integration to occur, unpairing of 
the donor DNA is required to expose the scissile phosphodiester bond (for 3?-P) and 
orient the 3? OH (for ST) near the IN active site. The model suggests that the terminal 
adenine (A17) of the reactive DNA strand dissociates from its base pair thymine (T3) in 
the complementary nontransferred strand, as the terminal bases of the DNA interacts with 
the CCD, CTD and CCD-CTD linker. The adenine 3? OH end is then positioned into the 
active site and is activated by the metal (coordinated between Asp64 and Asp116) to 
undergo SN2 nucleophilic attack at the phosphodiester bond of the host DNA. Raltegravir 
and other IN inhibitors have coplanar metal chelating hetero atoms that coordinate the 
two divalent metals in the IN active site.98,99 Furthermore, a halogenated benzyl group 
which is a common feature of IN inhibitors, according to the model, stacks against the 
penultimate cytosine of the reactive DNA strand and thereby displaces the terminal 
3?-OH out of the active site away from the metal ions. Thus, any disruption of the 
activation of the nucleophilic 3?-OH or its displacement from the active site upon drug 
binding inhibits ST step of retroviral integration.92,100 
 
     
HIV-1 IN Inhibitors 
 
HIV-IN does not have a human counterpart making it an attractive target for anti-
HIV therapy. During the last two decades of research, large numbers of IN inhibitors 
have been discovered. However, only few have advanced to clinical trials and only one, 
raltegravir, has been approved. IN inhibitors can be classified on the basis of those 
targeting selectively the 3?-P step, those that inhibit both 3?-P and ST, and those that 
selectively inhibit the ST catalytic step. The most advanced drugs selectively inhibit the 
ST reaction and have two common structural features viz., a hydrophobic halo benzyl 
group and a chelating motif capable of binding two Mg2+ ions. 
 
 In the early efforts, ribozymes were used to cleave HIV-1 IN and oligonucleotides 
were designed to form triplex DNA to inhibit the integration process.101-103 These efforts 
did not yield any potent inhibitor and were not pursued due to their significant risk of 
toxicity. Nucleotide analogs based on AZT were among the early IN inhibitors 
reported.104 Several di-, tri-, and tetra-nucleotides were then examined for their IN 
inhibitory activities. A G-quartet oligonucleotide composed of deoxyguanosine and 
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thymidine, zintevir, showed potent HIV-1 IN inhibitory activity and inhibition of viral 
replication in cell culture.105 Zintevir, which progressed to Phase I/II clinical trials, was 
later shown to inhibit viral gp120 binding and prevent viral entry into cells. 
 
 
DNA-Binding Agents 
 
Several DNA-binding agents were identified to inhibit HIV-1 IN by preventing 
the interaction of viral DNA with the DNA-binding domain of the enzyme. 
Benzimidazoles inhibited IN with an overall 50 % inhibitory concentration (IC50) of 5 
μM.106 Minor groove binders like netropsin are also reported to interfere with viral DNA-
IN binding. Lexitropsins have also been shown to inhibit IN by binding at the conserved 
AT sequence in HIV-1 LTR.107 The fluorescent dye Hoechst 33258 and its derivatives 
bind in a site-specific and non-covalent manner to the minor groove of DNA. N,N?-
(methylene-di-4,1-phenylene) bis-1-pyrrolidineacetamide was recently reported as novel 
anti-HIV agent that competes with viral DNA for binding to the IN CCD dimer 
interface.108 
 
 
Peptides/Proteins 
 
 Polyamides prevent the binding of viral DNA to IN and subsequently inhibit IN 
enzymatic activity. A hexamer peptide (HCKFWW) was identified to be an inhibitor of 
HIV-1 IN with micromolar affinity.109 In another study, a 30-mer peptide which 
corresponds to amino acids 147-175 of HIV-1 IN was shown to inhibit IN activity at a 
millimolar concentrations but was not active in cell culture.110 MAP30, luffin, and 
saporin which are members of the family of ribosome inactivating protein (RIP), have 
also been reported to have antiviral and anti-IN inhibitory activity.111 
 
 
Polyhydroxylated Aromatic Compounds 
 
 Polyhydroxylated aromatic compounds (Figure 1-13) were among the first small 
molecule inhibitors of HIV-IN in vitro. They include both natural and synthetic 
derivatives like flavones, tyrphostins, lignans, anthraquinones, catechols and bis-
catechols.112-116 These compounds possess two aryl groups which are separated by a 
linker. At least one aryl unit contains two ortho-hydroxyl groups meant for chelation with 
the IN active site metal ions. An example of a potent member of the class of bis-catechols 
is ?-conidendrol (17), which selectively inhibited both steps of HIV-1 IN with an IC50 of 
0.5 μM. However, when tested in cell cultures the in vitro inhibition did not translate into 
antiviral activity. Dicaffeoylquinic acids (DCQAs) represented by L-chicoric acid (18) 
and analogs were shown to be active against HIV-1 IN in vitro, and to also inhibit HIV-1 
replication in tissue culture in the low μM concentration range.117 Other bis-catechol IN 
inhibitors include the curcumin derivative rosmarinic acid (19).118 Curcumin analog 
dicaffeoyl methane (20) inhibited ST activity with an IC50 of 3.1 μM.118 One 
representative IN inhibitor of the catechol series, caffeic acid phenylethyl ester  
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Figure 1-13. Structures of poly-hydroxylated HIV-1 integrase inhibitors 
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(CAPE, 21) is shown in Figure 1-14.119 CAPE was the first selective (ten-folds 
selectively against ST relative to 3?-P) IN inhibitor that also showed weak antiviral 
activity. From these studies it was inferred that at least one catechol group is required for 
potent HIV IN inhibitory activity.119 Compounds without a catechol unit were also 
investigated for their HIV-IN inhibitory activity. NSC 158393 (Figure 1-15, compound 
22) contains four 4-hydroxycoumarin moieties with no catechol substructure and was 
active against both HIV-1 PR and IN.120 The utility of polyhydroxylated aromatic 
compounds as drug candidates is however limited by the fact that their catechol moiety is 
prone to oxidation in situ to a reactive quinone species which may lead to covalent 
protein modification. 
 
  
Styryl Quinolines 
 
 A novel series of compounds in which a quinoline ring system is attached to a 
hydroxyl containing aryl group by an ethylenic linker (Figure 1-16) was developed as 
potent HIV-1 IN inhibitors.121 Although, highly active compounds of the series, including 
FZ41 (23), have a catechol substituent, detailed structure activity relationship (SAR) 
studies showed that a catechol group was not an absolute pharmacophoric requirement 
for an IN inhibitor. These compounds were designed to chelate active site divalent metals 
and were found to inhibit both 3?-P and ST at sub-micromolar levels. They are believed to 
be competitive inhibitors of the binding of viral DNA to IN. Another study has shown 
that they prevented the nuclear import of recombinant IN.122 
 
 
Pyranodipyrimidines 
 
 Pyranodipyrimidines (Figure 1-17) were reported to inhibit HIV-1 integration at 
low μM concentrations. The most potent compound of the series V-165 (24) inhibited 
recombinant integrase in vitro and also HIV-1 replication in cell cultures.123 V-165 was 
more active against 3?-P with IC50 of 0.17 μM as compared to ST inhibitory IC50 value of 
16 μM. Time-of-addition experiments indicate that V-165 acts prior to the formation of 
the pre-integration complex (PIC) suggesting that it prevented the formation of DNA-IN 
complex by inhibiting the binding of IN to the viral DNA. It was however reported that 
V-165 was not selective for IN and was found to be active against RT as well. 
 
 
?-Diketo Acids 
 
The ?-Diketo acid pharmacophore was discovered from several fungi derived 
natural products which were reported as HIV-1 IN inhibitors. These fungal compounds 
contained a ?-hydroxy keto groups which were subsequently modified to a ?-diketo acid 
and its structural analogs.49,124 Although, not sufficient for activity, the diketo acid 
functionality was identified as an important requirement for an IN inhibitor.  Extensive 
research was thus directed to incorporate a ?-diketo acid functionality, which 
subsequently became the first representative pharmacophore of potent IN inhibitors. The  
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Figure 1-14. Structure of caffeic acid phenyl ester (CAPE) 
 
 
 
 
 
 
Figure 1-15. Structure of NSC 158393 HIV-1 integrase inhibitor 
 
 
 
  
 25 
 
 
 
Figure 1-16. Structure of  styryl quinoline integrase inhibitors 
 
 
 
 
 
 
Figure 1-17. Structure of  pyranodipyrimidine, V-165 
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coplanar heteroatoms in the ?-diketo acid motif were perceived to chelate the divalent 
metals in the IN active site.99 In pursuit of ?-diketo acid IN inhibitors shown in Figure  
1-18, researchers at the Shionogi & Co. Ltd discovered 5-CITEP (25) which contained a 
tetrazole as a bioisostere of carboxylic acid. 5-CITEP was highly selective for the ST 
catalytic step (IC50s of 0.4-4.0 μM for ST vs. 35 μM for 3?-P). Moreover, 5-CITEP was 
found to be a more potent inhibitor (ST IC50 of 0.4 μM) in the presence of Mn2+ than 
Mg2+ ( ST IC50 4.0 μM). It was also the first integrase inhibitor to have been co-
crystallized with the CCD of IN. Subsequently, Merck also discovered ?-diketo acid IN 
inhibitors; the most potent among them were L-731,988 (26) and L-708,906 (27), which 
have an acid functionality instead of its isostere tetrazole that was present in 5-
CITEP.50,124 SAR studies have shown that replacement of the lesser acidic tetrazole 
moiety with a carboxylate substantially improved the ST inhibitory activity in Mg2+ 
suggesting that a carboxylate might be important for metal coordination.50 L-731,988 and 
L-708,906 were also highly selective (70-100 folds) for the ST reaction in vitro. L-
731,988 and L-708,906 have ST IC50s values of 80 nM and 150 nM, respectively, and 
inhibited HIV-1 replication with micromolar  50 % effective concentration (EC50) values 
in cell culture. It was again shown that IN inhibition can be divalent-cation dependent. 
The IC50 of L-708,906 for 3?-P was 2.5 μM and 22 μM in Mg2+ and Mn2+ respectively, 
while its IC50 for ST was comparable with either metal. Another closely related 
compound from Shionogi, S-1360 (see Figure 1-7) showed potent inhibition of integrase 
in enzymatic assay and displayed antiviral activity in cell culture. Their antiviral activity 
was proved to be the result of their inhibition of the integration process in viral 
replication. S-1360 was also selective against ST with IC50 value of 20 nM and it became 
the first IN inhibitor to enter Phase I/II clinical trials.125 Its progression was however 
halted due to rapid metabolism of its ?-diketo acid functionality and subsequent 
formation of inactive metabolites. The SAR studies of the diketo acid derivatives 
revealed that the aromatic moiety is important for potency and ST selectivity. Several 
diketo acid derivatives were then synthesized with various aromatic systems containing 
different substitutions. Examples include MA-DKA which had an azido group on the aryl 
moiety designed for cross linking studies.126 One of the common aryl ring system present 
in potent IN inhibitors such as L-731,988 and S-1360 was a para-fluorobenzyl group, 
which was later identified as an important feature of potent ST selective inhibitors. 
Subsequent modifications were made to incorporate the diketo acid chelating heteroatom 
into a ring system also leading to potent sub micromolar and nanomolar inhibitory 
activities. 
 
 
Naphthyridine Carboxamide 
 
 To circumvent the metabolic issues of a free ?-diketo acid functionality, the 
diketoacid motif was embedded into a naphthyridine carboxamide core such that the 
carboxylic acid was replaced with a lone pair donor atom containing heterocycle. 
Examples of metabolically stable naphthyridine carboxamides include L-870,810 (28), L-
870,812 (29), and GSK-364735 (30) (Figure 1-19). L-870,810 and L-870,812 were 
found to be selective for ST inhibition and inhibited ST activity in vitro with potent IC50s 
of 8-15 nM and 40 nM, respectively. L-870,812 inhibited HIV replication with 95 %  
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Figure 1-18. Structures of diketo acid HIV-1 integrase inhibitors 
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Figure 1-19. Structures of naphthyridine carboxamide HIV-1 integrase inhibitors 
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inhibition concentration (IC95) of 250 nM and suppressed viral load in rhesus macaques 
infected with SHIV 89.6P recombinant strain.127 L-870,810 became the second candidate 
to enter clinical trials; its progression was however halted because of long-term 
hepatotoxicity observed in dogs.128 Furthermore, it also suffered from low bioavailability 
due to high serum protein binding. L-870,812 also entered clinical trials but its data were 
not made public and was discontinued probably because of similar in vivo profile as L-
870,810. Although integrase ST inhibitors were validated for the treatment of HIV, viral 
resistance against them soon emerged. Mutations T66I and F121Y selectively conferred 
resistance to diketo acids and naphthyridine carboxamides, respectively. Mutation 
N155H/S resulted in viral resistance to diketo acids and also showed cross resistance to 
naphthyridine carboxamides.129 GSK-364735 showed potent inhibition  of ST activity 
(IC50 value of 8.0 nM) of recombinant integrase in enzymatic assay.130 It also inhibited 
HIV replication in nanomolar concentrations (1.2 ± 0.4 nM in peripheral blood 
mononuclear cells and 5 ± 1.0 nM in MT-4 cells). It entered in Phase I clinical trials but 
its development was halted due to long-term toxicity issues.130 
 
 
Dihydroxypyridopyrazine-1,6-diones 
 
 The 1,6- naphthyridine carboxamide core was used to design 
dihydroxypyridopyrazine-1,6-diones (Figure 1-20) as a new class of IN inhibitors such 
that the diketo functionality was embedded in a pyridinone scaffold.131 Compound (31) 
showed ST IC50 value of 0.10 μM and inhibited HIV replication with EC50 value of 0.31 
μM. A series of analogs synthesized demonstrated in vitro potency, but they did not 
however offer improved anti-HIV activities. 
 
 
Pyrazolopyrazinone 
 
 A bicyclic system having pyrazolopyrazinone scaffold (Figure 1-21) was 
designed to enforce coplanarity of the metal-chelating atoms.132 Compound (32) had 
potent ST inhibitory activity value of < 10 nM and inhibited HIV-1 replication with EC50 
(10% FBS) value of 0.63 μM in cells. 
 
 
8-Hydroxy-3,4-dihydropyrrolo[1,2-a]pyrazine-1(2H)-ones 
 
 The pyridinone ring was substituted with a pyrrole ring (Figure 1-22) to design 
this new class of IN inhibitors.133 Several halogen substitutions were made on the benzyl 
group to confer ST selectivity and improve anti-HIV activity. Compound (33) had an ST 
IC50 value of 0.04 μM and an anti-HIV CIC50 value of 3.23 μM in cells. Another 
compound of the series, (34), showed a potent ST IC50 value of 0.01 μM and also 
inhibited HIV replication in cells with a CIC50 value of 0.31 μM. However, it was not 
metabolically stable and was readily eliminated with a short half-life of 0.5 h. To improve 
metabolic stability, the ester was replaced by an amide functionality in compound (35). 
Compound 35 inhibited ST activity with similar potency (IC50 value of 0.08 μM), but 
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Figure 1-20. Structure of dihydroxypyridopyrazine-1,6-diones HIV-1 integrase 
inhibitors 
 
 
 
 
 
 
Figure 1-21. Structure of pyrazolopyrazinone HIV-1 integrase inhibitors  
 
 
 
 
 
 
Figure 1-22. Structures of HIV-1 integrase inhibitors pyrrolopyrazine 
carboxamides 
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showed a marked decrease in the antiviral activity in cell culture (CIC50 value of 10 μM). 
Further modifications of the naphthyridine carboxamide core led to the development of 
dihydroxy pyrimidine carboxamides (Figure 1-23) as a new class of HIV-1 IN inhibitors 
showing potent nanomolar activity in the ST enzymatic assay.134,135 The most potent 
compound (36) of this class exhibited an IC50 of 80 nM against ST. However, the 
antiviral activity was lost in the presence of serum (EC50 value of 5.0 μM and 59 μM in 
the presence of 10% and 50% FBS, respectively). The dihydroxy pyrimidine group was 
optimized to a pyrimidinone scaffold having coplanar chelating atoms, which were meant 
for coordination with the active site metals. Extensive SAR studies established the para-
fluoro benzyl as an important group on the carboxamide moiety and the gem-dimethyl 
and oxadiazole substituents were identified as optimal groups in the 2? position. These 
efforts lead to the discovery of raltegravir as the first HIV-1 IN inhibitor to be approved 
for clinical use in AIDS patients.51 Recently reported 3D structures showed raltegravir in 
complex with the foamy virus IN and viral DNA. Raltegravir is developed by Merck 
Research Laboratories and is marketed as Isentress, a twice daily 400 mg oral tablet, and 
used in combination with other retroviral drugs. Raltegravir showed potent in vitro 
enzymatic inhibition with an IC50 of 15 nM in cell based assays in the presence of 50% 
human serum. Raltegravir is highly selective for IN and did not inhibit other Mg2+ 
dependant enzymes like HCV polymerases, RNaseH, and human ?, ?, and ? polymerases. 
Pharmacokinetic studies showed good oral bioavailability in animals (37%-45%).136 
Raltegravir is mainly eliminated through bile and urine via O-glucuronidation of the 5- 
hydroxyl group of the pyrimidinone ring, and is neither a substrate nor an inhibitor of 
cytochrome P450. In a 48-week study with 198-naive patients, raltegravir in a 
combination therapy showed effective reduction of viral load.137 Although raltegravir is 
active against several multidrug resistant HIV strains, resistant IN has however 
emerged.138,139 The most common mutations include T66I, N155H, Q148H /R, and 
G140S. N155H and Q148H/R are the two main mutations resulting in 10 and 25 folds of 
in vivo resistance, respectively. Double mutations like Q148H/R/G140S and 
N155H/E92Q resulted in about 400 and 64 folds decrease in viral susceptibility to 
raltegravir, respectively.140 Another pyrimidinone carboxamide that is structurally similar 
to raltegravir was developed by researchers at Bristol Meyers Squibb. BMS-707035 
showed potent in vitro activity (IC50 of 20 nM). It entered preclinical studies but its 
development was halted in Phase II clinical trials.141 
 
 
Bicyclic Pyrimidone 
 
 Researchers at Merck also incorporated the pyrimidone scaffold into a bicyclic 
system (Figure 1-24) giving compounds with potent ST and antiviral activity.142 
Sulphone and sulfonamide groups were introduced to improve antiviral activity. Some of 
the representative compounds include 37 and 38, both of which showed IC50 values of 7 
nM in ST assay and also inhibited HIV-1 replication with potent nM EC50 values in cell 
culture. 
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Figure 1-23. Structure of dihydroxypyrimidine carboxamide HIV-1 IN inhibitors 
 
 
 
            
 
 
Figure 1-24. Structures of bicyclic pyrimidone HIV-1 integrase inhibitors 
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4-Quinolone-3-carboxylic Acid 
 
Quinolone carboxylic acid IN inhibitor shown in  Figure 1-25 include elvitegravir 
(GS-9137, compound 39), which possesses a novel pharmacophore containing only two 
coplanar metal-chelating groups.143 It has also been co-crystallized with foamy virus IN-
DNA complex and is shown to bind in a similar mode to raltegravir. Elvitegravir has 
demonstrated potent inhibitory activity against ST with an IC50 value of 7.0 nM. It has 
also shown potent antiviral activity in vivo against HIV-1 mutatants resistant to other 
retroviral drugs.143 Elvitegravir is also active against HIV-2 strains, SIV and murine 
leukemia viruses. It is developed jointly by Japan Tobacco and Gilead Sciences as the 
next promising IN inhibitor. Elvitegravir has entered into Phase III clinical trials in 
antiretroviral (ARV) treatment-experienced patients and is also undergoing a Phase II 
study in subjects never exposed to ARV therapy. It has been found to effectively reduce 
viral loads and also demonstrated good safety and pharmacokinetic profiles.144 
Elvitegravir has showed good oral bioavailability in rats (34%) and dogs (30%). It is 
primarily metabolized by cytochrome P450 (CYP) 3A4 while the minor pathways 
include glucorinidation and oxidative metabolism. Combination therapy with ritonavir, a 
CYP3A4 inhibitor, has shown to boost elvitegravir concentrations and thus enhancing its 
efficacy (a 20 fold increase in oral bioavailability) to allow for a once-daily dosing. In 
vitro and clinical data suggests overlapping resistance profile with raltegravir.145,146 T66I, 
Q148H/R/K and E92Q mutations conferred resistance to both drugs while S153Y 
mutation resulted in greater resistance to elvitegravir. T66I and E92Q contributed the 
most to resistance, with 37 and 36 folds reduced susceptibility, respectively. A 
comparative study of the enzymatic activity of IN mutant using the dual ST and 3?-P 
assay showed that the 3?-P step was not significantly affected. Only Q148K mutation was 
found to severely impair 3?-P, while ST was defective for most of the viral mutants. 
 
 
Tricyclic IN Inhibitors 
 
 Conformational constraints were applied to incorporate the exocyclic 
carboxamide functionality of raltegravir into a ring system. Thus the 
pyrazinopyrrolopyridazine class was designed as a coplanar tricyclic core for HIV-1 IN 
inhibitors. Examples include MK-2048 (40) (Figure 1-26), which is a promising inhibitor 
active against both ST and HIV-1 replication at nanomolar concentrations. It is being 
developed by Merck as a second generation inhibitor to circumvent resistance associated 
with raltegravir and elvitegravir. Although MK-2048 retained activity against viruses 
resistant to raltegravir and elvitegravir, a recent study has shown that mutants G118R and 
G118R, E138K have decreased susceptibility to MK-2048 by two and eight folds, 
respectively.147 
 
 Another promising IN inhibitor which is currently undergoing Phase II clinical 
trials is S/GSK1349572 (dolutegravir, compound 41) developed by Shionogi and 
GlaxoSmithKline. Its structure is shown in Figure 1-27. It has potent ST IC50 of 2.7 nM. 
Dolutegravir has demonstrated encouraging results in clinical studies. It is being studied 
as an unboosted inhibitor with a once-daily dosage regimen.148 GS-9160 (42), a 
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Figure 1-25. Structure of Elvitegravir (GS-9137) 
 
 
 
 
 
 
Figure 1-26. Structure of MK-2048 
 
 
 
 
 
 
Figure 1-27. Structure of Dolutegravir (S/GSK-1349572) 
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tricyclic pyrroloquinolone shown in Figure 1-28, is a selective ST inhibitor also 
developed by GlaxoSmithKline. GS-9160 showed an IC50 value of 28 nM in ST assay 
and potent antiviral activity, with EC50 in the range 0.7 to 2.0 nM.148 Its development was 
halted because of an unfavorable pharmacokinetic profile and failure to achieve effective 
antiviral activity.149 
 
 
Miscellaneous Classes 
  
 Pyrrolinone derivatives (Figure 1-29) having coplanar chelating atoms have been 
reported as HIV-1 integrase inhibitors.150 Some representative examples of this series 
include compounds 43, 44 and 45, which had ST IC50 values of 0.03, 0.037, and 0.08 
μM, respectively. Their corresponding antiviral activities (EC50) were 0.18, 0.17, and 
0.24 μM, respectively. 
  
Coumarin scaffold containing N-benzylcarboxamide derivatives (Figure 1-30) 
were reported as HIV-1 IN inhibitors.151 Examples include compound 46 which showed 
moderate ST IC50 values of 7.0 μM. 
 
Phenanthrene and anthracene ?-diketo acids (Figure 1-31) have been reported as 
potent HIV-1 IN inhibitors by our laboratory.152 Compounds 47 and 48 exhibited ST 
inhibitory activities of 0.38 and 0.53 μM, respectively. 
 
Hydrazides (Figure 1-32) have been reported to inhibit both 3?-P and ST activities 
at micromolar levels.153 Examples include compound 49 which inhibited 3?-P and ST 
with corresponding IC50s of 6.9 and 1.6 μM. 
 
Tetracyclines derivatives (Figure 1-33) have been synthesized as HIV-1 integrase 
inhibitors.154 This class of compounds has displayed moderate potencies in micromolar 
concentrations against ST and against HIV-1 replication in cell cultures. Examples 
include compounds 50 and 51. 
 
Quinolinoyl diketo acids (Figure 1-34) combine the diketo acid pharmacophore 
with the quinolone system.155 They were reported as selective inhibitors of the ST 
catalytic step. A representative compound of the series (compound 52) had a ST IC50 
value of 0.18 μM and antiviral activity EC50 of 0.17 μM. 
 
Benzylindole scaffold (Figure 1-35) was attached to a diketo acid in compound 
(53).156 It inhibited ST with an IC50 of 0.03 μM but it showed reduced activity against 
HIV-1 replication with an EC50 value of 2.13 μM. 
 
Aryl sulfonamides (Figure 1-36) have been reported as HIV-IN inhibitors.157,158 
Examples include 2-mercaptobenzene sulfonamides (54) and their cyclic analogue (55), 
which inhibit ST activity at μM concentrations. 
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Figure 1-28. Structure of GS-9160 
 
 
 
        
 
 
Figure 1-29. Structures of pyrrolinone HIV-1 integrase inhibitors 
 
 
 
 
 
 
Figure 1-30. Structure of coumarin carboxamide HIV-1 integrase inhibitors 
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Figure 1-31. Structures of polycyclic ?-diketo acid HIV-1 integrase inhibitors 
 
 
 
 
 
 
Figure 1-32. Structures of hydrazides HIV-1 integrase inhibitors 
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Figure 1-33. Structures of tetracyclines HIV-1 integrase inhibitors 
 
 
 
 
 
 
Figure 1-34. Structures of quinolinoyl diketo acids HIV-1 integrase inhibitors 
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Figure 1-35. Structure of benzylindole HIV-1 integrase inhibitors 
 
 
 
           
 
 
Figure 1-36. Structures of aryl sulfonamides HIV-1 integrase inhibitors 
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Recently Reported HIV-1 IN Inhibitors 
 
N-1 aryl or benzyl substituted 5-hydroxyquinolone-3-carboxylic acids have been 
reported as a new series of HIV-1 IN inhibitors.159 The most active compound (56, 
Figure 1-37) inhibited wild type HIV-1 with an EC50 value of 3.1 μM in C8166 cells. 
 
On the basis of the C-2 symmetry present in the naphthyridinone core, a new 
series of related IN inhibitors have been designed and synthesized.160 Combining the A/B 
naphthyridinone type analogs into a single compound inhibited ST in low nM 
concentrations and significantly improved their antiviral activities. One of the most active 
compounds (Figure 1-38) of the series (57) inhibited ST with an IC50 of 8 nM and also 
showed potent antiviral activity, inhibiting HIV-1 replication with an EC50 of 3.0 nM. 
 
Ethyl malonate amides functionality has been discovered to inhibit HIV-1 IN.161 
One of the most active compounds of the series (58) shown in Figure 1-39 was active 
against ST with an IC50 of 2.0 μM. 
 
Bicyclic pyrimidinones and 4,5-dihydroxy-1H-isoindole-1,3(2H)-diones classes 
of IN inhibitors were combined to design tricyclic hydroxy-1H-pyrrolopyridine-trione as 
a novel class of HIV-1 IN inhibitors.162 The most active compound (59) of the series 
shown in Figure 1-40 selectively inhibited ST with an IC50 of 9.1 μM. Compound 59 was 
also shown to be less susceptible to the resistance producing effects of G140S/Q148H, 
N155H and Y143R mutations than raltegravir. 
 
In another study, a series of caffeoyl-anilides have been reported as dual 
inhibitors of HIV-1 IN and CCR5 co-receptors.163 Compound (60, Figure 1-41) showed 
ST IC50 of 44.6 μM and antiviral EC50 value of 0.90 μM in cell culture. 
 
2-hydroxyisoquinoline-1,3(2H,4H)-diones (Figure 1-42) were reported as 
inhibitors of HIV-1 RT ribonuclease (RNase) H domain and HIV-1 IN.164 Compound 61 
inhibited ST with an IC50 of 4.77 μM and was also active against HIV-1 RNase H with an 
IC50 of 61 nM. In another related publication165 compound 62 showed IC50s of 1.3 μM 
and 33.6 μM against ST and RT RNase H, respectively.  
 
N-Hydroxydihydronaphthyridinones has been designed and synthesized as potent 
orally available tricyclic HIV-1 IN inhibitors.166 Compound 63 shown in Figure 1-43 
inhibited ST with an IC50 of 2.9 nM, displayed potent antiviral activity with an EC50 of 
1.0 nM and, also showed good pharmacokinetic properties. 
 
6-substituted quinolonyl diketo acid HIV-1 IN inhibitors have been reported.167 
Compound 64 shown in Figure 1-44 was active against ST with an IC50 of 50 nM and 
inhibited HIV-1 replication with EC50 of 1.0 μM in TZM-bl cells. 
 
3-Hydroxypyrimidine-2,4-diones were reported as inhibitors of HIV-1 IN and 
RT.168 Compound 65 shown in Figure 1-45 exhibited IC50 of 3.5 μM against ST and 
inhibited HIV-1 replication with EC50 of 24 nM. Raltegravir resistant mutants  
 41 
 
 
 
Figure 1-37. Structure of 5-hydroxylquinolone-3-carboxylic acids HIV-1 integrase 
inhibitors 
 
 
 
 
 
 
Figure 1-38. Structure of naphthyridinone HIV-1 integrase inhibitors 
 
 
 
 
 
 
Figure 1-39. Structure of ethyl malonate amide HIV-1 integrase inhibitors 
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Figure 1-40. Structure of hydroxy-1H-pyrrolopyridine-trione HIV-1 integrase 
inhibitors 
 
 
 
 
 
 
Figure 1-41. Structure of caffeoyl-anilides HIV-1 integrase inhibitors 
 
 
 
                                                                   
 
 
Figure 1-42. Structure of 2-hydroxyisoquinoline-1,3(2H,4H)-diones HIV-1 
integrase inhibitors 
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Figure 1-43. Structure of N-hydroxy-dihydronaphthyridinones HIV-1 integrase 
inhibitors 
 
 
 
 
 
 
Figure 1-44. Structure of 6-substituted quinolonyl diketo acids HIV-1 integrase 
inhibitors 
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Figure 1-45. Structure of 3-hydroxypyrimidine-2,4-diones HIV-1 integrase 
inhibitors 
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showed lower resistance to compound 65 probably because of its anti-reverse 
transcriptase activity. 
 
Substituted benzyl indole diketo acids have been designed and synthesized as 
HIV-1 IN inhibitors.169 One representative compound of the series (66) shown in Figure 
1-46 had potent IC50 of 6 nM against ST step and moderate antiviral activity inhibiting 
HIV-1 replication with an EC50 of 8.5 μM. 
 
A new series of naphthyridinone and quinolone carboxylic acid HIV-1 integrase 
inhibitors were synthesized to improve their microsomal stability.170 Compound 67 
(Figure 1-47) had an EC50 of 9.9 nM and microsomal stability (% remaining) of 97%. 
 
2-Pyrrolinones were discovered from a pharmacophore model and synthesized as 
HIV-1 IN inhibitors.171 Compound 68 shown in Figure 1-48 inhibited both ST (IC50 = 40 
μM) in assays and HIV-1 replication (EC50  = 0.31 μM) in TZM-bl cells. 
 
Azaindole N-methyl  hydroxamic acids have been reported as potent HIV-1 IN 
inhibitors.172 Compound 69 shown in Figure 1-49 demonstrated an IC50 of 382 nM 
against ST and inhibited HIV-1 replication with an EC50 of 29 nM in CEM-SS cells. 
 
Pyrazolone was discovered as a novel scaffold for IN inhibition inhibiting ST 
with low μM concentrations.173 The most active compound (70) of the series shown in 
Figure 1-50 inhibited ST with an IC50 of 3.0 μM. 
 
A series of bicyclic inhibitors possessing the azoles, thiazole, and imidazole as 
metal chelating moieties (Figure 1-51) were synthesized as HIV-1 IN inhibitors. The 
most promising compound (71) had an EC50 of 6 nM.174 
 
2-Pyrrolidinyl-N-methyl pyrimidones (Figure 1-52) were explored and developed 
as orally bioavailable potent HIV-1 IN inhibitors.175 Compound 72 was highly active 
against viral replication (CIC95 = 5 nM) and also showed a good pharmacokinetic profile. 
 
2-Arylnaphthalenediols and polyhydroxylated compounds were reported as HIV-
1 IN inhibitors.176 One of the most promising compounds (73) shown in Figure 1-53 had 
an IC50 of 0.85 μM against ST and an EC50 of 3.0 μM in MT-4 cells. 
 
Structure-activity relationships studies on benzylindolediketo acids were 
developed by investigation of the hydrophobic region.177 One of the most active 
compounds of the series (74) shown in Figure 1-54 had an IC50 of 30 nM against ST and 
an EC50 of 0.43 μM against HIV-1 in MT-4 cells. 
 
A series of 2,3-dihydroxybenzamide (Figure 1-55) containing compound (75) 
was reported to inhibit ST and LEDGF with IC50s of 19 μM and 8 μM, respectively.178 
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Figure 1-46. Structure of indole diketo acids HIV-1 integrase inhibitors 
 
 
 
 
 
 
Figure 1-47. Structure of quinolone carboxylic acid HIV-1 integrase inhibitors 
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Figure 1-48. Structure of 2-pyrrolinones HIV-1 integrase inhibitors 
 
 
 
 
 
 
Figure 1-49. Structure of azaindole N-methyl hydroxamic acids HIV-1 integrase 
inhibitors 
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Figure 1-50. Structure of pyrazolone HIV-1 integrase inhibitors 
 
 
 
 
 
 
Figure 1-51. Structure of bicyclic pyrazole containing HIV-1 integrase inhibitors 
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Figure 1-52. Structure of 2-pyrrolidinyl-N-methyl pyrimidones HIV-1 integrase 
inhibitors 
 
 
 
 
 
 
Figure 1-53. Structure of 2-arylnaphthalenediols HIV-1 integrase inhibitors 
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Figure 1-54. Structure of benzylindole diketo acids HIV-1 integrase inhibitors 
 
 
 
 
 
 
Figure 1-55. Structure of 2,3-dihydroxybenzamide HIV-1 integrase inhibitors 
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CHAPTER 2.   RESEARCH OBJECTIVE 
 
 
Synthesis of HIV-1 Integrase Inhibitors 
 
The emergence of multi-drug resistance and failure of HAART therapy, which 
targets primarily the RT and PR, to eliminate HIV from patient demand inhibition of 
other steps essential for viral survival and replication. In this regard, HIV-1 IN, which is 
crucial enzyme for viral replication, has emerged as a promising target for the 
development of anti-retroviral drugs. 
 
Although highly promising IN inhibitors have been developed, raltegravir is the 
only IN inhibitor approved by the FDA. Emergence of resistance against raltegravir and 
the clinically advanced drug candidate, elvitegravir necessitates the development of novel 
scaffolds targeting IN. In this study, covered in Chapter 3, a novel series of 3-keto 
salicylic acid chalcones with diverse structural features were synthesized and biologically 
evaluated as promising integrase inhibitors. Few analogs of the series showed good 
activities against ST in in vitro enzymatic assay and were also equally potent against 
HIV-1 replication in cell cultures. 
 
In Chapter 4, the chalcone scaffold was modified to a structurally related amide to 
synthesize a new series of compounds. A vast majority of potent IN inhibitors, including 
raltegravir, have an amide functionality which gives a conformationally favorable 
orientation to the halo benzyl group present in these compounds. In this study, 10 new 
amide analogs were synthesized and evaluated as HIV-1 integrase inhibitors. A couple of 
amide derivatives showed good in vitro potencies against ST step and displayed moderate 
anti-viral activities in cell cultures. These compounds hold promise for further 
optimization to obtain more potent HIV-1 IN inhibitors. In the search of novel scaffolds 
for integrase inhibition, some structurally diverse compounds containing metal chelating 
atoms were also synthesized and tested for IN inhibitory activity. 
 
?-Diketo acid analogs were the first representative compounds that entered 
clinical trials. Previously, our laboratory has reported 5(H)-phenanthridin-6-one diketo 
acid as a new class of HIV-1 integrase inhibitors. In Chapter 5, 10 analogs of this series 
having electron withdrawing groups on the phenanthrene ring were synthesized and 
tested as HIV-1 integrase inhibitors. Most of the analogs showed good in vitro ST and 
3?-P activities and selected compounds when tested for their antiviral activity, showed 
moderate inhibition of HIV-1 replication. Modeling studies, described in Chapter 6, 
suggest that these compounds could be investigated against viral mutants resistant to 
currently available IN inhibitors. 
 
 
Computational Studies on HIV-1 Integrase Inhibitors 
 
Despite two decades of tremendous effort leading to promising IN inhibitors their 
binding modes, until recently, remained elusive. The absence of a complete DNA-bound 
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crystal structure has presented significant challenge to the structure-based design of IN 
inhibitors. Although X-ray structures of individual human HIV domains and their 
combinations have been reported, the absence of a 3D structure of HIV-1 IN and viral 
DNA along with the two-divalent metals in the active site make the structural information 
hitherto available limited and far from reality. To address this limitation, a homology 
model of HIV-1 integrase in complex with the viral DNA was constructed, by our 
collaborators at the Oak Ridge National Laboratory. The homology model was built 
based on the recently reported crystal structure of the foamy virus IN-DNA complex 
(PDB 3L2T and 3L2U).  
 
 In Chapter 6, a detailed computational study was undertaken to elucidate the 
binding modes of approved IN inhibitor raltegravir, elvitegravir, and our synthesized IN 
inhibitors. To determine the stereo-electronic features important for ligand binding, in the 
absence of a crystal structure of a full-length HIV-1 IN-DNA complex, a ligand-based 
approach was first employed. A PHASE pharmacophore model of the synthesized 
chalcone and amide derivatives was developed to determine their bio-active 
conformations which were then used for deriving 3D-QSAR CoMFA and CoMSIA 
models. The resulting QSAR models had limited predictive ability probably because of 
the narrow range of activities of compounds in the dataset. Next, with the goal of 
developing a statistically significant and predictive model capable of estimating potent 
compounds, a comprehensive 3D-QSAR CoMFA and CoMSIA study was undertaken. A 
data set of 103 compounds including our synthesized chalcone and structurally related 
amide IN inhibitors, raltegravir and elvitegravir and their analogs reported in literature 
were used for the 3D-QSAR study. Atom-fit alignments and MM-GBSA validated 
docking-based conformations were used for the 3D-QSAR modeling. This study has 
yielded statistically significant models that could be further optimized to predict the 
activities of novel related HIV-1 IN inhibitors. Binding free energies of the inhibitors 
were also derived using the Linear Interaction Approximation (LIA) calculations, and the 
energy parameters were then used for building a LIA QSAR model. The resulting energy 
contributions were also studied to gain insights into the binding modes of raltegravir and 
elvitegravir and to validate the binding conformations of our synthesized IN inhibitors. 
Another objective of the computational studies was to use structure-based design to 
rationally guide the synthesis of potential 3-ketosalicylic acid amides IN inhibitors. 
RACHEL, a drug optimization module was used to design compounds with an aim of 
having desired interaction with the enzyme. Finally, to determine the binding modes of 
our synthesized phenanthrene derivatives, docking studies were performed and their 
poses evaluated.  
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CHAPTER 3.   SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-KETO 
SALICYLIC ACID CHALCONES AS NOVEL HIV-1 INTEGRASE 
INHIBITORS* 
 
 
     Introduction 
 
 ?-Diketo acid derivatives and bioisosteres as represented by S-1360 constitute the 
first integrase inhibitor class to have entered clinical trials. Naphthyridine carboxamides 
such as L-870,810 have also advanced to clinical trials as have novel quinolone 
carboxylic acids such as GS-9137 (elvitegravir) which is currently undergoing Phase III 
clinical trials. Inspite of over two decades of extensive research leading to promising IN 
inhibitors, hitherto only one IN inhibitor, raltegravir, a pyrimidinone carboxamide, has 
been approved for clinical use. Moreover, emergence of resistance against raltegravir due 
to viral mutations usually T66I, N155H, Q148H/R and E92Q, demands exploration of 
novel scaffolds for IN inhibition in the treatment of HIV infection.138,139  
 
 In this chapter, is reported the synthesis and biological evaluation of chalcone 
derivatives having 3-keto salicylic acid moieties as a new class of IN inhibitors. We have 
undertaken substantial analog synthesis and carried out systematic exploration of the 
structure activity relationship. It is established that potent IN inhibitors have two common 
structural features viz., a hydrophobic benzyl group and a chelating motif capable of 
binding two Mg2+ ions. With a 3-keto salicylic acid as chelating pharmacophoric moiety, 
diverse structural modifications of the hydrophobic aromatic feature were made to 
synthesize 52 novel chalcone derivatives. 
 
 
Chemistry 
 
 In the present study, a novel series of IN inhibitors was discovered based on 
modification of the diketo acid pharmacophoric group as represented by structure III 
(Figure 3-1). The 2-position OH and 3-postion keto groups together mimic the keto-enol 
tautomer of the ?-diketo group. Attachment of the carboxylic acid at the 1-position gave 
the 3-keto salicylic acid moiety of III, intended to interact with IN similar to the ?-diketo 
acids. A styryl group was attached to the 3-position keto group to create chalcones (IV) 
(Figure 3-1), the type of which have not yet been investigated as HIV IN inhibitors to 
our knowledge. The chalcone moiety was also reduced to give an ethylene linker. 
 
 The synthesis of target chalcones was performed according to reaction (Scheme 
3-1). 5-substituted salicylic acid (X = COOH) starting materials 76 a-e were first 
acetylated with acetic anhydride and concentrated sulfuric acid. The acetylated  
 
* Adapted with permission. Sharma, H.; Patil, S.; Sanchez, T. W.; Neamati, N.; 
Schinazi, R. F.; Buolamwini, J. K. Synthesis, biological evaluation and 3D-QSAR studies 
of 3-keto salicylic acid chalcones and related amides as novel HIV-1 integrase inhibitors. 
Bioorg. Med. Chem. 2011, 19, 2030-2045.179  
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Figure 3-1. Design of 3-keto salicylic acid chalcone as HIV-1 integrase inhibitors 
 
 
 
Scheme 3-1. Synthesis of compounds 61-108 
 
 
 
 
 
Reagents and conditions: (a) Ac2O, H2SO4, 20 min; yield 75-88%(b) AlCl3, 160 °C, 3 h; 
yield 26-34% (c) ArCHO, NaOH, EtOH, rt, 1-5 days; yields 15-74%. 
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intermediates 77 a-e were then subjected to Fries rearrangement reaction using 
anhydrous aluminum chloride and heating at 160 °C to transfer the acetyl group from the 
2-position oxygen to the 3-position to yield 3-acetyl salicylic acid intermediates 78 a-e. 
The next step involved a Claisen-Schmidt condensation reaction of intermediate 78 with 
various aryl aldehydes at room temperature using NaOH to obtain the target chalcones 
81-128.180 The synthesis of compounds 129 and 130 was achieved following Scheme 3-2 
by using appropriate aromatic aldehydes and commercially available 1-(5-bromo-2-
hydroxy-3-nitro-phenyl)ethanone starting material. To determine the importance of the 
?,?-unsaturated bond (chalcone scaffold) to IN inhibitory activity, the synthesis of 
compound 131 and 132 was undertaken by reduction of compounds 81 and 107, 
respectively, by Pd/C-catalyzed hydrogenation (Scheme 3-3).   
 
 
Results and Discussions 
 
 
Structure-Activity Relationships 
 
 After synthesis, target compounds were tested for integrase inhibitory activity to 
assess their potency and study the SAR. In general, the compounds behaved as typical 
diketo acid IN inhibitors, being selective against the ST step (Table 3-1) compared to  
3?-P. The selected potent compounds of the series were then tested for their ability to 
inhibit HIV replication in cell culture. All the biological studies were performed by 
collaborators. 
 
 
Substitution on aromatic ring A. Compound 131, 2-hydroxy-3-(3-phenyl-
propyl)-benzoic acid, in which salicylic acid is connected to an unsubstituted phenyl ring 
B by a propylene linker exhibited only weak inhibitory activity with IC50 of >100 μM for 
3?-P and 91 μM for ST. Modification to an ?,?-unsaturated linker along with substitution 
with Br at R1 (compound 81 used as reference) demonstrated a significant increase in 
both activity and ST selectivity (IC50 25 μM for ST vs. IC50 75 μM for 3?-P). With the 
presence of bromine substituent at R1 on aromatic ring A being shown to be important for 
activity, chlorine and fluorine substituents were also investigated. Compounds with a Br 
substituent were the most active followed by F which was a little better than Cl. To 
determine the effect of hydrophobic interactions, a methyl group was substituted for the 
halogens at R1 (see compound 128). Compound 128 was found to be 13 times less active 
than the corresponding Br-substituted compound 96. Since Br and a methyl group are 
similar in steric terms, this implies that it is not the hydrophobic effect of the halogen, but 
possibly the electronegativity and/or polarizability that might be the dominant effect. The 
3-keto salicylic acid pharmacophore was designed to coordinate with Mg2+. To test this 
hypothesis, the carboxylic acid was replaced with a NO2 functionality (129, 130) and this 
modification diminished HIV inhibitory activity. Replacement of the carboxyl group with 
another polar group but with weaker coordination ability, CN (compound 127) also 
resulted in reduced inhibitory activity.  This probably indicates that the formal negative 
charge of the free ionizable acidic moiety, that would chelate better with the metal ion, is 
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Scheme 3-2. Synthesis of compounds 129 and 130 
 
 
 
 
 
Reagents and conditions: (a) ArCHO, NaOH, EtOH, rt; yields 58-65%. 
 
 
 
Scheme 3-3. Synthesis of compounds 131 and 132 
 
 
 
 
 
Reagents and conditions: (a) H2, Pd/C (10 mol%), methanol 10 h (b) H2, Pd/C (10 
mol%), methanol 2 h; yields 43-72%. 
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Table 3-1. Structure and HIV-1 integrase inhibitory activities of chalcones 
synthesized 
 
 
 
Cpd. Ar X R1   Activity IC50 (μM) 
 3?-Pa              STb           
81 Ph COOH Br 75 ± 14 25 ± 5 
82 2-Cl-Ph COOH Br 52 ± 13 14 ± 4 
83 2-F-Ph COOH Br 74 ± 25 32 ± 3 
84 3-Cl-Ph COOH Br 45 ± 10 9 ± 3 
85 4-Cl-Ph COOH Br 81 ± 28 12 ± 1 
86 4-Br-Ph COOH Br 11 ± 4 5 ± 2 
87 4-I-Ph COOH Br 69 35 
88 2,4-di-Cl-Ph COOH Br 28 ± 12 7 ± 4 
89 2,3-di-Cl-Ph COOH Br 58 ± 13 19 ± 11 
90 2,3-di-MeO-Ph COOH Br 62 ± 14 34 ± 6 
91 2,3,4-tri-MeO-Ph COOH Br 85 ± 20 51 ± 16 
92 2,5-di-Cl-Ph COOH Br 47 ± 14 18 ± 4 
93 2,6-di-Cl-Ph COOH Br 52 ± 12 16 ± 8 
94 3,4-di-Cl-Ph COOH Br 27 ± 11 14 ± 4 
95 2,3,5-tri-Cl-Ph COOH Br 20 ± 12 13 ± 5 
96 2,3,6-tri-Cl-Ph COOH Br 23 ± 12 <3.7 
97 4-Cl-Ph COOH Cl 85 ± 13 53 ± 21 
98 2,4-di-Cl-Ph COOH Cl >100 >100 
99 2,3-di-Cl-Ph COOH Cl 100 92 ± 14 
100 2,5-di-Cl-Ph COOH Cl 75 25 
101 2,3,5-tri-Cl-Ph COOH Cl 55 ± 40 17 ± 3 
102 2,3,6-tri-Cl-Ph COOH Cl 77 ± 20 30 ± 5 
103 3,4-di-Cl-Ph COOH Cl 87 ± 13 41 ± 9 
104 4-Cl-Ph COOH F 36 ± 13 17 ±3 
105 2,4-di-Cl-Ph COOH F 52 ± 13 24 ± 9 
106 2,3-di-Cl-Ph COOH F 55 ± 18 30 ± 9 
107 2,5-di-Cl-Ph COOH F 50 29 ± 6 
108 2,3,5-tri-Cl-Ph COOH F 33 ± 14 15 ± 4 
109 2,3,6-tri-Cl-Ph COOH F 82 ± 16 39 ± 6 
110 3,5-di-Me-Ph COOH Br >100 58 
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Table 3-1. (Continued) 
 
Cpd. Ar X R1 Activity IC50 (μM) 
3?-Pa         STb 
111 2-Cl-3,4-di-MeO-Ph COOH Br >100 76 
112 6-F-3,4-di-MeO-Ph COOH Br >100 76 
113 2-BzO-Ph COOH Br 21 9 
114 3-(4-Cl-PhO)-Ph COOH Br 25 18 
115 4-(4-Cl-PhO)-Ph COOH Br 22 16 
116 3-thienyl COOH Br 30 ± 12 18 ± 1 
117 3-(cyclopentyloxy)-Ph COOH Br 100 55 
118 3-(2-OEt-naphthyl) COOH Br 92 46 
119 5-MeO-naphthyl COOH Br 54 54 ± 25 
120 5-benzothiophene COOH Br 23 ± 3 11 ± 1 
121 2-furan-2-yl-Ph COOH Br >100 16 ± 2 
122 3-Cl-4,5-
methylenedioxy-Ph 
COOH Br 79 63 
123 3-OCF3-Ph COOH Br >100 52 
124 3-NO2-Ph COOH Br 49 ± 8 32 ± 6 
125 3-Br-Ph COOH Br 19 ± 4 18 ± 1 
126 3-F-Ph COOH Br 71 ± 1 59 ± 2 
127 2,3,6-tri-Cl-Ph CN Br >100 44 ± 2 
128 2,3,6-tri-Cl-Ph COOH CH3 >100 50 ± 9 
129 2,3,5-tri-Cl-Ph NO2 Br >333 68 ± 5 
130 2,3,6-tri-Cl-Ph NO2 Br 36 ± 4 21 ± 3 
131 
132 
S-1360 
N/Ac 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
>100 
>100 
11 ± 2 
91 
57 ± 5 
0.6 ± 0.1 
 
a 3?-P represents 3?-procesing; b ST represents strand transfer; c N/A means not applicable. 
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required for potent activity, supporting the hypothesis. Of course a chelation study will 
have to be done to confirm this. 
 
 
Substitution on aromatic ring B. Various groups were substituted on aromatic B 
to further explore the SAR. The presence of halogens on phenyl ring B produced 
noticeable improvements in potency based on the type, number and position on the 
aromatic ring. Fluorine substitution in the ortho and meta positions (compounds 83 and 
126) diminished activity, as did iodine substitution at the para position (compound 87). 
However, substitution with Cl enhanced activity specifically for ST in all the three 
positions (compounds 82, 84 and 85). Interestingly, compounds 125 and 86 with m-Br 
and p-Br substituent, respectively, were potent against both catalytic steps (compound 84 
showed IC50 of 5 μM against ST activity and 11 μM against 3?-P). The 2,3,6-trichloro-
substituted compound (96) was the most active, with IC50 of about ~ 4 μM against the ST 
reaction. This suggests a binding site pocket with high affinity for halogenated phenyl 
rings. This might be the site that binds the fluorobenzyl group common in potent IN 
inhibitors like the clinically used drug raltegravir (Figure 1-8). We next turned our 
attention to examining the following. 
 
(1) The effect of a bulky aryl B groups: benzyloxy and chloro substituted phenoxy 
in ortho, meta and para positions of phenyl ring B enhanced activity for both 3?-P and ST 
steps; whereas an ortho-furan substituent (compound 121) increased the inhibitory 
potency against ST but decreased potency against 3?-P;  the increase in activity was most 
pronounced for the o-benzyloxy substituent (compound 123), with the 3?-P and ST IC50 
values lowered to 21 and 9 μM, respectively, compared to corresponding values of 75 
and 25 μM for the parent phenyl compound 81. 
 
(2) The effects of electron donating or withdrawing groups: introduction of 
electron donating groups such as methoxy, methyl and cyclopentoxy (compounds 90, 110 
and 117) decreased integrase inhibitory activity; and, increasing the number of electron 
donating groups resulted in further decrease in activity (compare compounds 90 and 91). 
Introduction of strong electron withdrawing groups such as trifluoromethyl and nitro also 
diminished activity as shown by compounds 123 and 124, respectively. 
 
(3) Boisosteric replacement of phenyl ring B with polycyclic and heteroaromatic 
rings: replacement of phenyl with thiophene or benzothiophene, compounds 116 and 120, 
respectively, improved activity. Naphthalene derivatives on the other hand decreased 
activity (compounds 118 and 119). It thus appears that heteroaromatic B rings may 
improve integrase inhibitory activity. 
 
 
 Reduction of the ?,?-unsaturated double bond of the chalcones. To explore 
the importance of the ?,?-unsaturated bond of the chalcones on inhibitory activity, we 
reduced it to a single bond. Our first attempt at this was with compound 96, but reduction 
also led to a loss of the Br substituent. However, reduction (Scheme 3-3) of analog 107, 
having a fluorine substituent, which is not as good a leaving group as Br, was successful 
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in achieving our objective. The reduction product, compound 132, was less active (ST 
IC50 of 57 μM) than the unsaturated analog, showing that the reduction of the double 
bond in the chalcone template is detrimental to activity.  
 
 
Inhibition of HIV Replication in Cell Culture 
 
To evaluate the potential of these new IN inhibitors as antiviral agents, five potent 
analogs were tested for the ability to inhibit HIV-1 replication in primary human 
peripheral blood mononuclear cells (PBMCs) infected with the virus. The toxicity of the 
compounds was also tested against PBMC and human CEM lymphoblastic leukemia 
cells. All four compounds tested inhibited HIV replication (Table 3-2). The most potent 
compounds, 96 and 86 showed comparable EC50 values of 7.3 and 8.3 μM, respectively. 
Compound 120 (integrase ST IC50 = 11 μM) exhibited an EC50 of 10 μM, while analog 
88 (integrase ST IC50 = 7.0 μM) displayed an EC50 of 13.9 μM. Thus, in general the cell-
based activity correlated well with the IN inhibitory potency.  Moreover, the two most 
potent IN inhibitory compounds of the set tested, 86 and 96, were also found to have the 
highest activity against HIV replication, suggesting that IN might indeed be their antiviral 
target. These results demonstrate moderate anti-viral activity, which is not very different 
from early members of the diketo acid IN inhibitors, which served as important lead 
compounds such as L-706,908 which had an EC50 of 5.7 ± 4.7 μM for inhibition of HIV 
replication.181 The compounds showed cytotoxicity, with selectivity index up to 4-fold 
for compound 120. It may be noteworthy that compound 120 is the only compound 
among the antiviral test set that had a 5-benzothiophene for ring B; this may offer clues 
for improving selectivity index. These results demonstrate reasonable anti-viral activity 
when compared to the anti-viral activity of reported diketo acid inhibitors like L-706,908 
which has an EC50 of 5.7 ± 4.7 μM for inhibition of HIV replication. To put data in 
perspective with regard to AZT’s activity, in the same assay, AZT had an EC50 of 0.001 
μM.181 
 
 
Experimental Section 
 
 
Chemistry 
 
All the reagents and solvents were purchased from the Aldrich Chemical 
Company and used without further purification. Progress of reactions was monitored by 
TLC on silica gel GHLF-250 micron plates (Analtech, Inc.). Fisher scientific Da visil 
grade 1740 (170–400 mesh) silica gel was used for flash column chromatography. 1H 
NMR spectra were recorded on Brucker AR, 300 or 500-MHz spectrometer: chemical 
shifts are expressed in ? values (ppm) and coupling constants (J) in Hertz (Hz). Mass 
spectral data were determined on a Brucker-HP Esquire-LC spectrometer (ESI-MS). 
Melting points were determined using a Fisher-Johns melting point apparatus and are 
reported uncorrected. HPLC analysis of final compounds was carried out using a reverse 
phase SUPELCOSIL 5 μm C-18 column of dimensions 25 cm x 4.6 cm. Area % purity  
 60 
Table 3-2. Anti-HIV activities of selected chalcone derivatives 
 
Cpd. Anti-HIV-1 activity in PBMCsa  Cytotoxicity (IC50 μM) 
EC50(μM)b         EC90(μM)b     PBMCs     CEM 
86 8.7 21.0 24.4 27.5 
88 13.9 26.0 22.1 23.8 
96 7.3 20.3 22.7 19.0 
120 10.1 24.3 39.1 20.7 
AZT 0.0025 0.01 >100 56.1 
L-706,908 5.7 ± 4.7c N/A N/A  N/A 
 
a PBMCs represents Human Peripheral blood mononuclear cells; b EC50 and EC90 are the 
effective concentrations inhibiting 50% and 90% HIV replication, respectively; c in the 
assay on human leukemic T-cell line MOLT-4, the EC50 of AZT was 0.001 μM. 
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was detected at 254 nm.  An initial isocratic method comprising 40%  water (solvent A) 
and 60% methanol (solvent B) for 20 min at a flow rate of 1.2 mL/min was optimized to 
a linear gradient elution with water (A) and methanol (B) at a flow-rate of 1.7 mL/min. 
Gradient elution of the mobile phase was either (a) 80% A to 35% A from 0-5 min, 35% 
A, 65% B for 5-12 min, and 35% A to 80% A from 12-15 min or (b) 60% A to 20% A 
from 0-4 min, 20% A and 80% B for 4-12 min and 20% A  to 60% A from 12-15 min. 
The purity of all, but two, compounds was found to be ? 95%. 
 
 
General procedure for the synthesis of intermediates 76a-76e. 5-Halogenated 
salicylic acids (46 mmol) were stirred with acetic anhydride (20 mL), and 80 μL of conc. 
H2SO4 was then added. After a few (20) min, the reaction mixture solidified and was 
poured into cold water. The solid so obtained was filtered and extracted with ethyl 
acetate, washed with brine and dried over Na2SO4. The solvent was evaporated under 
reduced pressure to obtain a crude solid, which was recrystallized from ethyl 
acetate/hexane to afford white crystals (76a-76e). 
 
2-acetoxy-5-bromo-benzoic acid (76a). Yield 88%; mp 155-157 °C; 1H NMR (300 
MHz, DMSO-d6): ? 13.44 (br s, 1H, COOH), 8.0 (d, 1H, J = 2.4 Hz, ArH), 7.85 (dd, 1H, 
J1 = 8.7 Hz, J2 = 2.7 Hz, ArH), 7.20 (d, 1H, J = 8.7 Hz, ArH), 2.2 (s, 3H, OCOCH3); MS 
(ESI): m/z 216.6 [M?COCH3]?. 
 
2-acetoxy-5-fluoro-benzoic acid (76b). Yield 85%; mp 133-134 °C; 1H NMR (300 
MHz, DMSO-d6): ? 13.42 (br s, 1H, COOH), 7.67 (dd, 1H, J1 = 9.0 Hz, J2 = 3.3 Hz, 
ArH), 7.51 (ddd, 1H, J1 = 8.7 Hz, J2 = 8.1 Hz, J3 = 3.3 Hz, ArH), 7.26 (dd, 1H, J1 = 4.8 
Hz, J2 = 8.7 Hz, ArH), 2.24 (s, 3H, OCOCH3); MS (ESI): m/z 154.7 [M?COCH3]? . 
 
2-acetoxy-5-chloro-benzoic acid (76c). Yield 85%; mp 150-152 °C; 1H NMR (300 
MHz, DMSO-d6): ? 7.88 (d, 1H, J = 2.7 Hz, ArH), 7.72 (dd, 1H, J1 = 9.0 Hz, J2 = 2.7 Hz, 
ArH), 7.27 (d, 1H, J = 8.4 Hz, ArH), 2.24 (s, 3H, OCOCH3); MS (ESI): m/z 170.7 
[M?COCH3]?. 
 
Acetic acid-4-bromo-2-cyano-phenyl ester (76d). Yield 76%; mp 60-61°C; 1H NMR 
(300 MHz, DMSO-d6) : ? 8.26 (d, 1H, J = 2.7 Hz, ArH), 8.0 (dd, 1H, J1 = 8.7 Hz, J2 = 2.4 
Hz, ArH), 7.44 (d, 1H, J = 8.7 Hz, ArH), 2.29 (s, 3H, OCOCH3); MS (ESI): m/z  197.5 
[M?COCH3]?. 
 
2-acetoxy-5-methyl-benzoic acid (76e). Yield 75%; mp 158-160 °C; 1H NMR (300 
MHz, DMSO-d6) : ? 8.01 (d, 1H, J = 1.5 Hz, ArH), 7.50 (dd, 1H, J1 = 8.4 Hz, J2 = 1.8 Hz, 
ArH), 7.12 (d, 1H, J = 8.1 Hz, ArH), 2.43 (s, 3H, OCOCH3), 2.27 (s, 3H, CH3); MS 
(ESI): m/z  150.7 [M?COCH3]?. 
 
 
General procedure for the synthesis of intermediates 77a-77e. The O-
acetylated intermediates (38.61 mmol) and AlCl3 (120 mmol) were mixed in a three-
necked flask and heated to 160 °C under mechanical stirring. After 3 h, the reaction 
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mixture was cooled to rt and poured into ice containing 20 mL concentrated HCl. The 
slurry was extracted with ethyl acetate, acidified with 1M HCl, washed with brine and 
dried over Na2SO4. The solvent was evaporated to give the crude product, which was 
washed with dichloromethane for removal of impurities, filtered and dried to give 3-
acetyl salicylic acids (77a-77e) as pale brown powders. 
 
2-acetoxy-3-acetyl-5-bromo-benzoic acid (77a). Yield 34%; mp 182-185 °C; 1H NMR 
(300 MHz, DMSO-d6): ? 8.06 (d, 1H, J = 2.7 Hz, ArH), 7.97 (d, 1H, J = 2.7 Hz, ArH), 
2.60 (s, 3H, COCH3); MS (ESI): m/z 258.7 [M?H]?. 
 
2-acetoxy-3-acetyl-5-fluoro-benzoic acid (77b). Yield 31%; mp 135-136 °C; 1H NMR 
(300 MHz, DMSO-d6): ? 7.78 (dd, 1H, J1 = 8.1 Hz, J2 = 3.3 Hz, ArH), 7.72 (dd, 1H, J1 = 
8.7 Hz, J2 = 3.3 Hz, ArH), 2.62 (s, 3H, COCH3); MS (ESI): m/z 196.7 [M?H]?.  
 
2-acetoxy-3-acetyl-5-chloro-benzoic acid (77c). Yield 32%; mp 160-163 °C; 1H NMR 
(300 MHz, DMSO-d6): ? 7.95 (d, 1H, J = 3.0 Hz, ArH), 7.85 (d, 1H J = 2.7 Hz, ArH), 
2.61 (s, 3H, COCH3); MS (ESI): m/z 212.7 [M?H]?. 
 
3-acetyl-5-bromo-2-hydroxy-benzonitrile (77d). Yield 26%; mp 75-77 °C; 1H NMR 
(300 MHz, DMSO-d6): ? 13.17 (s, 1H, OH), 8.41 (d, 1H, J = 2.4 Hz, ArH), 8.32 (d, 1H, 
 J = 2.4 Hz, ArH), 2.68 (s, 3H, COCH3); MS (ESI): m/z 239.6 [M?H]?. 
 
3-acetyl-2-hydroxy-5-methyl-benzoic acid (77e). Yield 28%; mp >180 °C (dec); 1H 
NMR  (300 MHz, DMSO-d6): ? 7.80 (s, 1H, ArH), 7.64 (s, 1H, ArH), 2.59 (s, 3H, 
COCH3), 2.24 (s, 3H, CH3); MS (ESI): m/z  192.7 [M?H]?. 
 
 
General procedure for the synthesis of chalcones (81-128). Equimolar amounts 
of aromatic aldehydes and intermediates 77a-77e were dissolved in 10 mL of ethanol, 
and 5 mL of 25% aq NaOH was added. More solvent was added to help stirring in cases 
of excessive precipitation. The reaction mixture was stirred at rt for 1-5 days or until 
completion of reaction (6 h for compound 127). The mixture was then poured into ice and 
acidified with 3M HCl to pH 4. The yellow precipitate formed was filtered and washed 
with water. The crude solid was purified by column chromatography (10-25% ethyl 
acetate/hexane) and/or recrystallized with ethanol or THF/water to yield pure chalcones. 
 
5-bromo-2-hydroxy-3-(3-phenyl-acryloyl)-benzoic acid (81). Yellow solid, yield 58%; 
mp 210-212 °C; 1H NMR (300 MHz, MeOH-d4): ? 8.08 (d, 1H, J = 2.4 Hz, ArH), 8.04 
(d, 1H, J = 2.7 Hz, ArH), 7.81 (dd, 2H, J1 = 7.5 Hz, J2 = 2.1 Hz, ArH), 7.68 (s, 2H, H-? 
and H-?), 7.42-7.44 (m, 3H, ArH); MS (ESI): m/z 346.6  [M?H]? ; HPLC: tR 7.71 min, 
purity 99.10%. 
 
5-bromo-3-[3-(2-chloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (82). Yellow solid, 
yield 60%; mp 211-214 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.08 (d, 1H, J = 2.7 Hz, 
ArH), 8.03 (d, 1H, J = 2.7 Hz, ArH), 8.01 (dd, 1H, J1 = 5.5 Hz, J2 = 1.5 Hz, ArH), 7.94 
(d, 1H, J = 15.9 Hz, H-?), 7.78 (d, 1H, J = 15.9 Hz, H-?), 7.59 (dd, 1H, J1 = 8.4 Hz, J2 = 
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1.8 Hz, ArH), 7.46 (ddd, 2H, J1 = 7.5 Hz, J2 = 7.2 Hz, J3 = 1.8Hz, ArH); MS (ESI): m/z 
380.6 [M?H]?; HPLC: tR  8.05 min, purity 98.82%. 
 
5-bromo-3-[3-(2-fluoro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (83). Yellow solid, 
yield 47%; mp 185-187 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.05 (d, 1H, J  = 2.1 Hz, 
ArH), 8.0 (s, 1H, H-?), 7.93 (t, 1H, J = 7.2 Hz, ArH), 7.74 (s, 1H, H-?), 7.73 (d, 1H, J = 
2.7 Hz, ArH), 7.51 (d, 1H, J = 6.9 Hz, ArH), 7.31 (dd, 1H,  J1 = 8.7 Hz, J2 = 7.2 Hz,  
ArH), 7.29 (t, 1H, J = 7.2, ArH); MS (ESI): m/z  364.7 [M?H]?; HPLC: tR  7.24 min, 
purity 99.39%.     
                           
5-bromo-3-[3-(3-chloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (84). Yellow solid, 
yield 56%; mp 234-236 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.06 (d, 1H, J = 2.7 Hz, 
ArH), 8.01 (d, 1H, J = 2.7 Hz, ArH), 7.92 (s, 1H, ArH), 7.76 (d, 1H, J = 15.9 Hz, H-?), 
7.75 (t, 1H, J = 7.8 Hz ArH), 7.63 (d, 1H, J = 15.9 Hz, H-?), 7.50 (dd, 2H, J1 = 8.7 Hz,  
J2 = 1.5 Hz, ArH); MS (ESI): m/z 380.6 [M?H]?; HPLC: tR 7.67 min, purity 99.30%. 
 
5-bromo-3-[3-(4-chloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (85). Yellow solid, 
yield 62%; mp 238-241 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.04 (d, 1H, J = 15.3 Hz, 
H-?), 7.91 (d, 1H, J = 2.4 Hz, ArH), 7.74 (d, 2H, J = 8.4 Hz, ArH), 7.71 (d, 1H, J = 3.0 
Hz, ArH), 7.58 (d, 1H, J = 15.3 Hz, H-?), 7.50 (d, 2H, J = 8.4 Hz, ArH); MS (ESI): m/z 
380.6 [M?H]?; HPLC: tR 8.1 min, purity 99.10%. 
 
5-bromo-3-[3-(4-bromo-phenyl)-acryloyl]-2-hydroxy-benzoic acid (86). Yellow solid, 
yield 34%; mp 236-238 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.06 (d, 1H, J = 2.7 Hz, 
ArH), 8.02 (d, 1H, J = 2.7 Hz, ArH), 7.74 (d, 2H, J = 8.7 Hz, ArH), 7.69 (s, 1H, H-?), 
7.67 (d, 2H, J = 8.7 Hz, ArH), 7.65 (s, 1H, H-?); MS (ESI): m/z 424.6 [M?H]?; HPLC: tR 
6.05 min, purity: 99.02%. 
 
5-bromo-2-hydroxy-3-[3-(4-iodo-phenyl)-acryloyl]-benzoic acid (87). Yellow solid, 
yield 48%; mp 237-239 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.06 (d, 1H,  J = 2.7 Hz, 
ArH), 8.01 (d, 1H, J = 2.7 Hz, ArH), 7.83 (d, 1H, J = 8.4 Hz, ArH), 7.73 (d, 1H, J = 15.9 
Hz, H-?), 7.69 (d, 1H, J = 8.4 Hz, ArH), 7.60 (d, 1H, J = 15.3 Hz, H-?), 7.59 (d, 2H J = 
8.4 Hz, ArH); MS (ESI): m/z 472.6 [M?H]?; HPLC: tR 6.46 min, purity 94.70%.  
 
5-bromo-3-[3-(2,4-dichloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (88). Yellow 
solid, yield 54%; mp 234-235 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.08 (d, 1H, J = 2.7 
Hz, ArH), 8.05 (d, 1H, J = 8.4 Hz, ArH), 8.05 (d, 1H, J = 2.7 Hz, ArH), 7.87 (d, 1H, J = 
15.9 Hz, H-?), 7.76 (d, 1H, J = 15.9 Hz, H-?), 7.76 (d, 1H, J = 2.1 Hz, ArH), 7.52 (dd, 
1H, J1 = 8.4 Hz, J2 = 1.5 Hz, ArH); MS (ESI): m/z 414.8 [M?H]?; HPLC: tR 10.91 min, 
purity 98.23%. 
 
5-bromo-3-[3-(2,3-dichloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (89). Yellow 
solid, yield 50%; mp 226-228 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.08 (d, 1H, J = 2.7 
Hz, ArH), 8.03 (d, 1H, J = 2.4 Hz, ArH), 7.98 (d, 1H, J = 8.1 Hz, ArH), 7.91 (s, 1H, H-
?), 7.77 (d, 1H, J = 15.6 Hz, H-?), 7.74 (d, 1H, J = 7.8 Hz, ArH), 7.46 (t, 1H, J = 7.8 Hz,  
ArH); MS (ESI): m/z 414.8 [M?H]?; HPLC: tR 6.46 min, purity: 99.08%.  
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5-bromo-3-[3-(2,3-dimethoxy-phenyl)-acryloyl]-2-hydroxy-benzoic acid (90). Yellow 
solid, yield 51%; mp 195-197 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.02 (s, 1H, ArH), 
7.92 (s, 1H, ArH), 7.86 (d, 1H, J = 16.2 Hz, H-?), 7.75 (d, 1H, J = 15.9 Hz, H-?), 7.40 
(dd, 1H, J1 = 5.7 Hz, J2 = 3.0 Hz, ArH), 7.13-7.15 (m, 2H, ArH), 3.83 (s, 3H, OCH3), 
3.77 (s, 3H, OCH3); MS (ESI): m/z 406.8 [M?H]?; HPLC: tR 7.03 min, purity: 99.7%. 
 
5-bromo-2-hydroxy-3-[3-(2,3,4-trimethoxy-phenyl)-acryloyl]-benzoic acid (91). 
Yellow solid, yield 49%; mp 194-195 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.05 (d, 1H, 
J = 1.8 Hz , ArH), 8.02 (d, 1H, J = 1.8 Hz ArH), 7.80 (d, 1H, J = 15.9 Hz, H-?), 7.63 (d, 
1H, J = 8.7 Hz, ArH), 7.10 (d, 1H, J = 15.9 Hz, H-?), 6.92 (d, 1H, J = 8.7 Hz, ArH), 3.87 
(s, 1H, OCH3), 3.84 (s, 1H, OCH3), 3.77 (s, 1H, OCH3); MS (ESI): m/z  436.8 [M?H]?; 
HPLC: tR 6.88 min, purity: 99.36%. 
 
5-bromo-3-[3-(2,5-dichloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (92). Yellow 
solid, yield 51%; mp 232-234 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.16 (d, 1H, J = 2.4 
Hz, ArH), 8.11 (d, 1H, J = 2.7 Hz, ArH), 8.0 (d, 1H, J = 2.7 Hz, ArH), 7.87 (s, 2H, H-? 
and H-?), 7.65 (d, 1H, J = 8.4 Hz, ArH),  7.57 (dd, 1H, J1 = 8.4 Hz, J2 = 2.4 Hz, ArH); 
MS (ESI): m/z  414.7 [M?H]?; HPLC: tR 8.03 min, purity 97.30%.  
 
5-bromo-3-[3-(2,6-dichloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (93). Yellow 
solid, yield 54%; mp 235-237 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.08 (d, 1H, J = 2.7 
Hz, ArH), 7.96 (d, 1H, J = 2.7 Hz, ArH), 7.79 (d, 1H, J = 16.5 Hz, H-?), 7.67 (d, 1H, J = 
16.5 Hz, H-?), 7.60 (d, 2H, J = 8.1 Hz, ArH), 7.41-7.46 (t, 1H, J = 8.7 Hz, ArH); MS 
(ESI): m/z 414.6 [M?H]?; HPLC: tR 7.96 min, purity 96.60%. 
 
5-bromo-3-[3-(3,4-dichloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (94). Yellow 
solid, yield 48%; mp 218-221 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.07 (d, 1H, J = 
15.9 Hz, H-?), 8.0 (s, 1H, ArH), 7.93 (d, 1H, J = 2.7 Hz, ArH), 7.72 (d, 1H, J = 2.7 Hz, 
ArH), 7.70 (d, 2H, J = 7.5 Hz), 7.56 (d, 1H, J = 15.9 Hz, H-?); MS (ESI): m/z  414.6 
[M?H]?; HPLC: tR 7.25 min, purity 97.0%. 
 
5-bromo-2-hydroxy-3-[3-(2,3,5-trichloro-phenyl)-acryloyl]-benzoic acid (95). Yellow 
solid, yield 54%; mp 212-214 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.10 (d, 1H, J = 2.4 
Hz, ArH), 8.08 (d, 1H, J = 2.7 Hz, ArH), 8.05 (d, 1H, J = 2.7 Hz, ArH), 7.96 (d, 1H, J = 
2.4 Hz, ArH), 7.84 (br s, 2H, H-? and H-?); MS (ESI): m/z 448.6 [M?H]?; HPLC: tR 7.41 
min, purity 98.21%. 
 
5-bromo-2-hydroxy-3-[3-(2,3,6-trichloro-phenyl)-acryloyl]-benzoic acid (96). Yellow 
solid, yield 57%; mp 220-223 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.07 (d, 1H, J = 2.7 
Hz, ArH), 7.97 (d, 1H, J = 2.4 Hz, ArH), 7.73 (d, 1H, J = 8.7 Hz, ArH), 7.71 (d, 1H, J = 
16.2 Hz, H-?), 7.61-7.64 (m, 2H, H-? and ArH); MS (ESI): m/z 448.6 [M?H]?; HPLC: tR 
7.13 min, purity 99.20%. 
 
5-chloro-3-[3-(4-chloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (97). Yellow solid,  
yield 43%; mp 213-215 °C; 1H NMR (300 MHz, DMSO-d6): ? 7.95 (d, 1H, J = 2.1 Hz, 
ArH), 7.93 (d, 1H, J = 2.7 Hz, ArH), 7.84 (dd, 2H, J1 = 6.9 Hz, J2 = 1.5 Hz, ArH), 7.66 
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(s, 2H, H-? and H-?), 7.51 (dd, 2H, J1 = 6.9 Hz, J2 = 1.5 Hz, ArH); MS (ESI): m/z 336.9 
[M?H]?; HPLC: tR 6.13 min, purity 99.55%. 
 
5-chloro-3-[3-(2,4-dichloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (98). Yellow 
solid, yield 48%; mp 248-250 °C; 1H NMR (300 MHz, MeOH-d4): ? 8.05 (d, 1H, J = 
15.9 Hz, H-?), 7.93 (d, 1H, J = 8.7 Hz, ArH), 7.84 (d, 1H, J = 2.4 Hz, ArH), 7.80 (d, 1H, 
J = 15.3 Hz, H-?), 7.73 (d, 1H, J = 2.1 Hz, ArH), 7.65 (d, 1H, J = 2.7 Hz, ArH), 7.52 (dd, 
1H, J1 = 8.4 Hz, J2 = 2.1 Hz, ArH);  MS (ESI): m/z 370.8 [M?H]?; HPLC: tR 6.76 min, 
purity 99.14%. 
 
5-chloro-3-[3-(2,3-dichloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (99). Yellow 
solid, yield 41%; mp 250-252 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.10 (d, 1H, J = 
15.3 Hz, H-?), 7.85-7.89 (m, 3H, H-? and ArH), 7.70 (d, 1H, J = 7.2 Hz, ArH), 7.62 (s, 
1H, ArH), 7.45 (t, 1H, J = 7.5 Hz, ArH); MS (ESI): m/z 370.8 [M?H]?; HPLC: tR 6.06 
min, purity 96.61%. 
 
5-chloro-3-[3-(2,5-dichloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (100). Yellow 
solid, yield 42%; mp 247-249 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.20 (d, 1H, J = 1.2 
Hz, ArH), 8.04 (s, 2H, H-? and ArH), 7.90 (s, 2H, H-? and ArH), 7.67 (d, 1H, J = 8.4 Hz, 
ArH), 7.61 (dd, 1H, J1 = 8.4 Hz, J2 = 1.5 Hz, ArH);  MS (ESI): m/z 370.7 [M?H]?; 
HPLC: tR 8.39 min, purity 99.0%. 
 
5-chloro-2-hydroxy-3-[3-(2,3,5-trichloro-phenyl)-acryloyl]-benzoic acid (101). 
Yellow solid, yield 37%; mp 235-237 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.05 (d, 1H,  
J  = 15.9 Hz, H-?), 7.91 (d, 2H, J = 1.2 Hz, ArH), 7.82 (d, 1H, J = 3.0 Hz, ArH), 7.75 (d, 
1H, J = 15.6 Hz, H-?), 7.60 (d, 1H, J = 2.7 Hz, ArH); MS (ESI): m/z 404.6 [M?H]?; 
HPLC: tR  7.18 min, purity 98.81%. 
 
5-chloro-2-hydroxy-3-[3-(2,3,6-trichloro-phenyl)-acryloyl]-benzoic acid (102). 
Yellow solid, yield 49%; mp 229-231 °C; 1H NMR (300 MHz, DMSO-d6): ? 7.99 (d, 1H, 
J = 16.2 Hz, H-?), 7.86 (d, 1H, J = 2.1 Hz, ArH), 7.71 (d, 1H, J = 2.7 Hz, ArH), 7.69 (d, 
1H, J = 7.8 Hz, ArH), 7.65 (d, 1H, J = 8.4 Hz, ArH), 7.60 (d, 1H, J = 16.2 Hz, H-?); MS 
(ESI): m/z 404.6 [M?H]?; HPLC: tR 6.58 min, purity 95.66%. 
 
5-chloro-3-[3-(3,4-dichloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (103). Yellow 
solid, yield 54%; mp >240 °C (dec); 1H NMR (300 MHz, DMSO-d6): ? 8.05 (d, 1H, J = 
15.9 Hz, H-?), 7.99 (s, 1H, ArH), 7.80 (d, 1H, J = 3.0 Hz, ArH), 7.71 (d, 2H, J = 6.0 Hz, 
ArH), 7.58 (d, 1H, J = 3.0 Hz, ArH), 7.56 (d, 1H, J = 15.9 Hz, H-?); MS (ESI): m/z 
370.8 [M?H]?; HPLC: tR 6.78 min, purity 99.60%. 
 
3-[3-(4-chloro-phenyl)-acryloyl]-5-fluoro-2-hydroxy-benzoic acid (104). Yellow solid, 
yield 56%; mp 198-200 °C; 1H NMR (300 MHz, DMSO-d6): ? 7.91 (d, 1H, J = 15.9 Hz, 
H-?), 7.60 (d, 1H, J = 15.9 Hz, H-?), 7.68 (dd, 1H, J1 = 8.4 Hz, J2 = 3.3 Hz, ArH), 7.76 
(d, 2H, J = 8.4 Hz, ArH), 7.49 (d, 2H, J = 8.7 Hz, ArH), 7.54 (dd, 1H, J1 = 9.3 Hz, J2 =  
3.3 Hz, ArH); MS (ESI): m/z 318.8 [M?H]?; HPLC: tR 7.11 min, purity 99.11%. 
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3-[3-(2,4-dichloro-phenyl)-acryloyl]-5-fluoro-2-hydroxy-benzoic acid (105). Yellow 
solid, yield 41%; mp 260-262 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.12 (d, 1H,  J = 
15.6 Hz, H-?), 7.93 (d, 1H, J = 8.4 Hz, ArH), 7.81 (d, 1H, J = 15.9 Hz, H-?), 7.74 (d, 1H, 
J = 2.1 Hz, ArH), 7.65 (dd, 1H, J1 = 8.7 Hz, J2 = 3.3 Hz, ArH), 7.52 (dd, 1H, J1 = 8.4 Hz, 
J2 = 2.1 Hz, ArH), 7.43 (dd, 1H, J1 = 9.3 Hz, J2 = 3.3 Hz, ArH); MS (ESI): m/z 352.8 
[M?H]?; HPLC: tR 6.51 min, purity 99.5%.  
 
3-[3-(2,3-dichloro-phenyl)-acryloyl]-5-fluoro-2-hydroxy-benzoic acid (106). Yellow 
solid, yield 47%; mp 222-224 °C; 1H NMR (500 MHz, DMSO-d6): ? 7.94 (d, 1H, J = 7.8 
Hz, ArH), 7.90 (s, 2H, H-? and H-?), 7.77 (dd, 1H, J1 = 8.5 Hz, J2 = 3.0 Hz, ArH), 7.73 
(d, 1H, J = 8.0 Hz, ArH), 7.46 (t, 1H, J = 8.0 Hz, ArH), 7.66 (dd, 1H, J1 = 9.0 Hz, J2 = 
2.5 Hz, ArH); MS (ESI): m/z 352.8 [M?H]?; HPLC: tR 5.68 min, purity 97.20%. 
 
3-[3-(2,5-dichloro-phenyl)-acryloyl]-5-fluoro-2-hydroxy-benzoic acid (107). Yellow 
solid, yield 59%; mp 238-240 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.07 (d, 1H, J = 
15.9 Hz, H-?), 7.93 (d, 1H, J = 2.4 Hz, ArH), 7.76 (d, 1H, J = 15.9 Hz, H-?), 7.66 (dd, 
1H, J1 = 8.4 Hz, J2 = 3.6 Hz, ArH), 7.60 (d, 1H, J = 8.7 Hz, ArH), 7.52 (dd, 1H, J1 =8.7 
Hz, J2 = 2.4 Hz, ArH), 7.42 (dd, 1H, J1  = 9.3 Hz, J2 = 3.6 Hz, ArH); MS (ESI): m/z 
352.8 [M?H]?; HPLC: tR 6.02 min, purity 98.43%. 
 
5-fluoro-2-hydroxy-3-[3-(2,3,5-trichloro-phenyl)-acryloyl]-benzoic acid (108). 
Yellow solid, yield 53%; mp 231-233 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.02 (d, 1H, 
J = 2.4 Hz, ArH), 7.95 (d, 1H, J = 15.9 Hz, H-?), 7.92 (d, 1H, J = 2.4 Hz, ArH), 7.79 (d, 
1H, J = 15.6 Hz, H-?), 7.74 (dd, 1H, J1 = 8.4 Hz, J2 = 3.3 Hz, ArH), 7.64 (dd, 1H, J1 = 
9.0 Hz, J2 = 3.3 Hz, ArH); MS (ESI): m/z 388.6 [M?H]?; HPLC: tR 8.11 min, purity 
97.86%. 
 
5-fluoro-2-hydroxy-3-[3-(2,3,6-trichloro-phenyl)-acryloyl]-benzoic acid (109). 
Yellow solid, yield 46%; mp 235-237 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.11 (d, 1H, 
J = 16.2 Hz, H-?), 7.70 (d, 1H, J = 8.7 Hz, ArH), 7.62 (d, 1H, J = 8.7 Hz, ArH), 7.58 (d, 
1H, J = 16.2 Hz, H-?), 7.66 (dd, 1H, J1 = 8.4 Hz, J2  = 3.6 Hz, ArH), 7.44 (dd, 1H, J1 = 
9.3 Hz, J2 = 3.6 Hz, ArH); MS (ESI): m/z 388.6 [M?H]?; HPLC: tR 7.57 min, purity 
97.57%. 
 
5-bromo-3-[3-(3,5-dimethyl-phenyl)-acryloyl]-2-hydroxy-benzoic acid (110). Yellow 
solid, yield 51%; mp 223-225 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.06 (d, 1H, J = 2.7 
Hz, ArH), 7.99 (d, 1H, J = 1.8 Hz, ArH), 7.61 (d, 1H, J = 16.5 Hz, H-?), 7.58 (d, 1H, J = 
16.5 Hz, H-?), 7.40 (s, 2H, Hz, ArH), 7.10 (s, 1H, ArH), 2.32 (s, 6H, CH3); MS (ESI): 
m/z 374.9 [M?H]?; HPLC: tR 6.59 min, purity 99.0%. 
 
5-bromo-3-[3-(2-chloro-3,4-dimethoxy-phenyl)-acryloyl]-2-hydroxy-benzoic acid 
(111). Yellow solid, yield 21%; mp 217-220 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.05 
(d, 1H, J = 2.7 Hz, ArH), 8.00 (d, 1H, J = 2.7 Hz, ArH), 7.90 (d, 1H, J = 15.6 Hz, H-?), 
7.81 (d, 1H, J = 8.7 Hz, ArH), 7.68 (d, 1H, J = 15.6 Hz, H-?), 7.16 (d, 1H, J = 8.7 Hz, 
ArH), 3.90 (s, 3H, OCH3), 3.77 (s, 3H, OCH3); MS (ESI): m/z 440.8 [M?H]?; HPLC: tR  
6.46 min, purity 99.0%. 
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5-bromo-3-[3-(2-fluoro-4,5-dimethoxy-phenyl)-acryloyl]-2-hydroxy-benzoic acid 
(112). Yellow solid, yield 32%; mp 193-195 °C; 1H NMR (300 Hz, DMSO-d6): ? 8.03 (d, 
1H, J = 2.7 Hz, ArH), 7.93 (d, 1H, J = 2.7 Hz, ArH), 7.66 (s, 2H, H-? and H-?), 7.38 (d, 
1H, J = 7.2 Hz, ArH), 7.00 (d, 1H, J = 12.3 Hz, ArH), 3.84 (s, 3H, OCH3), 3.82 (s, 3H,  
OCH3); MS (ESI): m/z 424.8 [M?H]?; HPLC: tR 7.19 min, purity 97.51%. 
 
3-[3-(2-benzyloxy-phenyl)-acryloyl]-5-bromo-2-hydroxy-benzoic acid (113). Yellow 
solid, yield 26%; mp > 165 °C (dec);  1H NMR (300 MHz, MeOH-d4): ? 7.92-7.95 (m, 
2H, H-? and ArH), 7.72 (d, 1H, J = 7.5 Hz, ArH), 7.65 (d, 1H, J = 2.7 Hz, ArH), 7.47 (d, 
2H, J = 7.2 Hz, ArH), 7.30-7.42 (m, 5H, H-?, and ArH), 7.20 (d, 1H, J = 8.1 Hz, ArH), 
7.0 (t, 1H, J = 7.5 Hz, ArH), 5.22 (s, 2H, CH2); MS (ESI): m/z 452.8 [M?H]?; HPLC: tR 
7.83 min, purity 95.65%.  
 
5-bromo-3-{3-[3-(4-chloro-phenoxy)-phenyl]-acryloyl}-2-hydroxy-benzoic acid 
(114). Yellow solid, yield 42%; mp 162-165 °C; 1H NMR (300 MHz, DMSO-d6): ? 7.94 
(s, 2H, ArH), 7.74 (d, 1H, J = 6.9 Hz, ArH), 7.70 (d, 1H, J = 15.9 Hz, H-?), 7.40-7.46 (m, 
6H, H- ? and ArH), 7.20 (d, 1H, J = 7.8 Hz, ArH), 7.0 (t, 1H, J = 6.9 Hz, ArH); (ESI): 
m/z 472.6 [M?H]?; HPLC: tR 5.86 min, purity 96.8%. 
 
5-bromo-3-{3-[4-(4-chloro-phenoxy)-phenyl]-acryloyl}-2-hydroxy-benzoic acid 
(115). Yellow solid, yield 35%; mp 219-220 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.06 
(d, 1H, J = 2.1 Hz, ArH), 8.02 (d, 1H, J = 2.1 Hz, ArH), 7.84 (d, 2H, J = 8.4 Hz, ArH), 
7.67 (d, 1H, J = 15.9 Hz, H-?), 7.59 (d, 1H, J = 15.9 Hz, H-?), 7.48 (d, 2H, J = 8.7 Hz, 
ArH), 7.13 (d, 2H, J = 8.7 Hz, ArH), 7.07 (d, 2H, J = 8.7 Hz, ArH); MS (ESI): m/z 472.6 
[M?H]?; HPLC: tR 7.23 min, purity 99.44%. 
 
5-bromo-2-hydroxy-3-(3-thiophen-3-yl-acryloyl)-benzoic acid (116). Yellow solid, 
yield 54%; mp 207-210 °C; 1H NMR (300 MHz, DMSO-d6): ? 7.97 (s, 2H, ArH), 7.75 
(d, 1H, J = 15.9 Hz, H-?), 7.65 (s, 1H, ArH), 7.61 (s, 1H, ArH), 7.58 (d, 1H, J = 15.6 Hz, 
H-?), 7.48 (d, 1H, J = 4.2 Hz, ArH); MS (ESI): m/z  352.6 [M?H]?; HPLC: tR 6.91 min, 
purity 99.71%.  
 
5-bromo-3-[3-(3-cyclopentyloxy-4-methoxy-phenyl)-acryloyl]-2-hydroxy-benzoic 
acid (117). Yellow solid, yield 31%; mp 233-235 °C; 1H NMR (300 MHz, MeOH-d4): ? 
7.91 (d, 1H, J = 2.7 Hz, ArH), 7.82 (d, 1H, J = 15.6 Hz, H-?), 7.67 (d, 1H, J = 3.0 Hz, 
ArH), 7.59 (d, 1H, J = 15.9 Hz, H-?), 7.26 (d, 1H, J = 8.7 Hz, ArH), 7.25 (s, 1H, ArH), 
6.99 (d, 1H, J = 8.1 Hz, ArH), 4.86 (p, 1H, J = 5.7 Hz, cyclopentyl), 3.79 (s, 3H, CH3) 
1.87-1.92 (m, 2H, cyclopentyl), 1.66-1.72 (m, 4H, cyclopentyl), 1.57-1.60 (m, 2H, 
cyclopentyl); MS (ESI): m/z 460.8 [M?H]?; HPLC: tR 7.19 min, purity 97.51%.  
 
5-bromo-3-[3-(2-ethoxy-naphthalen-1-yl)-acryloyl]-2-hydroxy-benzoic acid (118). 
Yellow solid, yield 23%; mp 216-218 °C; 1H NMR (300 MHz, MeOH-d4): ? 8.48 (d, 1H, 
J = 15.9 Hz, H-?), 8.30 (d, 1H, J = 8.4 Hz, ArH), 8.19 (d, 1H, J = 2.7 Hz, ArH), 8.17 (d, 
1H, J = 15.9 Hz, H-?), 7.92 (d, 1H, J = 9.0 Hz, ArH), 7.88 (d, 1H, J = 2.7 Hz, ArH), 7.84 
(d, 1H, J = 8.4 Hz, ArH), 7.55 (t, 1H, J = 7.2 Hz, ArH), 7.37-7.44 (m, 2H, ArH), 4.33 (q, 
2H, J = 6.9 Hz, CH2), 1.55 (t, 3H, J = 6.9 Hz, CH3); MS (ESI): m/z 440.9 [M?H]?;  
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HPLC: tR 8.53 min, purity 95.0%. 
 
5bromo-2-hydroxy-3-[3-(6-methoxy-naphthalen-2-yl)-acryloyl]-benzoic acid (119). 
Yellow solid, yield 15%; mp 239-241 °C; 1H NMR (300 Hz, MeOH-d4): ? 8.17 (d, 1H,  
J = 2.4 Hz, ArH), 8.01 (s, 1H, H-?), 7.86 (d, 1H, J = 7.9 Hz, ArH), 7.84 (d, 2H, J = 8.1 
Hz, ArH), 7.83 (d, 1H, J = 2.4 Hz, ArH), 7.80 (s, 2H, H-?, and ArH),  7.26 (d, 1H, J = 
2.4 Hz, ArH), 7.16 (dd, 1H, J1 = 8.7 Hz, J2 = 2.4 Hz, ArH), 3.93 (s, 3H, OCH3); MS 
(ESI): m/z 426.8 [M?H]?; HPLC: tR 6.07 min, purity 98.93%. 
 
3-(3benzo[b]thiophen-5-yl-acryloyl)-5-bromo-2-hydroxy-benzoic acid (120). Yellow 
solid, yield 21%; mp 235-237 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.21 (s, 1H, ArH), 
8.1 (d, 1H, J = 15.9 Hz, H-?), 8.0 (s, 1H, ArH), 7.92 (d, 1H, J = 2.7 Hz, ArH), 7.82 (d, 
1H, J = 5.4 Hz, ArH), 7.73 (d, 1H, J = 15.9, H-?), 7.72 (d, 1H, J = 3 Hz, ArH), 7.72 (s, 
1H, ArH), 7.53 (d, 1H, J = 5.1 Hz, ArH); MS (ESI): m/z  402.8 [M?H]?; HPLC: tR 5.53 
min, purity 98.31%. 
 
5-bromo-3-[3-(2-furan-2-yl-phenyl)-acryloyl]-2-hydroxy-benzoic acid (121). Yellow 
solid, yield 36%; mp 208-209 °C; 1H NMR (300 MHz, DMSO-d6): ? 7.92 (m, 3H, H-? 
and ArH), 7.87 (s, 1H, H-?), 7.81 (d, 1H, J = 2.7 Hz, ArH), 7.70 (s, 1H, ArH), 7.68 (d, 
1H, 9.6 Hz, ArH), 7.48 (t, 2H, J = 7.5 Hz, ArH), 6.66 (s, 1H, ArH), 6.63 (s,1H, ArH); MS 
(ESI): m/z 412.8 [M?H]?; HPLC: tR 5.77 min, purity 95.02%. 
 
5-bromo-3-[3-(6-chloro-benzo[1,3]dioxol-5-yl)-acryloyl]-2-hydroxy-benzoic acid 
(122). Yellow solid, yield 18%; mp 228-231 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.10 
(s, 1H, ArH), 8.07 (s, 1H, ArH), 7.90 (d, 1H, J = 15 Hz, H-?), 7.66 (s, 1H, ArH), 7.63 (d, 
1H, J = 14.7 Hz, H-?), 7.21 (s, 1H, ArH), 6.16 (s, 2H, CH2); MS (ESI): m/z 424.6 
[M?H]?; HPLC: tR 7.82 min, purity 99.0%. 
 
5-bromo-2-hydroxy-3-[3-(3-trifluoromethoxy-phenyl)-acryloyl]-benzoic acid (123). 
Yellow solid, yield 44 %; mp 217-219 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.07 (d, 
1H, J = 2.7 Hz, ArH), 8.03 (d, 1H, J = 2.7 Hz, ArH), 7.80-7.84 (br s, 2H, H-? and H-?), 
7.72 ( s, 1H, ArH), 7.70 (s, 1H, J = 4.0 Hz, ArH), 7.58 (t, 1H, J = 7.8 Hz, ArH), 7.45 (d, 
1H, J = 7.5 Hz, ArH); MS (ESI): m/z  430.8 [M?H]?; HPLC: tR 6.06 min, purity 99.30%. 
 
5-bromo-2-hydroxy-3-[3-(3-nitro-phenyl)-acryloyl]-benzoic acid (124). Yellow solid, 
yield 62%; mp 200-202 °C; 1H NMR (500 MHz, DMSO-d6): ? 8.62 (s, 1H, ArH), 8.26 (s, 
2H, ArH), 8.07 (s, 1H, H-?), 8.02 (s, 1H, H-?), 7.81 (d, 2H, J = 7.0 Hz, ArH), 7.75 (t, 1H, 
J = 7.0 Hz, ArH); MS (ESI): m/z 391.8 [M?H]?; HPLC: tR 11.47 min, purity 95.59%. 
 
5-bromo-3-[3-(3-bromo-phenyl)-acryloyl]-2-hydroxy-benzoic acid (125). Yellow 
solid, yield 31%; mp 235-237 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.0 (d, 1H, J = 15.9 
Hz, H-?), 7.92 (d, 1H, J = 2.7 Hz, ArH), 7.90 (s, 1H, ArH), 7.72 (d, 1H, J = 6.6 Hz, 
ArH), 7.70 (d, 1H, J = 2.4 Hz, ArH), 7.59 (d, 1H, J = 8.4 Hz, ArH), 7.55 (d, 1H, J = 15.9  
Hz, H-?), 7.39 (t, 1H, J = 7.8 Hz, ArH); MS (ESI): m/z 424.6 [M?H]?; HPLC: tR 6.14  
min, purity 98.81%. 
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5-bromo-3-[3-(3-fluoro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (126). Yellow  
solid, yield 59%; mp 190-193 °C; 1H NMR (500 MHz, DMSO-d6): ? 8.0 (d, 1H, J = 2.0 
Hz, ArH), 7.93 (s, 1H, ArH), 7.80 (d, 1H, J = 16.0 Hz, H-?), 7.60-7.77 (m, 3H, H-? and 
ArH), 7.48 (d, 1H, J = 6.5 Hz, ArH), 7.28 (d, 1H, J = 8.0 Hz, ArH); MS (ESI): m/z 364.7 
[M?H]?; HPLC: tR 5.39 min, purity 92.5%. 
 
5-bromo-2-hydroxy-3-[3-(2,3,6--trichloro-phenyl)-acryloyl]-benzonitrile (127). 
Orange solid, yield 74%; mp 139-141 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.34 (d, 1H, 
J = 16.2 Hz, H-?), 7.69 (d, 1H, J = 3.0 Hz, ArH), 7.66 (d, 1H, J = 9.0 Hz, ArH), 7.58 (d, 
1H, J = 8.7 Hz, ArH), 7.46 (d, 1H, J = 2.4 Hz, ArH), 7.43 (d, 1H, J = 16.2 Hz, H-?); MS 
(ESI): m/z  431.6 [M?H]?; HPLC: tR 6.37 min, purity: 95.69%. 
  
2-hydroxy-5-methyl-3-[3-(2,3,6--trichloro-phenyl)-acryloyl]-benzoic acid (128). 
Yellow solid, yield 58.5%; mp 205-208 °C; 1H NMR (300 MHz, DMSO-d6): ? 7.87 (s, 
1H, ArH), 7.74 (s, 1H, ArH), 7.70 (d, 1H, J = 8.7 Hz, ArH), 7.59-7.64 (m, 3H, H-?, H-? 
and ArH), 2.29 (s, 3H, CH3); MS (ESI): m/z 384.8 [M?H]?; HPLC: tR 6.01 min, purity 
97.84%. 
 
 
General procedure for the synthesis of chalcones (129 -130). A similar 
procedure to the one mentioned above for the synthesis of chalcones (81-128) was 
followed (Scheme 1-2) with appropriate aromatic aldehydes starting materials 79, 80 and 
commercially available 1-(5-bromo-2-hydroxy-3-nitro-phenyl)-ethanone, 78f to 
synthesize chalcones 129 and 130. 
 
1-(5-bromo-2-hydroxy-3-nitro-phenyl)-3-(2,3,5-trichloro-phenyl)-propenone (129). 
Yellow solid, yield 65%; mp 175-178 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.13 (d, 1H, 
J = 15.6 Hz, H-?), 7.76 (d, 1H, J = 15.9 Hz, H-?), 8.05 (d, 1H, J = 2.7 Hz, ArH), 8.0 (d, 
2H, J = 2.4 Hz, ArH), 7.92 (d, 1H, J = 2.4 Hz, ArH); MS (ESI): m/z 451.8 [M?H]?; 
HPLC: tR 5.46 min, purity 97.30%. 
 
1-(5-bromo-2-hydroxy-3-nitro-phenyl)-3-(2,3,6-trichloro-phenyl)-propenone (130). 
Yellow solid, yield 58%; mp 153-154 °C; 1H NMR (500 MHz, DMSO-d6): ? 8.32 (s, 1H, 
ArH), 8.24 (s, 1H, ArH), 7.77 (d, 1H, J = 16.5 Hz, H-?), 7.75 (d, 1H, J = 9.0 Hz, ArH), 
7.65 (d, 1H, J = 15.0 Hz, H-?), 7.63 (d, 1H, J = 8.0 Hz, ArH); MS (ESI): m/z 451.8 
[M?H]?; HPLC: tR 6.53 min, purity 98.0%. 
 
2-hydroxyl-3-(3-phenylpropyl) benzoic acid (131). Compound 81 (0.05 g, 0.195 mmol) 
was dissolved in ethanol (10 mL) and Pd/C (10 mol%, 5 mg) was added. The resulting 
solution was stirred under hydrogen at atmospheric pressure for 10 h at rt. After the 
reaction was complete, the reaction mixture was filtered through celite, and evaporated to 
dryness. The resulting crude solid was purified by preparative TLC to give a white solid, 
yield 72%; mp 125-127 °C; 1H NMR (300 MHz, DMSO-d6): ? 11.66 (s,1H, OH), 7.67 
(dd, 1H, J1 = 7.8 Hz, J2 = 1.5 Hz, ArH), 7.39 (dd, 1H, J1 = 7.2 Hz, J2 = 1.5 Hz, ArH), 
7.16-7.30 (m, 5H, ArH), 6.85 (t, 1H, J = 7.8 Hz, ArH), 2.62 (t, 4H, J = 7.2 Hz, CH2), 
1.81-1.91 (m, 2H, CH2); MS (ESI): m/z 254.8 [M?H]?; HPLC: tR 7.61 min, purity 98 %. 
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3-[3-(2,5-dichloro-phenyl)-propionyl]-5-fluoro-2-hydroxy-benzoic acid (132). 
Compound 107 (0.2 g, 0.563 mmol) was dissolved in methanol (10 mL) and Pd/C (10 
mol %, 20 mg) was added. The resulting solution was stirred under hydrogen at 
atmospheric pressure for 2 h at room temperature. After the reaction was complete, the 
reaction mixture was filtered through celite, and evaporated to dryness. The resulting 
crude solid was recrystallized from ethanol to give a white solid, yield 43%; mp 163- 
164 °C; 1H NMR (300 MHz, DMSO-d6): ? 7.79 (d, 1H, J = 8.4 Hz, ArH), 7.74 (d, 1H, 
 J = 9.0, ArH), 7.49 (s, 1H, ArH), 7.45 (d, 1H, J = 8.7 Hz, ArH), 7.31 (d, 1H, J = 8.1 Hz, 
ArH), 3.39 (t, 2H, J = 6.9 Hz, CH2), 3.02 (t, 2H, J = 6.9 Hz, CH2); MS (ESI): m/z 356.9 
[M?H]?; HPLC: tR 8.34 min, purity 96.36%. 
 
 
Biological Assays  
 
 
Materials, chemicals, and enzymes. All compounds were dissolved in DMSO 
and the stock solutions were stored at -20 °C. ?[32P]-ATP was purchased from either 
Amersham Biosciences or ICN. The expression systems for wild-type IN were a 
generous gift from Dr. Robert Craigie, Laboratory of Molecular Biology, NIDDK, NIH, 
Bethesda, MD. Cell lines were obtained from American Type Culture Collection (ATCC, 
Rockville, MD). 
  
 
 Preparation of oligonucleotide substrates. The oligonucleotides 21top, 5?-
GTGTGGAAAATCTCTAGCAGT-3?, and 21bot, 5?-ACTGCTAGAGATTTTCCACAC-
3?, were purchased from the Norris Cancer Center Microsequencing Core Facility 
(University of Southern California) and purified by UV shadowing on polyacrylamide 
gel. To analyze the extent of 3?-P  and ST using 5?-end labeled substrates, 21top was 
5?-end labeled using T4 polynucleotide kinase (Epicentre, Madison, WI) and ?[32P]-ATP 
(Amersham Biosciences or ICN). The kinase was heat-inactivated and 21-bot was added 
in 1.5M excess. The mixture was heated at 95 °C, allowed to cool slowly to rt, and run 
through a G25 mini spin column (USA Scientific) to separate double-stranded 
oligonucleotide from unincorporated material. 
 
 
 Integrase assays. To determine the extent of 3?-P and ST, wild-type IN was 
preincubated at a final concentration of 200 nM with the inhibitor in reaction buffer (50 
mM NaCl, 1 mM HEPES, pH 7.5, 50 μM EDTA, 50 μM dithiothreitol, 10% glycerol 
(w/v), 7.5 mM MnCl2, 0.1 mg/mL bovine serum albumin, 10 mM 2-mercaptoethanol, 
10% dimethylsulfoxide, and 25 mM MOPS, pH 7.2) at 30 °C for 30 min. An aliquot 
(5μL) was electrophoresed on a denaturing 20% polyacrylamide gel (0.09 M Tris- borate, 
pH 8.3, 2 mM EDTA, 20% acrylamide, and 8M urea). Gels were dried, exposed in a 
phosphorImager cassette, and analyzed using a Typhoon 8610 Variable Mode Imager 
(Amersham Biosciences) and quantitated using ImageQuant 5.2. Percent inhibition (%I) 
was calculated using (Equation 3-1); 
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                                      ??? ? ??? ? ?? ? ?? ? ???? ? ??                                  (Eq. 3-1) 
 
where C, N, and D are the fractions of 21-mer substrate converted to 19-mer (3?-P 
product) or ST products for DNA alone, DNA plus IN, and IN plus compound, 
respectively. The IC50 values were determined by plotting the logarithm of compound 
concentration versus percent inhibition to obtain the concentration that produced 50% 
inhibition. 
 
 
Anti-HIV-1 activity assay. The testing of the ability of potent compounds to 
inhibit HIV replication in cell culture was done according to a previously reported 
procedure.182 PBMC (107 cells/T25flask) were stimulated with phytohemagglutinin for 3 
days and infected with a wild-type HIV-1 strain (strain LAI) at 100 50% tissue culture 
infective doses, as described previously.182 The cultures were kept for 5 days in the 
presence of test compounds at serial 1-log dilutions. Subsequently, human PBMC were 
removed from the culture supernatant by centrifugation (400g, 10 min, 4 °C). This 
clarified supernatant was tested by a reverse transcriptase assay. 
 
 
Cytotoxicity assays. The cytotoxicity of compounds was evaluated using 
uninfected PBMC and CEM leukemia cells according to a previous method.183 PBMC 
were obtained from whole blood of healthy individuals, while CEM were obtained from 
the ATCC (Rockville, MD). The PBMC and CEM cells were cultured in the presence or 
absence of compound for 6 days. After this time period, cells were stained with Trypan 
blue dye, and counted for cell proliferation and viability according to the previously 
reported procedure.184 
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CHAPTER 4.   SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-KETO 
SALICYLAMIDE AS NOVEL HIV-1 INTEGRASE INHIBITORS* 
 
 
Introduction 
 
 The benzyl carboxamide group was recognized as an important moiety with the 
discovery of naphthyridine carboxamides as a new class of HIV-IN inhibitors. Examples 
include L-870,810 and L-870,812 (Figure 1-20). Further efforts led to the development 
of the pyrimidinone carboxamide class containing the approved drug raltegravir.51 The 
carboxamide moiety though not an absolute requirement is believed to give a 
conformationally favorable orientation to the halogenated benzyl group present in potent 
inhibitors to bind into the cavity formed by protein-DNA interface. In this chapter, the 
?,?-unsaturated moiety of our synthesized chalcone  derivatives (described in Chapter 3) 
was modified to an amide functionality to synthesize a novel series of compounds, 
salicylic acid 3-carboxamides.  
 
 
Chemistry  
 
The synthesis of target compound 149 is shown in Scheme 4-1. Commercially 
available 5-bromo salicylic acid (133a) was first formylated with chloroform at the 2-
position (ortho) by the Reimer-Tiemann reaction185 to yield the aldehyde intermediate 
134. In the next step, intermediate 134 was coupled with 4-fluorobenzyl amine to afford 
intermediate 135 which was subsequently subjected to oxidation with KMnO4 to yield 
compound 149.186 
 
 Low yield of the formylation step (8-10%), and a potential side product (Schiffs 
base) in the coupling reaction prompted us to employ an alternate synthetic route 
(Scheme 4-2). Thus, for the synthesis of compounds 150-152, 3-formyl salicylaldehyde 
(133b) was used as the starting material, which was brominated with N-bromo 
succinimide (NBS) in acetonitrile to afford intermediate 134 in higher (90%) yields.187 
Next, the sequence of subsequent steps was altered in that the intermediate 134 was first 
subjected to KmNO4 oxidation to form a di-acid derivative 136. Intermediate 136 was 
then coupled with equimolar amounts of the appropriate amines in the presence of HOBt 
and EDCI to form the desired amides 150 and 151.188 For the synthesis of compound 152, 
the di-acid intermediate 136 was treated with excess of 4-fluorobenzyl amine (2.2 eq) 
under similar conditions. 
 
For the synthesis of amide compounds 153-156, shown in Scheme 4-3, 
commercially available acids (137–140) were subjected to HOBt/EDCI coupling with   
 
* Portions of this chapter adapted with permission. Sharma, H.; Patil, S.; Sanchez, T. W.; 
Neamati, N.; Schinazi, R. F.; Buolamwini, J. K. Synthesis, biological evaluation and 3D-
QSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1 
integrase inhibitors. Bioorg. Med. Chem. 2011, 19, 2030-2045.179
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Scheme 4-1. Synthesis of compound 149 
 
 
 
 
 
Reagents and conditions: (a) CHCl3, NaOH, H2O, reflux, 48 h; yield 13% (b) 4-F 
benzylamine, EDCI, HOBt, Et3N, rt, overnight; yield 41% (c) KMnO4, H2O/Pyridine,  
90 °C, overnight; yield 80%. 
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Scheme 4-2. Synthesis of compounds 150-152 
 
 
 
 
 
Reagent and conditions: (a) NBS, CH3CN, rt, 3 h; yield 90% (b) KMnO4, H2O/Pyridine, 
90 °C , overnight; 80% (c) amines (0.90 eq), EDCI, HOBt, Et3N, rt, overnight; yields 34-
62% (d) 4-F benzylamine (2.2 eq), EDCI, HOBt, Et3N, rt, overnight; yield 48%. 
  
 75 
Scheme 4-3. Synthesis of compounds 153-156 
 
 
 
 
Reagent and conditions: (a) 4-F benzylamine, EDCI, HOBt, Et3N, rt, overnight; yields 
53-76%.  
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4-fluoro benzyl amine. The synthesis of compound 157 was performed according to 
Scheme 4-4. The commercially available 5-acetyl-2-hydroxy-3-methoxybenzoic acid 
(141) was first converted to the corresponding amide with standard HOBt/EDCI 
coupling. The methoxy substituent in amide intermediate (142) was then demethylated 
using BBr3 in DCM at 0 °C.189 The hydroxyl intermediate (143) was then reacted with 
benzaldehyde, using aq. sodium hydroxide by Aldol condensation to afford the desired 
final ?,?-unsaturated compound 157. The synthesis of compound 158 was achieved using 
Scheme 4-5 in which the 3-acetyl-5-bromo-2-hydroxybenzoic acid intermediate (78a), 
which was synthesized in Chapter 3, was subjected to routine HOBt/EDCI amide 
coupling followed by an Aldol condensation. The synthesis of compound 159, shown in 
Scheme 4-6, was achieved according to a method previously reported.190 First, a solution 
of peracetic acid was synthesized by stirring a mixture of acetic anhydride and H2O2 at 
ice for 4 h. N-hydroxylation of the starting material, 6-hydroxy picolinic acid was 
achieved by peracetic acid in a mixture of trifluoroacetic acid and glacial acetic acid and 
heating at 80 °C for 10 h. In the next step, the N-hydroxyl group of intermediate 146 was 
protected using benzyl chloride and K2CO3 in methanol to obtain benzyl-protected 
intermediate 147. The acid moiety in intermediate 147 was then converted to acid 
chloride using oxalyl chloride in the presence of a catalytic amount of DMF in toluene 
and heating at 80 °C for 4 h. The acid chloride formed was then subsequently reacted 
with 4-fluorobenzyl amine in THF by stirring at 60 °C for overnight to afford 
intermediate 148. In the last step, the benzyl group was deprotected with acid to give 
final compound 159. 
 
 
Results and Discussions 
 
 
Structure Activity Relationship (SAR) 
 
The chalcone functionality contained in compounds synthesized in Chapter 3 was 
modified to a structurally related amide to synthesize a new series of HIV-IN inhibitors. 
Compound 149 having an acid functionality at the X position (Table 4-1) showed low 
μM ST inhibitory activity (IC50 value of 15 μM) suggesting that the ?,?-unsaturated 
moiety of chalcones could be replaced with an amide functionality with retention of 
comparative inhibitory activity but with an increase in ST selectivity. Intermediate 135 
having an aldehyde group at the X position was also tested for SAR purposes and was 
found to be more active than the corresponding acid containing compound 149. The 
synthesis of compounds 153 and 154 was undertaken to determine the ability of two-
chelating atoms in inhibiting HIV-IN activity. The discovery of elvitegravir has showed 
that the presence of even two coplanar chelating moieties, represented by the ?-ketone 
and a carboxylic acid is sufficient for potent clinically relevant IN inhibition. Compound 
153 (X= CH3 R1 = H) was found to be inactive with ST IC50 > 100 μM. In order to 
further ascertain if the loss in activity of compound 153 was due to the lack of a chelating 
atom at the X position, compound 154 (X= CH3 R1 = Br) was synthesized. Compound 
154 also showed ST IC50 > 100 μM indicating the importance of a metal-chelating group 
at the X position. Next, an OH substituted compound 155 was synthesized and was found  
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Scheme 4-4. Synthesis of compound 157 
 
 
 
 
 
Reagent and conditions: (a) 4-F benzylamine, EDCI, HOBt, Et3N, rt, overnight; yield 
74% (b) BBr3, DCM, 0 °C to rt, overnight; (c) C6H5CHO, NaOH, ethanol, rt, overnight; 
overall (steps b and c) yield 36%. 
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Scheme 4-5. Synthesis of compound 158 
 
 
 
 
 
Reagent and conditions: (a) Ac2O, H2SO4, 20 min; yield 88% (b) AlCl3, 160 °C, 3 h; 
yield 34% (c) 4-F benzylamine, EDCI, HOBt, Et3N, rt, overnight; yield 41% (d) ArCHO, 
NaOH, EtOH, rt, 24 h; yield 51%.  
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Scheme 4-6. Synthesis of compound 159 
 
 
 
 
Reagent and conditions: (a) H2O2, Ac2O, 4 h; (b) TFA, GAA, 80 °C, 6 h; overall (steps 
a and b) yield 60% (c) BnCl, K2CO3, MeOH, 16 h, reflux; yield 41% (d) (COCl)2, 
toluene, DMF, 60 °C, 4 h; (e) 4-F benzylamine, Et3N, THF, 60 °C,12 h; overall (steps d 
and e) yield 41% (f) HOAc /Conc. HCl, rt, 2 days; yield 67%.  
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Table 4-1. Structures and activities of 3-keto salicylic acid amides HIV-1 
integrase inhibitors                                          
 
 
 
Cpd. X R1 R2 Activity IC50 (μM) 
3?-Pa          STb 
135 CHO Br 4-F >100 
144 
149 
COCH3 
COOH 
Br 
Br 
4-F 
4-F 
>100 
>100 
8 ± 1 
150 COOH Br 4-Br >100 >100 
15 ± 3 
151 COOH Br 2,4-di-F-3-Cl >100 69 ±13 
152 CONHCH2- 
4-F-Ph 
Br 4-F >100 4 ± 1 
153 H Br 4-F >100 6 ± 2 
154 CH3 H 4-F >100 >100 
155 OH Br 4-F 53 ± 2 >100 
157 OH COCHCH-Ph 4-F 64 ± 6 13 ± 6 
158 
 
156 
159  
COCHCH-2,3,6- 
tri-Cl-Ph 
N/A 
N/A 
Br 
 
N/A 
N/A 
4-F 
 
N/A 
N/A 
>100 
 
>100 
>333 
21 ± 6 
 
100 
255 ± 6 
 
a 3?-P = 3?-procesing; b ST = strand transfer. 
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to be marginally better (ST IC50 = 13 μM) than the acid containing compound suggesting 
that a catechol substituent is well tolerated. This is in agreement with literature as 
polyhydroxylated compounds have been reported as HIV-IN inhibitors.112 The chalcone 
series of IN inhibitors have demonstrated that substitution at the R1 position resulted in 
notable changes in ST activities. For further development of this series of compounds 
structure-based design, described in Chapter 6, was attempted using the RACHEL lead 
optimization software (Tripos Inc). Thus, compound 157 was designed and synthesized 
based on the binding interactions of raltegravir. It has an extended side chain with an 
aromatic ring to serve as an oxadiazole mimic for obtaining ?-stacking interactions with 
Tyr143 in the IN active site. The phenyl ring was thus connected to the core 3-keto 
salicylamide ring with an ?,?-unsaturated linker. Unfortunately, this modification 
resulted in a loss of activity (ST IC50 = 21 μM) relative to its reference compound (13 
μM). Further modifications with various linkers and heterocyclic ring system need to be 
explored to determine the SAR at this position. The diamide compound 152 was designed 
with the objective of increasing contacts with the protein. This modification resulted in 
improvement in ST activity with IC50 of 6.0 μM opening the possibilities of further 
modifications. Compounds 150 and 151 were synthesized to determine the effects of 
other halogens on the phenyl ring of their benzyl carboxamide moieties. Compound 150 
with a p-bromo substituent at the R2 position was four times less active than compound 
149. Moreover, compound 151 resulted in 4-folds improvement in inhibitory activity 
with IC50 of 4.0 μM in ST assay with respect to compound 149 and fifteen-folds more 
active than compound 150 indicating that further modifications, possibly with different 
halogens, could improve the ST activities of this series of compounds. 
 
 With an aim of discovering new pharmacophores for inhibiting HIV-1 IN, 
synthesis of compounds 156 and 159 was undertaken. Compound 159 is a 3-hydroxy-2-
pyridinone which has been reported to have strong metal (Fe3+) chelating191,192 properties. 
This compound was inactive against IN suggesting that this system may not chelate Mg2+ 
with similar potencies. 
 
 
Inhibition of HIV Replication in Cell Culture  
 
 To evaluate the potential of the amide derivatives as antiviral agents, three active 
analogs were tested for the ability to inhibit HIV-1 replication in primary human 
peripheral blood mononuclear cells (PBMCs) infected with the virus. The toxicity of the 
compounds was also tested against PBMC and human CEM lymphoblastic leukemia 
cells. In general, the compounds showed reduced anti-viral activities. Compounds 135 
and 152 showed moderate activities while compound 151 was inactive in inhibiting HIV 
replication (Table 4-2). The low antiviral activities may have to do with solubility, 
absorption, binding to serum proteins in cell culture media and/or cellular distribution 
factors. 
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Table 4-2. Anti-HIV activity of selected amide derivatives 
 
Cpd. Anti-HIV-1 activity in PBMCsa  Cytotoxicity (IC50 μM) 
EC50(μM)b      EC90(μM)b     PBMCs     CEM 
135 30.8 52.7  44.0 40.2 
151 >100 >100  26.4 26.4 
152 49.6 ± 4.2 >100  18.0 14.3 
AZT 0.0025 0.01  >100 56.1 
L-706,908 5.7 ± 4.7c N/Ad  N/A N/A 
 
a PBMCs represents Human Peripheral blood mononuclear cells; b EC50 and EC90 are the 
effective concentrations inhibiting 50% and 90% HIV replication, respectively; c in the 
assay on human leukemic T-cell line MOLT-4, the EC50 of AZT was 0.001 μM; d N/A 
represents not available. 
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Experimental Section 
 
Chemistry 
 
 All the reagents and solvents were purchased from the Aldrich Chemical 
Company and used without further purification. Progress of reactions was monitored by 
TLC on silica gel GHLF-250 micron plates (Analtech, Inc.). Fisher scientific Da visil 
grade 1740 (170-400 mesh) silica gel was used for flash column chromatography. 1H 
NMR spectra were recorded on Brucker AR, 300 or 500-MHz spectrometer: chemical 
shifts are expressed in ? values (ppm) and coupling constants (J) in Hertz (Hz). Mass 
spectral data were determined on a Brucker-HP Esquire-LC spectrometer (ESI-MS). 
Melting points of solids were determined using a Fisher-Johns melting point apparatus 
and are reported uncorrected. HPLC analysis of final compounds was carried out using a 
reverse phase SUPELCOSIL 5 μm C-18 column of dimensions 25 cm x 4.6 cm. Area % 
purity was detected at 254 nm.  An initial isocratic method comprising 40%  water 
(solvent A) and 60% methanol (solvent B) for 20 min at a flow rate of 1.2 mL/min was 
optimized to a linear gradient elution with water (A) and methanol (B) at a flow-rate of 
1.7 mL/min. Gradient elution of the mobile phase was either 80% A to 35% A from 0-5 
min, 35% A and 65% B for 5-12 min and 35% A  to 80% A from 12-15 min or 80% A to 
20% A from 0-4 min, 20% A and 80% B for 4-17 min and 20% A  to 80% A from 17-20 
min.  
 
5-bromo-3-formyl-2-hydroxy-benzoic acid (134). Method (a): NaOH (5.53 g, 0.138 
mol) was added to a solution of 5-bromosalicylic acid (5 g, 23.0 mmol) in DCM (45 mL) 
and water (1 mL, 55.55 mmol) at rt. The reaction mixture was refluxed for 48 h, diluted 
with water and acidified with 6M HCl to pH 1.0. The resulting solution was extracted 
with ethyl acetate washed with brine and dried over Na2SO4. The organic layer was 
evaporated to yield a crude product which was purified by column chromatography (25-
35% MeOHl/DCM) to give a white solid, yield 13%; mp 172-174 °C; 1H NMR (300 
MHz, DMSO-d6): ? 10.27 (s, 1H, CHO), 8.12 (d, 1H, J = 2.7, ArH), 7.93 (d, 1H, J = 2.7 
ArH); MS (ESI): m/z 244.7 [M?H]?. 
 
5-bromo-N-(4-fluoro-benzyl)-3-formyl-2-hydroxy-benzamide (135). To a solution of 
intermediate (0.4 g, 1.63 mmol), HOBt (0.441 g, 3.26 mmol) and Et3N (0.45 mL, 3.26 
mmol) in DCM (20 mL) was added EDCI (0.344 g, 1.8 mmol) at 0 °C. 4-
fluorobenzylamine (0.20 mL, 1.8 mmol) was then added and the reaction mixture stirred 
overnight at rt. The reaction mixture was extracted with ethyl acetate, washed with dilute 
hydrochloric acid and sodium bicarbonate solution. The organic layer was further washed 
with brine and dried over sodium sulfate. The crude was purified by recrystalization with 
ethyl acetate/hexane to give a yellow solid. yield 41%; mp 135-137 °C; 1H NMR (300 
MHz, DMSO-d6): ? 10.27 (s,1H, CHO), 9.90 (s, 1H, NH), 8.41 (s, 1H, ArH), 7.87 (s, 1H, 
ArH), 7.40 (d, 2H, J = 8.1 Hz, ArH), 7.18 (t, 2H, J = 8.1 Hz, ArH), 4.52 (s, 2H, CH2); 
MS (ESI): m/z 351.9 [M?H]?. 
       
5-bromo-N-(4-fluoro-benzyl)-2-hydroxy-isopthalamic acid (149). Intermediate 135 
(0.20 g, 0.568 mmol) was added to a mixture of water (2.5 mL) and pyridine (2.5 mL). 
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the reaction mixture was heated to 90 °C, KMnO4 (0.18 g, 1.13 mmol) was added to the 
hot solution was and the heating continued overnight at 90 °C. After completion, the 
mixture was filtered through celite and evaporated to dryness. The resulting residue was 
purified by recrystalization from ethyl acetate/hexane. White solid; yield 80 %; mp 208-
210 °C; 1H NMR (300 MHz, DMSO-d6): ? 10.20 (s, 1H, NH), 7.98 (s, 1H, ArH), 7.85 (s, 
1H, ArH), 7.13-7.34 (m, 4H, ArH), 4.50 (s, 2H, CH2); MS (ESI): m/z 367.9 [M?H]?; 
HPLC: tR 4.21 min, purity 97.7%. 
 
5-bromo-3-formyl-2-hydroxy-benzoic acid (134). Method (b): 3-formyl salicylic acid 
hydrate starting material (1.0 g, 6.0 mmol) was dissolved in dry acetonitrile (20 mL). N-
bromo succinimide (1.02 g, 5.73 mmol) was added and the reaction mixture stirred at rt 
for 3 h. The white crystals formed were filtered and washed with water. The filtrate was 
extracted with ethyl acetate, and washed with brine. The organic layer was dried over 
Na2SO4 and evaporated to dryness. The two fractions were combined to give intermediate  
as white crystals, yield  90%; mp 172-174 °C; 1H NMR (300 MHz, DMSO-d6): ? 10.27 
(s, 1H, CHO), 8.12 (d, 1H, J = 2.7, ArH), 7.93 (d, 1H, J = 2.7 ArH); MS (ESI): m/z 244.7 
[M?H]?. 
 
5-bromo-2-hydroxyisophthalic acid (136). Intermediate 134 (0.30 g, 1.22 mmol) was 
added to a mixture of water (3.5 mL) and pyridine (3.5 mL). The reaction mixture was 
heated to 90 °C, KMnO4 (0.387g, 2.45 mmol) was added to the hot solution was and the 
heating continued overnight at 90 °C. After completion, the mixture was filtered through 
celite and evaporated to dryness. The resulting residue was washed with ethyl acetate and 
purified by recrystalization from ethanol. Yield 68%; mp  >220  °C; 1H NMR (300 MHz, 
DMSO-d6): ? 10.25 (s, 1H, OH), 7.60 (s, 1H, ArH), 7.92 (s, 1H, ArH); MS (ESI): m/z 
260.7 [M?H]?. 
 
 
General procedure for the synthesis of compounds 150 and 151. Intermediate 
136 (0.50 g, 1.91 mmol), HOBt (0.517g, 3.83 mmol) and triethyl amine (0.534 mL, 3.83 
mmol) were added to a mixture of DCM (10 mL) and DMF (10 mL) at 0 °C. EDCI 
(0.404 g, 2.10 mmol) was added to the above solution followed by 4-bromo-benzylamine 
(0.22 mL, 1.82 mmol) or 3-chloro-2,4-difluorobenzylamine (0.323 gm,  1.82 mmol) for 
compounds 150 and 151, respectively. The reaction mixture was then stirred overnight at 
rt. After the reaction, the reaction mixture was evaporated and poured into excess water, 
and extracted with ethyl acetate. The organic layer was washed with dilute hydrochloric 
acid and sodium bicarbonate solution and then with brine and dried over sodium sulfate. 
The resulting crude solid was washed with hexane and recrystalization with ethyl acetate. 
 
 5-bromo-3-((4-bromobenzyl)carbamoyl)-2-hydroxybenzoic acid (150).White solid, 
yield  34%; mp >220 °C dec; 1H NMR (500 MHz, DMSO-d6): ? 9.28 (s, 1H, NH), 8.07 
(d, 1H, J = 2.0 Hz, ArH), 7.96 (d, 1H, J = 2.0 Hz, ArH), 7.52 (d, 1H, J = 8.0 Hz, ArH), 
7.27 (d, 1H, J = 8.0 Hz, ArH), 4.47 (d, 2H, J = 6.0 Hz, CH2); MS (ESI): m/z [M?H]?; 
HPLC: tR 6.41 min, purity 99.7%. 
 
5-bromo-N-(3-chloro-2,4-difluorobenzyl)-2,3-dihydroxybenzamide (151). Yellow  
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solid, yield 62%; mp 140-142 °C; 1H NMR (300 MHz, DMSO-d6): ? 9.73 (s, 1H, NH), 
8.02 (s, 1H, ArH), 7.92 (s, 1H, ArH), 7.45 (d, 1H, J = 7.8 Hz, ArH), 7.27 (d, 1H, J = 9.0 
Hz, ArH), 4.56 (d, 2H, J = 5.1 Hz, CH2); MS (ESI): m/z 419.8 [M?H]?; HPLC: tR 4.43 
min, purity 97.7%. 
 
5-bromo-N1,N3-bis(4-fluorobenzyl)-2-hydroxyisophthalamide (152). Intermediate 136  
(0.20 g, 0.766 mmol), HOBt (0.415 g, 3.06 mmol) and Et3N (0.22 mL, 1.53 mmol) was 
added in a mixture of DCM (20 mL) and DMF (5 mL) at 0 °C. EDCI (0.323 g, 1.69 
mmol) was added to the above solution followed by 4-fluorobenzylamine (0.20 mL, 1.69 
mmol) after which the reaction mixture was kept at 0 °C for 1 h and stirred overnight at 
rt. The reaction mixture was then evaporated and poured into excess water, and extracted 
with ethyl acetate. The organic layer was washed with dilute hydrochloric acid and 
sodium bicarbonate solution and then with brine and dried over sodium sulfate. The crude 
was washed with hexane and purified by column chromatography with 5-10% of 
MeOH/DCM to give pure compound 152. Yellow solid; yield 48%; mp 235-237 °C; 1H 
NMR (300 MHz, DMSO-d6): ? 9.23 (bs, 2H, NH), 8.09 (d, 1H, J = 2.7 Hz, ArH), 7.98 (d, 
1H, J = 2.7 Hz, ArH), 7.29-7.39 (m, 4H, ArH), 4.48 (d, 1H, J = 4.2 Hz, CH2); MS (ESI): 
m/z 474.8 [M?H]?. 
 
 
General procedure for the synthesis of compounds 153-156. Similar procedure 
for amide coupling described above for compound 149 was used such that appropriate 
commercially available acids (0.25 g, 0.98 mmol), HOBt (0.29 g, 2.1 mmol) and Et3N 
(0.15 mL, 0.98 mmol) were added to either DCM or THF (15 mL) at 0 °C. EDCI (0.22 g, 
1.07 mmol) was added to the above solution followed by 4-fluorobenzylamine (0.12 mL, 
0.98 mmol) after which the reaction mixture was kept at ice for 1 h and then allowed to 
come to rt and stirred overnight for 14 h. The reaction mixture was then evaporated and 
extracted with ethyl acetate. The organic layer was washed with dilute hydrochloric acid 
and sodium bicarbonate solution and then with brine and dried over sodium sulfate. The 
resulting crude was washed with hexane and purified by column chromatography (10-
20% ethyl acetate/ hexane or recrystallized with ethyl acetate/hexane. 
 
N-(4-fluoro-benzyl)-2-hydroxy-3-methyl-benzamide (153). White solid; yield 76%; 
mp 165-166 °C; 1H NMR (300 MHz, DMSO-d6): ? 13.10 (s, 1H, OH), 9.43 (t, 1H, J = 
6.0 Hz, NH), 7.72 (d, 1H, J = 7.2 Hz, ArH), 7.37 (d, 1H, J = 8.7 Hz, ArH), 7.35 (d, 1H,  
J = 8.4 Hz, ArH), 7.31 (d, 1H, J = 7.2 Hz, ArH), 7.15 (t, 2H, J = 9.0 Hz, ArH), 6.78 (t, 
1H, J = 7.5 Hz, ArH), 4.48 (d, 1H, J = 6.0 Hz, CH2), 2.15 (s, 3H, CH3); MS (ESI): m/z 
257.9 [M?H]?; HPLC: tR 8.63 min, purity 99.11%. 
 
5-bromo-N-(4-fluoro-benzyl)-2-hydroxy-benzamide (154). White solid; yield 62%; mp 
83-84 °C; 1H NMR (300 MHz, DMSO-d6): ? 12.47 (s,1H, OH), 9.37 (t, 1H, J = 5.7 Hz, 
NH), 8.07 (d, 1H, J = 2.4 Hz, ArH), 7.55 (dd, 1H, J1 = 8.7 Hz, J2  = 2.4 Hz, ArH), 7.36 
(dd, 2H, J1 = 8.1 Hz, J2  =5.7 Hz, ArH), 7.15 (t, 2H, J = 9.0, ArH), 6.89 (d, 1H, J = 8.7 
Hz, ArH), 4.47 (d, 2H, J = 5.7 Hz, CH2); MS (ESI): m/z 323.8 [M?H]?; HPLC: tR 9.7  
min, purity 98.66%.  
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5-bromo-N-(4-fluorobenzyl)-2,3-dihydroxybenzamide (155). Yellow solid; yield  
61 %; mp  215-217 °C; 1H NMR (300 MHz, DMSO-d6): ? 9.42 (t, 1H, J = 5.4 Hz, NH), 
7.56 (d, 1H, J = 2.4 Hz, ArH), 7.36 (dd, 2H, J1 = 8.1 Hz, J2 = 2.4 Hz, ArH), 7.16 (t, 2H,  
J = 8.7 Hz, ArH), 7.05 (d, 1H, J = 2.4 Hz, ArH), 4.47 (d, 2H, J = 5.4 Hz, CH2); MS 
(ESI): m/z 339.8 [M?H]?. 
 
N-(4-fluorobenzyl)-4-oxo-1,4-dihydrobenzo[h]quinoline-3-carboxamide (156). White 
solid; yield 53%; 1H NMR (500 MHz, DMSO-d6): ? 8.83 (s, 1H, NH), 8.61 (d, 1H, J = 
6.5 Hz, NH), 8.30 (d, 1H, J = 9.0 Hz, ArH), 8.08 (d, 1H, J = 9.0 Hz, ArH), 7.85 (d, 1H,  
J = 8.5 Hz, ArH), 7.75-7.77 (m, 2H, ArH), 7.42 (dd, 3H, J1 = 9.0 Hz, J2 = 1.5 Hz), 7.06 
(t, 3H, J = 9.0 Hz, ArH); MS (ESI): m/z 344.9 [M?H]?. 
 
5-acetyl-N-(4-fluorobenzyl)-2-hydroxy-3-methoxybenzamide (142). 5-acetyl-2-
hydroxy-3-methoxybenzoic acid starting material (1.0 g, 4.76 mmol), HOBt (1.28 g, 9.51 
mmol) and Et3N (0.66 mL, 4.76 mmol) was added in a THF (20 mL) at 0 °C. EDCI (1.0 
g, 5.23 mmol) was added to the above solution followed by 4-fluorobenzylamine (0.54 
mL, 4.76 mmol) after which the reaction mixture was kept at 0 °C for 1 h and stirred 
overnight at rt. After the reaction, the reaction mixture was evaporated to a small volume 
and extracted with ethyl acetate. The organic layer was washed with dilute hydrochloric 
acid and sodium bicarbonate solution and then with brine and dried over sodium sulfate. 
The resulting crude was washed with hexane and recrystallized with ethyl acetate/hexane 
to give pure intermediate 142. White solid, mp 165-167 °C; yield 74%; 1H NMR (500 
MHz, DMSO-d6): ? 9.67(s, 1H, NH), 8.20 (d, 1H, J = 1.0 Hz, ArH), 7.55 (d, 1H, J = 1.0 
Hz, ArH), 7.39 (dd, 2H, J1 = 8.5 Hz, J2 = 6.0 Hz, ArH), 7.17 (t, 2H, J = 8.5 Hz, ArH), 
4.53 (d, 2H, J = 6.0 Hz, CH2), 3.85 (s, 3H, 3.85, OCH3), 2.55 (s, 3H, 2.55, COCH3); MS 
(ESI): m/z 316.0 [M?H]?. 
 
5-cinnamoyl-N-(4-fluorobenzyl)-2,3-dihydroxybenzamide (157). To a solution of 
intermediate 142 (1.0 g, 3.15 mmol) in DCM (20 mL) was added BBr3 (6.30 mL of 1M 
solution in DCM) at 0 °C. The reaction mixture was allowed to come to room 
temperature and stirred for 16 h. After the reaction, the mixture was quenched with ice 
cold water and extracted with DCM. The organic layer was evaporated and dried in 
vacuo to give the demethoxy intermediate 143, which was used for the next step without 
further purification (MS (ESI): m/z 301.9 [M?H]?). Intermediate 143 (0.80 gm, 2.64 
mmol) and benzaldehyde (0.26 mL, 2.64 mmol), were dissolved in 10 mL of ethanol, and 
5 mL of 25% aq NaOH was added. The reaction mixture was stirred at room temperature 
for 24 h. The mixture was then poured into ice and acidified with 3 M HCl to pH 4. The 
yellow precipitate formed was filtered and washed with water. The crude solid was 
purified by preparative chromatography (DCM: ethyl acetate, 8:2) to afford pure 
compound 157. Brown solid; overall yield 36%; mp 170-173 °C; 1H NMR (300 MHz, 
DMSO-d6): ? 13.56 (s, 1H, OH), 9.73 (s, 1H, NH), 9.66 (s, 1H, OH), 8.26 (s, 1H, ArH), 
7.75-7.93 (m, 4H, ArH, H?, H?), 7.67 (s, 1H, ArH), 7.37-7.54 (m, 5H, ArH), 7.18 (m, 
2H, ArH), 4.57 (s, 2H, CH2); MS (ESI): m/z 390.0 [M?H]?. 
 
3-acetyl-5-bromo-N-(4-fluorobenzyl)-2-hydroxybenzamide (144). Intermediate 78a 
(1.0 g, 3.86 mmol), which was synthesized as an intermediate in the Chapter 3, HOBt 
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(1.04 g, 7.72 mmol) and triethylamine (0.53 mL, 3.86 mmol) were added in DCM (20 
mL) at 0 °C. EDCI (0.81 g, 4.24 mmol) was added to the above solution followed by 4-
fluorobenzylamine (0.44 mL, 3.86 mmol) after which the reaction mixture was kept at ice 
for 1 h and stirred overnight at rt. After the reaction, the reaction mixture was evaporated 
to a small volume and extracted with ethyl acetate. The organic layer was washed with 
dilute hydrochloric acid and sodium bicarbonate solution and then with brine and dried 
over sodium sulfate. The resulting crude was washed with hexane and purified by column 
chromatography (10-20% ethyl acetate/hexane).  White solid; mp 125-126 °C; yield 
41%; mp 125-126 °C; 1H NMR (500 MHz, DMSO-d6): ? 9.43 (t, 1H, J = 6.0 Hz, NH), 
8.26 (s, 1H, ArH), 7.98 (s, 1H, ArH), 7.38-7.42 (m, 2H, ArH), 7.16 (t, 2H, J = 8.5 Hz, 
ArH), 2.63 (s, 3H, COCH3); MS (ESI): m/z 365.9 [M?H]?. 
 
(E)-5-bromo-N-(4-fluorobenzyl)-2-hydroxy-3-(3-(2,3,6-trichlorophenyl) acryloyl) 
benzamide (158). Intermediate 144 (0.53 g, 1.44 mmol) and 2,3,6-trichlorobenzaldehyde 
(0.33 g, 1.44 mmol) were dissolved in 10 mL of ethanol, and 5 mL of 25% aq NaOH was 
added. The reaction mixture was stirred at rt for 24 h. The mixture was then poured into 
ice and acidified with 3M HCl to pH 4. The yellow precipitate formed was filtered and 
washed with water. The crude was purified using preparative TLC to give pure 
compound 158. Yellow solid; yield 51%; mp 108-110 °C; 1H NMR (500 MHz, DMSO-
d6): ? 9.43 (t, 1H, J = 5.0 Hz, NH), 8.16 (s, 1H, ArH), 7.81-7.97 (m, 2H, ArH, H-?), 7.68 
(d, 1H, J = 8.5 Hz, ArH), 7.59 (d, 1H, J = 8.5 Hz, ArH), 7.50 (d, 1H, J = 16.0 Hz, H-?), 
7.34 (dd, 2H, J1 = 8.0 Hz, J2 = 5.5 Hz), 7.13 (t, 2H, J = 8.5 Hz), 4.47 (d, 2H, J = 5.0 Hz, 
CH2); MS (ESI): m/z  555.8 [M?H]?. 
 
1-hydroxy-6-oxo-1,6-dihydropyridine-2-carboxylic acid (146). A mixture of acetic 
anhydride (4 mL) and 30% H2O2 (1 mL) was stirred in ice bath for 4 h to form a 
homogenous peracetic acid solution. The peracetic acid formed was then added drop-wise 
to a stirring solution of 6-hydroxypicolinic acid (0.25 gm, 1.79 mmol) in a mixture of 
trifluoro acetic acid (3 mL) and glacial acetic acid (3 mL). The reaction mixture was 
stirred at rt for 1h and then heated gradually to 80 °C and kept at 80 °C for 10 h. After the 
reaction, the reaction mixture was evaporated and 10% KOH solution was added to the 
residue and the solution stirred at 80 °C for another 6 h after which the product was 
precipitated with conc. HCl. The crude was purified using column chromatography (10- 
25% MeOH: DCM) to afford pure 146. White solid; yield 60%; 1H NMR (300 MHz, 
DMSO-d6): ? 7.45 (dd, 1H, J1 = 9.0 Hz, J2 = 7.2 Hz, ArH), 6.73 (dd, 1H, J1 = 9.0 Hz, J2 = 
1.8 Hz, ArH), 6.65 (dd, 1H, J1 = 6.9 Hz, J2 = 1.5 Hz, ArH); MS (ESI): m/z 153.7 
[M?H]?. 
 
1-(benzyloxy)-6-oxo-1,6-dihydropyridine-2-carboxylic acid (147). Benzyl chloride 
(3.09 mmol, 0.357 mL) was added to a solution of intermediate 146 (0.40 gm, 2.58 
mmol) and anhydrous K2CO3 (5.16 mmol) in methanol (20 mL). The reaction was then 
refluxed for 16 h. After the reaction, the reaction mixture was filtered and evaporated to 
dryness. The residue was dissolved in water and acidified with 6M HCl to a pH 2.0. The 
white precipitate formed was filtered, washed with cold water and dried to give a pure 
product.  White solid; mp 178-180 °C; yield 41%; 1H NMR (300 MHz, DMSO-d6): ? 
7.40-7.52 (m, 6H, ArH), 6.74 (dd, 1H, J1 = 9.1 Hz, J2 = 1.8 Hz, ArH), 6.56 (dd, 1H, J1 =  
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6.6 Hz, J2 = 1.5 Hz, ArH), 5.28 (s, 2H, CH2); MS (ESI): m/z 243.8 [M?H]?. 
 
1-(benzyloxy)-N-(4-fluorobenzyl)-6-oxo-1,6-dihydropyridine-2-carboxamide (148). 
Excess oxalyl chloride was added to a suspension of intermediate 147 (0.475 gm, 1.93 
mmol) in toluene (10 mL). DMF (1 drop) as catalyst was added after which the mixture 
became clear. The resulting solution was stirred at 60 °C for 4 h and the solvent 
evaporated to dryness. The resulting residue (acid chloride) was directly used for the next 
reaction. The crude acid chloride (0.45 g, 1.71 mmol) was dissolved in dry THF and Et3N 
(0.24 mL) was added. 4-fluoro benzyl amine (0.19 mL, 1.71 mmol) was then added to the 
above solution and reaction mixture stirred overnight at 60 °C. After the reaction was 
complete, the solvent was evaporated and extracted with DCM. The organic layer was 
washed with 1M NaOH and 1M HCl and evaporated to get the crude product. The crude 
was purified using column chromatography (10-20% ethyl acetate/hexane) to get pure 
intermediate 148. White solid; mp 183-185 °C; overall yield 41%; 1H NMR (300 MHz, 
DMSO-d6): ? 9.41 (t, 1H, J = 5.5 Hz, NH), 7.50 (dd, 1H, J1 = 8.5 Hz, J2 = 6.5 Hz, ArH), 
7.36-7.40 (m, 5H, ArH), 7.32 (dd, 2H, J1 = 8.0 Hz, J2 = 6.0 Hz, ArH), 7.04 (t, 2H, J = 8.5 
Hz, ArH), 6.66 (d, 1H, J = 9.0 Hz, ArH), 6.35 (d, 1H, J = 6.5 Hz, ArH), 5.23 (s, 2H, 
CH2), 4.41 (d, 2H, J = 5.5 Hz, CH2); MS (ESI): m/z 375.1 [M+23]. 
 
N-(4-fluorobenzyl)-1-hydroxy-6-oxo-1,6-dihydropyridine-2-carboxamide (159). The 
intermediate 148 (0.27 gm, 0.766 mol) was deprotected using a 1:1 mixture of HCl and 
glacial acetic acid and stirring at rt for 48 h. the reaction mixture was then evaporated, 
dissolved in minimum amount of water, filtered and dried. The crude was crystallized 
with ethyl acetate. White solid; yield 67%; mp 138-140 °C; 1H NMR (300 MHz, DMSO-
d6): ? 9.31(t, 1H, J = 5.5 Hz, NH), 7.36-7.42 (m, 3H, ArH), 7.16 (t, 2H, J = 9.0 Hz, 6.58 
(d, 1H, J = 9.5 Hz, ArH), 6.33 (d, 1H, J = 7.0 Hz), 4.41 (d, 2H, J = 5.5 Hz); MS (ESI): 
m/z 285.0 [M+23]. 
 
 
Biological Assays 
  
 
Materials, chemicals, and enzymes. All compounds were dissolved in DMSO 
and the stock solutions were stored at -20 °C. ?[32P]-ATP was purchased from either 
Amersham Biosciences or ICN. The expression systems for wild-type IN were a 
generous gift from Dr. Robert Craigie, Laboratory of Molecular Biology, NIDDK, NIH, 
Bethesda, MD. Cell lines were obtained from American Type Culture Collection (ATCC, 
Rockville, MD). 
 
  
Preparation of oligonucleotide substrates. The oligonucleotides 21top, 5?-
GTGTGGAAAATCTCTAGCAGT-3?, and 21bot, 5?-ACTGCTAGAGATTTTCCACAC-
3?, were purchased from the Norris Cancer Center Microsequencing Core Facility 
(University of Southern California) and purified by UV shadowing on polyacrylamide 
gel. To analyze the extent of 3?-P  and ST using 5?-end labeled substrates, 21top was 5?-
end labeled using T4 polynucleotide kinase (Epicentre, Madison, WI) and ?[32P]-ATP 
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(Amersham Biosciences or ICN). The kinase was heat-inactivated and 21-bot was added 
in 1.5M excess. The mixture was heated at 95 °C, allowed to cool slowly to rt, and run 
through a G25 mini spin column (USA Scientific) to separate double-stranded 
oligonucleotide from unincorporated material. 
 
  
Integrase assays. To determine the extent of 3?-P and ST, wild-type IN was 
preincubated at a final concentration of 200 nM with the inhibitor in reaction buffer (50 
mM NaCl, 1 mM HEPES, pH 7.5, 50 μM EDTA, 50 μM dithiothreitol, 10% glycerol 
(w/v), 7.5 mM MnCl2, 0.1 mg/mL bovine serum albumin, 10 mM 2-mercaptoethanol, 
10% dimethylsulfoxide, and 25 mM MOPS, pH 7.2) at 30 °C for 30 min. An aliquot 
(5μL) was electrophoresed on a denaturing 20% polyacrylamide gel (0.09 M Tris-borate, 
pH 8.3, 2 mM EDTA, 20% acrylamide, and 8M urea). Gels were dried, exposed in a 
PhosphorImager cassette, and analyzed using a Typhoon 8610 Variable Mode Imager 
(Amersham Biosciences) and quantitated using ImageQuant 5.2. Percent inhibition (%I) 
was calculated using (Equation 3-1). The IC50 values were determined by plotting the 
logarithm of compound concentration versus percent inhibition to obtain the 
concentration that produced 50% inhibition. 
 
 
Anti-HIV-1 activity assay. The testing of the ability of potent compounds to 
inhibit HIV replication in cell culture was done according to a previously reported 
procedure.182 PBMC (107 cells/T25flask) were stimulated with phytohemagglutinin for 3 
days and infected with a wild-type HIV-1 strain (strain LAI) at 100 50% tissue culture 
infective doses, as described previously.182 The cultures were kept for 5 days in the 
presence of test compounds at serial 1-log dilutions. Subsequently, human PBMC were 
removed from the culture supernatant by centrifugation (400g, 10 min, 4 °C). This 
clarified supernatant was tested by a reverse transcriptase assay. 
 
 
Cytotoxicity assays. The cytotoxicity of compounds was evaluated using 
uninfected PBMC and CEM leukemia cells according to a previous method.183 PBMC 
were obtained from whole blood of healthy individuals, while CEM were obtained from 
the ATCC (Rockville, MD). The PBMC and CEM cells were cultured in the presence or 
absence of compound for 6 days. After this time period, cells were stained with Trypan 
blue dye, and counted for cell proliferation and viability according to the previously 
reported procedure.184  
 90 
CHAPTER 5.   SYNTHESIS AND BIOLOGICAL STUDIES OF 
PHENANTHRENE DIKETO ACIDS AS HIV-1 INTEGRASE INHIBITORS 
 
 
Introduction 
 
Raltegravir is currently the only IN inhibitor approved by the FDA.51 
Unfortunately, clinical studies have reported viral mutants particularly T66I,  G148H, 
N155H, and double mutant G148H G140S,  that are resistant to both raltegravir and 
elvitegravir.138,139 Thus, it is highly imperative to design new chemical classes as second 
generation HIV-1 IN inhibitors that not only have potent inhibitory activities, but also 
have the potential to circumvent the eminent failure resulting from the emergence of viral 
resistance to current IN inhibitors. 
 
Previously, our laboratory has reported 5(H)-phenanthridin-6-one diketo acids 
and related compounds as a novel class of HIV-1 IN inhibitors.152 In this chapter, I have 
synthesized a series of substituted phenanthrene ?-diketo acids having potent in vitro IN 
inhibitory activities. Selected compounds were also tested for their abilities to inhibit 
HIV-1 replication in cell culture. 
 
 
Chemistry 
 
 The synthesis of target phenanthrenes ?-diketo acids was accomplished by first 
synthesizing the acetyl phenanthrene intermediates 168a-168h using Scheme 5-1. On the 
basis of commercial availability, two different sets of starting materials were used to 
perform the Suzuki coupling reaction. Thus, either the acetyl boronic acid derivatives 
(160a-160d) were reacted with the aldehyde containing halogen partners (161a-161d) to 
synthesize intermediates 164a-164d or alternatively, the formyl boronic acid derivatives 
(162e-162h) were coupled with iodo acetyl starting materials (163e-163h) to synthesize 
intermediates 164e-164h. For the coupling reaction, our first attempt with Pd (PPh3)4 in 
toluene did not yield the desired product. The reaction was then successfully optimized 
by using a polymer bound Pd (PPh3)4 with triethyl amine as a base in a dioxane-ethanol 
solvent under inert atmosphere.193,194 Conditions varied from ice-cold (0 °C) to reflux and 
the reaction was stirred from 6 h to 48 h depending upon the starting materials used. The 
aldehyde intermediates were converted to the corresponding alkynes by Seyferth-Gilbert 
homologation under which, a mixture of intermediates 164a-164h, dimethyl-(1-diazo-2-
oxopropyl) phosphonate, and K2CO3 was stirred in methanol at 0 °C for 17 h.195 The 
alkyne intermediates 165a-165h were then subjected to a 6-endo dig cyclization with 
PtCl2 by refluxing in toluene for 24 h under inert conditions to yield desired 
phenanthrenes 168a-168h.196 An alternative efficient microwave synthesis reported by 
Kim et al.197 was also used to synthesize the acetyl phenanthrene derivatives 168i and 
168j (Scheme 5-2). This one-pot synthesis of 9?-acetyl phenanthrenes was accomplished 
by a step-wise Suzuki-Miyaura coupling reaction followed by an intramolecular Aldol 
condensation. Therefore, 166a and 166b phenyl propanone starting materials were 
coupled with (2-formyl-4-methoxyphenyl) boronic acid (167) using Pd (PPh3)4 with  
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Scheme 5-1. Synthesis of intermediates 168a-168h 
 
 
 
 
 
Reagent and conditions: (a) Polymer bound Pd (PPh3)4 (1mol%), Et3N, dioxane, EtOH  
ice/reflux , 6 h-2 days; yields 34-78% (b) dimethyl-(1-diazo-2-oxopropyl) phosphonate, 
K2CO3, MeOH, ice, 17 h; yields 35-64% (c) PtCl2, toluene, reflux, 24 h; yields 43-60%. 
 
 
 
Scheme 5-2. Synthesis of intermediates 168i-168j 
 
 
CHO
B
HO OH
OMe
X
O
R2
O
MeO
R2a
166a, 166b
167
168i-168j
+
168i. R2 = F
168j. R2 = H
166a. R2 = F ; X = Cl
166b. R2 = H ; X = Br  
 
 
Reagent and conditions: (a) Microwave: 10 min, 150 °C, Pd (PPh3)4 (4 mol%), S-Phos 
(6 mol%), Cs2CO3, toluene-EtOH (2:1); yields 48-51%.  
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cesium carbonate as a base and S-Phos as catalyst. The reaction was performed in 
toluene/ethanol (2:1) mixture and irradiated at 60-80 W power and 150 °C for 10 min. 
All the acetyl phenanthrene intermediates 168i-168j were then subjected to oxalylation 
reaction. Our initial attempt with diethyl oxalate did not yield the desired product. 
Literature reports198 suggest terbutyl methyl oxalate as an oxalylating agent for halogen-
substituted acetophenones. The use of terbutyl methyl oxalate (170), which was prepared 
according to literature199 by the reaction of methyl chlorooxo acetate, t-butanol and 
pyridine in anhydrous ether, successfully resulted in the formation (Scheme 5-3) of the 
corresponding diketo esters 171i-171j. The ester derivatives were taken to the next step 
directly without further purification and hydrolyzed with aq. NaOH to their 
corresponding desired diketo acid final products 172-181. 
 
 
Biological Results and Discussion 
 
 The synthesized target compounds (Table 5-1) were then tested for their ability to 
inhibit strand transfer (ST) and 3?-processing (3?-P). The structure activity relationship 
around these halogen-substituted phenanthrene derivatives suggests that the ?-diketo acid 
functionality is well tolerated at R1 and R2 positions. For e.g., compare analogs 176, 177, 
and 179 all of which have potent and similar ST IC50s of 1.4, 1.3, and 1.2 μM, 
respectively. However, comparison of compounds 179 vs. 178 and 172 vs. 173 indicates 
that the ?-diketo acid functionality is slightly more favorable at R2 position. In particular, 
compound 159 was about four times more active than compound 178 against ST reaction. 
Our laboratory has previously reported unsubstituted phenanthrene derivative 182 with 
diketo acid at the R2 position had ST IC50 value of 2.7 μM.152 With respect to compound 
182, while substitution of chlorine moiety at R6 position (compound 179) improved 
activity, a fluoro substituent at this position (compound 172) resulted in a slight loss of 
potency; also implying that the Cl substituent did better than the fluoro counterpart 
(compare compounds 179 and 172) at this position.  That fluorine may not be an optimal 
substituent at R6 position is also evident when one considers that compound 181 (ST IC50 
of 3 μM) was two-folds more active than compound 180 (ST IC50 of 6 μM). Chlorine 
was also found to improve activity at R4 and R5 positions. Compounds 177 and 176 were 
about four times more potent than their unsubstituted counterparts (2,4-dioxo-4-
(phenanthren-2-yl) butanoic acid, ST IC50 of 4.8 μM), synthesized previously.152 
Chlorine substitution at R5 in compound 176 also improved selectivity (nine-folds) for 
the ST step. Compound 177 showed potent activities against both 3?-P and ST reactions 
with IC50s of 5.0 μM and 1.3 μM, respectively. The reason for the dramatic loss of 
potency for both ST and 3?-P with compound 174 is not very apparent. It might be due to 
ineffective metal chelation by the ?-diketo acid functionality considering, the electron 
withdrawing effect of the adjacent fluorine substituent. The improvement of activity of 
compound 175 (ST IC50 of 8.0 μM) implies a favorable effect of the fluorine substituent 
at the R5 position. This may be one of the reasons why compound 176, having a more 
hydrophobic Cl at the R5 position, has improved activity over compound 175; also 
implying that hydrophobic interaction at this position may be an important contributor to 
activity. Compound 181, with an electron donating methoxy group at the R1 position, and 
the diketo acid moiety at R7 showed an IC50 of 3 μM against ST. This is a significant loss 
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Scheme 5-3. Synthesis of compounds 172-181 
 
 
 
 
 
Reagent and conditions: (a) t-butanol, pyridine, ether, rt, 2 h; (b) NaOMe, MeOH,  
60 °C, 4 h; (c) aq. NaOH, MeOH-THF(1:1), 6 h; overall (steps b and c) yield 78-93%.
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Table 5-1. Structure and HIV-1 IN inhibitory activities of phenanthrene ?-diketo 
acids 
 
 
 
Cpd. R1 R2 R3 R4 R5 R6 R7 Activity (IC50 μM) 
 3?-Pa        STb 
172 H DKAc H H H F H 11 ± 2 3 ± 2 
173 DKA H H H H F H 35 ± 13 4 ± 1 
174 H DKA F H H H H 83 ± 15 63 ± 16 
175 H DKA F H F H H 63 ± 12 8 ± 2 
176 DKA H H H Cl H H 12 ± 3 1.4 
177 DKA H H Cl H H H 5 ± 3 1.3 ± 0.1 
178 DKA H H H H Cl H 19 ± 2 4 ± 1 
179    H  DKA H H H Cl H 11 ± 4 1.2 ± 0.3 
180 OCH3 H H H H F DKA 44 ± 10 6 ± 2 
181 OCH3 H H H H H DKA 32 ± 12 3 ± 2 
182d H DKA H H H H H 25 ± 7 2.7 ± 2 
 
a 3?-P = 3?-procesing; b ST = Strand Transfer; c DKA = diketo acid; d compound 
previously reported.152 
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of activity when compared to its parent unsubstituted diketo acid analog, 2,4-dioxo-4-
(phenanthren-9-yl)butanoic acid (ST IC50 of 0.38 μM) that our laboratory has earlier 
reported.152 This suggests that the R1 position is sensitive to modifications and could be 
further exploited to determine the structure activity relationship around this novel class of 
IN inhibitors. 
 
 Next, to determine their potential as anti-HIV agents, two potent analogs 
(compounds 176 and 177) were tested for their ability to inhibit HIV-1 replication in 
primary human peripheral blood mononuclear cells (PBMC). Both compounds showed 
moderate inhibition of HIV replication with IC50s of 20.7 and 27.5 μM, respectively, 
(Table 5-2). The reduced antiviral potency might be because of poor solubility, binding 
to serum proteins and/or cellular distribution factors. The cytotoxicity assays showed that 
the selected compounds, 176 and 177, have toxicities when tested against PBMC, human 
CEM lymphoblastic leukemia cells and African green monkey Vero cells. However, a 
phenanthrene analog (183) which our lab has previously reported possessed potent anti-
HIV activity (EC50 of 8.0 μM) and had selectivity index of 10 for inhibition of HIV 
replication in cell culture. This indicates that this series could be further developed with 
optimization efforts directed at reducing their cell-based toxicities and simultaneously 
enhancing their anti-viral activities. 
 
 
Experimental Section 
 
 
Chemistry 
 
All the reagents and solvents were purchased from the Aldrich Chemical 
Company and used without further purification. Progress of reactions was monitored by 
TLC on silica gel GHLF-250 micron plates (Analtech, Inc.). Fisher scientific Da visil 
grade 1740 (170–400 mesh) silica gel was used for flash column chromatography. 1H 
NMR spectra were recorded on Brucker AR, 300 or 500-MHz spectrometer: chemical 
shifts are expressed in ? values (ppm) and coupling constants (J) in Hertz (Hz). Mass 
spectral data were determined on a Brucker-HP Esquire-LC spectrometer (ESI-MS). Infra 
red (IR) spectra of alkyne derivatives were recorded on a Perkin Elmer Spectrum 100 FT-
IR spectrometer. HPLC analysis of final compounds was carried out using a reverse 
phase SUPELCOSIL 5 μm C-18 column of dimensions 25 cm x 4.6 cm. Area % purity 
was detected at 254 nm.  A linear gradient elution with water (A) and methanol (B) at a 
flow-rate of 1.5 mL/min was used. Gradient elution of the mobile phase was 80% A to 
20% A from 0-3 min, 20% A and 80% B for 3-17 min and 20% A  to 80% A from 17-20 
min. Melting points of solids were determined using a Fisher-Johns melting point 
apparatus and are reported uncorrected. 
 
 
General procedure for the synthesis of intermediates 164a-164h. Acetyl 
phenyl boronic acid derivatives (3.78 g, 20.77 mmol) were reacted with halogen 
containing aldehyde partners (4 g, 16 mmol) or alternatively, aldehyde phenyl  
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Table 5-2. Anti-HIV activities of selected phenanthrene compounds 
 
Comp. R1 R4 R5 EC50 (μM) Cytotoxicity  (IC50 μM) 
PBMCa      CEMb      VEROc 
176 
177 
DKA 
DKA 
H 
Cl 
Cl 
H 
20.9 ± 15.8 
27.5 ± 10.2 
14.1 
4.0 
12.1 
13.1 
7.2 
4.5 
 
a Human Peripheral blood mononuclear cells; b CEM lymphoblastic leukemia cells; c 
African green monkey Vero cells.  
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boronic acid starting materials (3.9 g, 21.13 mmol) were reacted with halogen substituted 
acetophenones (4.0 g, 16.25 mmol) for the Suzuki coupling reaction. Thus, aryl halide 
and polymer bound Pd (PPh3)4 (0.25 g, 1.35 mol%) were added to a dioxane-ethanol (30 
mL, 4:1) mixture. This was followed by the addition of triethylamine (1.17 mL, 32 
mmol) and the boronic acid derivative. The resultant solution was degassed several times 
with argon and stirred in ice or refluxed for 6-48 h depending upon the starting materials 
used. After the reaction, the mixture was filtered through celite and evaporated to 
dryness. The crude material was purified by column chromatography (10-20% ethyl 
acetate/ hexane) to obtain pure intermediates 164a-164h. 
 
3'-acetyl-3-fluoro-[1,1'-biphenyl]-2-carbaldehyde (164a). Yellow solid; mp 73-75 °C; 
yield 42%; 1H NMR (300 MHz, DMSO-d6): ? 9.94 (s, 1H, CHO), 8.04 (d, 1H, J = 7.2 
Hz, ArH), 7.95 (s, 1H, ArH), 7.77 (dd, 1H, J1 = 9.0 Hz, J2 = 3.0 Hz, ArH), 7.65 (d, 2H,  
J = 7.2 Hz, ArH), 7.45 (t, 1H, J = 7.8 Hz, ArH), 7.35 (d, 1H, J = 7.8 Hz, ArH), 2.62 (s, 
3H, COCH3); MS (ESI): m/z 265.0 [M+Na]+. 
 
4'-acetyl-3-fluoro-[1,1'-biphenyl]-2-carbaldehyde (164b). Yellow solid; mp  
106-108 °C; yield 63%; 1H NMR (300 MHz, DMSO-d6): ? 9.94 (s, 1H, CHO), 8.05 (d, 
2H, J = 8.4 Hz, ArH), 7.74-7.82 (m, 1H, ArH), 7.55 (d, 2H, J = 8.1 Hz, ArH), 7.46 (t, 1H, 
J = 8.4 Hz, ArH), 7.35 (d, 1H, J = 7.5 Hz, ArH), 2.64 (s, 3H, COCH3); MS (ESI): m/z 
265.0 [M+Na]+. 
 
3'-acetyl-2'-fluoro-[1,1'-biphenyl]-2-carbaldehyde (164c). White solid; mp 74-76 °C; 
yield 45%; 1H NMR (300 MHz, DMSO-d6): ? 9.89 (d, 1H, J = 2.1 Hz, CHO), 8.0 (d, 1H, 
J = 7.8 Hz, ArH), 7.87-7.93 (m, 1H, ArH), 7.79-7.84 (m, 1H, ArH), 7.66-7.72 (m, 2H, 
ArH), 7.52 (d, 1H, J = 7.5 Hz, ArH), 7.42-7.48 (m, 1H, ArH), 2.58 (d, 3H, J = 4.2 Hz, 
COCH3); MS (ESI): m/z 265.0 [M+Na]+. 
 
3'-acetyl-2',5-difluoro-[1,1'-biphenyl]-2-carbaldehyde (164d). Light yellow solid; mp 
48-50 °C; yield 34 %; 1H NMR (300 MHz, DMSO-d6): ? 9.82 (d, 1H, J = 2.4 Hz, CHO), 
8.09 (dd, 1H, J1 = 8.4 Hz, J2 = 6.0 Hz, ArH), 7.92 (dt, 1H, J1 = 7.5 Hz, J2 = 1.8 Hz, ArH), 
7.73 (dt, 1H, J1 = 7.8 Hz, J2 = 1.8 Hz, ArH), 7.55 (dt, 1H, J1 = 8.7 Hz, J2 = 2.7 Hz, ArH), 
7.43-7.50 (m, 2H, ArH), 2.60 (d, 3H, J = 4.2 Hz, COCH3); MS (ESI): m/z 283.0 
[M+Na]+.  
 
4'-acetyl-4-chloro-[1,1'-biphenyl]-2-carbaldehyde (164e). White solid; mp  
138-140 °C; yield 71%; 1H NMR (300 MHz, DMSO-d6): ? 9.83 (s, 1H, CHO), 8.08 (d, 
2H, J = 8.1 Hz, ArH), 7.92 (d, 1H, J = 2.1 Hz, ArH), 7.85 (dd, 1H, J1 = 8.4 Hz, J2 = 2.4 
Hz, ArH), 7.62 (d, 2H, J = 8.4 Hz, ArH), 7.60 (d, 1H, J = 8.4 Hz, ArH), 2.64 (s, 3H, 
COCH3); m/z 281.0 [M+Na]+. 
 
4'-acetyl-5-chloro-[1,1'-biphenyl]-2-carbaldehyde (164f). White solid; mp 100-102 °C; 
yield 71%; 1H NMR (300 MHz, DMSO-d6): ? 9.83 (s, 1H, CHO), 8.07 (d, 2H, J = 8.4 
Hz, ArH), 7.97 (d, 1H, J = 8.4 Hz, ArH), 7.71 (d, 1H, J = 8.4 Hz, ArH), 7.66 (d, 2H, J = 
7.5 Hz, ArH), 7.63 (s, 1H, ArH), 2.65 (s, 3H, COCH3); MS (ESI): m/z 281.0 [M+Na]+. 
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4'-acetyl-3-chloro-[1,1'-biphenyl]-2-carbaldehyde (164g). Light yellow solid; mp 95-
97 °C; yield 78%; 1H NMR (300 MHz, DMSO-d6): ? 10.13 (s, 1H, CHO), 8.02 (dd, 2H, 
J1 = 8.11 Hz, J2 = 1.5 Hz, ArH), 7.66-7.73 (m, 2H, ArH), 7.50 (dd, 2H, J1 = 8.1 Hz, J2 = 
1.2 Hz, ArH), 7.43-7.46 (m, 1H, ArH), 2.63 (d, 3H, J = 1.5 Hz, COCH3); MS (ESI): m/z 
281.0 [M+Na]+. 
 
3'-acetyl-3-chloro-[1,1'-biphenyl]-2-carbaldehyde (164h).  White solid; mp 86-88 °C; 
yield 58%; 1H NMR (300 MHz, DMSO-d6): ? 10.15 (s, 1H, CHO), 7.99-8.02 (m, 1H, 
ArH), 7.91 (s, 1H, ArH), 7.58-7.73 (m, 4H, ArH), 7.47 (dd, 1H, J1 = 6.6 Hz, J2 = 1.8 Hz, 
ArH), 2.61 (s, 1H, COCH3); MS (ESI): m/z 281.0 [M+Na]+. 
 
 
General procedure for the synthesis of intermediates 165a-165h. Dimethyl-(1-
diazo-2-oxopropyl) phosphonate (4.46 g, 23.21 mmol) was added drop wise to a mixture 
of K2CO3 (4.0 g, 28.94 mmol) in methanol (30 mL) at 0 °C. The solution was stirred for 
10 min during which the color turned yellow. Aldehyde intermediates 164a-164h (3.0 g, 
11.62 mmol) were then added to the above solution and the reaction stirred in ice for 17 
h. After completion of reaction, the reaction mixture was evaporated. Saturated NaHCO3 
solution was added to the residue and extracted with ethyl acetate. The ethyl acetate layer 
was evaporated to dryness and the crude was purified by column chromatography (5-15% 
ethyl acetate/hexane) to afford pure intermediates 165a-165h. 
 
1-(2'-ethynyl-3'-fluoro-[1,1'-biphenyl]-3-yl)ethanone (165a). Brown flakes; mp  
56-58 °C; yield 59%; IR neat 3288 cm-1 (alkyne C-H), 2107 cm-1 (alkyne C-C); 1H NMR 
(300 MHz, DMSO-d6): ? 8.15 (s, 1H, ArH), 8.06 (d, 1H, J = 7.5 Hz, ArH), 7.83 (d, 1H,  
J = 7.2 Hz, ArH), 7.52-7.65 (m, 2H, ArH), 7.36 (t, 2H, J = 7.8 Hz, ArH), 4.48 (s, 1H, 
alkyne CH), 2.62 (s, 3H, COCH3); MS (ESI): m/z 261.0 [M+Na]+. 
 
1-(2'-ethynyl-3'-fluoro-[1,1'-biphenyl]-4-yl)ethanone (165b). Off-white solid; mp 100-
102 °C; yield 63 %; IR neat 3282 cm-1 (alkyne C-H), 2116 cm-1 (alkyne C-C);  1H NMR 
(300 MHz, DMSO-d6): ? 8.05 (d, 2H, J = 8.1 Hz, ArH), 7.72 (d, 2H, J = 8.4 Hz, ArH), 
7.56 (dd, 1H, J1 = 7.8 Hz, J2 = 7.5 Hz, ArH), 7.39 (t, 1H, J = 8.7 Hz, ArH), 7.34 (d, 1H,  
J = 7.5 Hz, ArH), 4.5 (s, 1H, alkyne CH), 2.64 (s, 3H, COCH3); MS (ESI): m/z 261.0 
[M+Na]+. 
 
1-(2'-ethynyl-2-fluoro-[1,1'-biphenyl]-3-yl)ethanone (165c). Violet liquid; yield 57%; 
1H NMR (300 MHz, DMSO-d6): ? 7.84 (t, 1H, J = 7.5 Hz, ArH), 7.64 (d, 2H, J = 6.9 Hz, 
ArH), 7.37-7.56 (m, 4H, ArH), 4.11 (s, 1H, alkyne CH), 2.60 (d, 1H, J = 4.2 Hz, 
COCH3); MS (ESI): m/z 261.0 [M+Na]+. 
 
1-(2'-ethynyl-2,5'-difluoro-[1,1'-biphenyl]-3-yl)ethanone (165d). Violet solid; mp 51-
53 °C; yield 35%; IR neat 3312 cm-1 (alkyne C-H); 1H NMR (300 MHz, DMSO-d6): ? 
7.83-7.90 (m, 1H, ArH), 7.66-7.73 (m, 2H, ArH), 7.32-7.44 (m, 3H, ArH), 4.10 (s, 1H, 
alkyne CH),  2.64 (dd, 3H, J1 = 1.8 Hz, J2 = 1.5 Hz, COCH3); MS (ESI): m/z 279.0 
[M+Na]+. 
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1-(4'-chloro-2'-ethynyl-[1,1'-biphenyl]-4-yl)ethanone (165e). White solid; mp  
138-140 °C; yield 61%; IR neat 3230 cm-1 (alkyne C-H ), 2097 cm-1 (alkyne C-C);  1H 
NMR (300 MHz, DMSO-d6): ? 8.04 (d, 2H, J = 7.8 Hz, ArH), 7.71 (s, 1H, ArH), 7.70 (d, 
2H, J = 8.1 Hz, ArH), 7.61 (d, 1H, J = 8.1 Hz, ArH), 7.50 (d, 1H, J = 8.4 Hz, ArH), 4.25 
(s, 1H, alkyne CH), 2.63 (s, 3H, COCH3); m/z 277.0 [M+Na]+. 
 
1-(5'-chloro-2'-ethynyl-[1,1'-biphenyl]-4-yl)ethanone (165f). White solid; mp  
102-104 °C; yield 64%; IR neat 3224 cm-1 (alkyne C-H ), 2106 cm-1 (alkyne C-C);  1H 
NMR (300 MHz, DMSO-d6): ? 8.02 (d, 2H, J = 8.1 Hz, ArH), 7.71 (d, 2H, J = 7.8 Hz, 
ArH), 7.65 (d, 1H, J = 8.1 Hz, ArH), 7.54 (d, 1H, J = 1.5 Hz, ArH), 7.49-7.52 (m, 1H, 
ArH), 4.26 (s, 1H, alkyne CH), 2.64 (s, 3H, COCH3); MS (ESI): m/z 277.0 [M+Na]+. 
 
1-(3'-chloro-2'-ethynyl-[1,1'-biphenyl]-4-yl)ethanone (165g). Light yellow solid; mp 
123-125 °C; yield 50%; IR neat 3266 cm-1 (alkyne C-H ), 2109 cm-1 (alkyne C-C);  1H 
NMR (300 MHz, DMSO-d6): ? 8.05 (dd, 2H, J1 = 8.1 Hz, J2 = 1.5 Hz, ArH), 7.70 (dd, 
2H, J1 = 8.1 Hz, J2 = 1.5 Hz, ArH), 7.63 (d, 1H, J = 8.7 Hz, ArH), 7.52 (dt, 1H, J1 = 7.8 
Hz, J2 = 1.8 Hz, ArH), 7.42 (d, 1H, J = 7.8 Hz, ArH), 4.96 (s, 1H, alkyne CH), 2.63 (d, 
3H, J = 1.8 Hz, COCH3); MS (ESI): m/z 277.0 [M+Na]+. 
 
1-(3'-chloro-2'-ethynyl-[1,1'-biphenyl]-3-yl)ethanone (165h). White solid; mp  
97-99 °C; yield 46%; IR neat 3293 cm-1 (alkyne C-H ), 2104 cm-1 (alkyne C-C); 1H NMR 
(300 MHz, DMSO-d6): ? 8.13 (s, 1H, ArH), 8.00 (d, 1H, J = 7.2 Hz, ArH), 7.81 (d, 1H,  
J = 7.2 Hz, ArH), 7.61-7.65 (m, 2H, ArH), 7.53 (t, 1H, J = 7.8 Hz, ArH), 7.45 (d, 1H, J = 
7.8 Hz, ArH), 4.53 (s, 1H, alkyne CH); MS (ESI): m/z 277.0 [M+Na]+. 
 
 
General procedure for the synthesis of intermediates 168a-168h. A solution of 
alkyne intermediates 165a-165h (1.0 g, 4.19 mmol) and PtCl2 (0.55 g, 5 mol%) in 
toluene (20 mL) was stirred at 80 °C in argon for 24 h. After the reaction, the solution 
was filtered through celite and evaporated to dryness. The crudes were then purified by 
column chromatography (5-15% ethyl acetate/hexane) to give pure intermediates 168a-
168h. 
 
1-(8-fluorophenanthren-3-yl)ethanone (168a). White solid; mp 80-82 °C; yield 60%; 
1H NMR (300 MHz, DMSO-d6): ? 9.36 (s, 1H, ArH), 8.83 (d, 1H, J = 7.8 Hz, ArH), 
8.09-8.16  (m, 3H, ArH), 7.99 (d, 1H, J = 9.0 Hz, ArH), 7.77 (d, 1H, J = 7.8 Hz, ArH),  
7.55 (d, 1H, J = 7.8 Hz, ArH), 2.81 (s, 3H, COCH3); MS (ESI): m/z 261.0 [M+Na]+. 
 
1-(8-fluorophenanthren-2-yl)ethanone (168b). Light yellow solid; mp 128-130 °C; 
yield 51%; 1H NMR (300 MHz, DMSO-d6): ? 8.95 (d, 1H, J = 8.7 Hz, ArH), 8.75 (d, 1H, 
J = 8.4 Hz, ArH), 8.73 (s, 1H, ArH), 8.21 (dd, 1H, J1 = 8.7 Hz, J2 = 1.5 Hz, ArH), 8.12 
(d, 1H, J = 9.0 Hz, ArH), 8.07 (d, 1H, J = 9.0 Hz, ArH), 7.72-7.79 (m, 1H, ArH), 7.58 (t, 
1H, J = 7.8 Hz, ArH), 2.75 (s, 3H, COCH3); MS (ESI): m/z 261.0 [M+Na]+. 
 
1-(4-fluorophenanthren-3-yl)ethanone (168c). Off-white solid; mp 80-82 °C; yield 
57%; 1H NMR (300 MHz, DMSO-d6): ? 9.03 (d, 1H, J = 7.8 Hz, ArH), 8.11 (d, 1H, J = 
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7.5 Hz, ArH), 8.07 (d, 1H, J = 9.0 Hz, ArH), 7.92-8.01 (m, 3H, ArH), 7.74-7.84 (m, 2H, 
ArH), 2.78 (d, 3H, J = 4.5 Hz, COCH3); MS (ESI): m/z 261.0 [M+Na]+. 
 
1-(4,6-difluorophenanthren-3-yl)ethanone (168d). White solid; mp 128-130 °C; yield 
53%; 1H NMR (300 MHz, DMSO-d6): 8.60 (d, 1H, J = 12.6 Hz, ArH), 8.18  (t, 1H, J = 
7.8 Hz, ArH), 8.06 (d, 1H, J = 8.7 Hz, ArH), 7.87-8.01 (m, 3H, ArH),  7.66 (t, 1H, J = 8.4  
Hz, ArH), 2.76 (d, 3H, J = 4.5 Hz, COCH3); MS (ESI): m/z 279.0 [M+Na]+. 
 
1-(7-chlorophenanthren-2-yl)ethanone (168e). Light yellow solid; mp 122-124 °C; 
yield 43%;1H NMR (300 MHz, DMSO-d6): ? 8.92 (dd, 2H, J1 = 8.7 Hz, J2 = 2.1 Hz, 
ArH), 8.69 (s, 1H, ArH), 8.20 (d, 1H, J = 9.3 Hz, ArH), 8.18 (s, 1H, ArH), 8.08 (d, 1H,  
J = 9.0 Hz, ArH), 7.93 (d, 1H, J = 9.0 Hz, ArH), 7.76 (dd, 1H, J1 = 8.7 Hz, J2 = 2.1 Hz, 
ArH), 2.74 (s, 3H, COCH3); MS (ESI): m/z 277.0 [M+Na]+. 
 
1-(6-chlorophenanthren-2-yl)ethanone (168f). Yellow solid; mp 103-105 °C; yield 
53%;1H NMR (300 MHz, DMSO-d6): ? 8.99 (d, 1H, J = 8.7 Hz, ArH), 8.96 (s, 1H, ArH), 
8.68 (d, 1H, J = 1.5 Hz, ArH), 8.17 (dd, 1H, J1 = 8.7 Hz, J2 = 1.8 Hz, ArH), 8.08 (d, 1H, 
J = 8.4 Hz, ArH), 8.04 (d, 1H, J = 9.0 Hz, ArH), 7.96 (d, 1H, J = 9.0 Hz, ArH), 7.75 (dd, 
1H, J1 = 8.4 Hz, J2 = 1.8 Hz, ArH), 2.75 (s, 3H, COCH3); MS (ESI): m/z 277.0 [M+Na]+. 
 
1-(8-chlorophenanthren-2-yl)ethanone (168g). White solid; mp 108-110 °C; yield 
54%; 1H NMR (300 MHz, DMSO-d6): ? 8.98 (d, 1H, J = 8.7 Hz, ArH), 8.75 (s, 1H, 
ArH), 8.24 (d, 1H, J = 8.1 Hz, ArH), 8.04 (d, 1H, J = 6.9 Hz, ArH), 7.91 (d, 1H, J = 7.5 
Hz, ArH), 7.70 (d, 1H, J = 6.9 Hz, ArH), 7.52 (t, 1H, J = 7.8 Hz, ArH), 7.41 (d, 1H, J = 
7.5 Hz, ArH), 2.63 (s, 3H, COCH3); MS (ESI): m/z 277.0 [M+Na]+. 
 
1-(8-chlorophenanthren-1-yl)ethanone and 1-(8-chlorophenanthren-3-yl)ethanone 
isomer (168h). White solid; mp 110-112 °C yield 60%; 1H NMR (300 MHz, DMSO-d6): 
? 9.13 (d, 1H, J = 8.4 Hz, ArH), 8.94 (d, 1H, J = 8.4 Hz, ArH), 8.58 (d, 1H, J = 9.6 Hz, 
ArH), 8.16-8.23 (m, 3H, ArH), 8.13 (s, 1H, ArH), 7.99 (d, 1H, J = 7.8 Hz, ArH), 7.87 (d, 
2H, J = 8.1 Hz, ArH), 7.82 (d, 1H, J = 7.8 Hz, ArH), 7.75 (t, 2H, J = 7.5 Hz, ArH), 7.62-
7.70 (m, 1H, ArH), 7.40-7.60 (m, 2H, ArH), 2.78 (s, 3H, COCH3), 2.63 (s, 3H, COCH3); 
MS (ESI): m/z 277.0 [M+Na]+.   
  
 
General procedure for the synthesis of intermediates 168i and 168j. To a 
thick-well borosilicate glass vial (10 mL) was added phenyl propanone starting materials 
(0.20 g, 0.94 mmol), 4-methoxy-2-formyl boronic acid (0.20 g, 1.12 mmol), Pd (PPh3)4  
(0.043 g, 4mol %), Cs2CO3 ( 0.91 g, 2.82 mmol) and S-Phos (0.022 g, 6 mol%) 
sequentially in a toluene: ethanol (4 mL:2 mL) mixture. The reaction vial was then sealed 
and placed in a microwave reactor and irradiated with 60-80 W power at 150 °C for 10 
min. The reaction mixture was then cooled to room temperature and diluted with excess 
ethyl acetate. The resulting solution was filtered through celite and concentrated in vacuo. 
The crude solid was purified by column chromatography (10-15% ethyl acetate/hexane). 
 
1-(8-fluoro-2-methoxyphenanthren-9-yl)ethanone (168i). Yellow solid; mp  
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110-112 °C; yield 48%; 1H NMR (300 MHz, DMSO-d6): ? 8.76 (dd, 1H, J1 = 9.0 Hz,  
J2 = 2.4 Hz, ArH), 8.65 (dd, 1H, J1 = 8.4 Hz, J2 = 2.7 Hz, ArH), 7.88 (d, 1H, J = 2.7 Hz, 
ArH), 7.68-7.74 (m, 1H, ArH), 7.56 (bs, 1H, ArH), 7.39-7.48 (2H, m, ArH), 3.94 (d, 3H, 
J = 2.7 Hz, OCH3), 2.61(t, 3H, J = 2.4 Hz, COCH3); MS (ESI): m/z 291.0 [M+Na]+. 
 
1-(2-methoxyphenanthren-9-yl)ethanone (168j). Yellow solid; mp 97-99 °C; yield 
51%; 1H NMR (300 MHz, DMSO-d6): ? 8.78 (d, 1H, J = 7.5 Hz, ArH), 8.76 (d, 1H, J = 
8.4 Hz, ArH), 8.58 (d, 1H, J = 8.7 Hz, ArH), 8.50 (s, 1H, ArH), 7.64 (s, 1H, ArH), 7.59-
7.72 (m, 2H, ArH), 7.43 (d, 1H, J = 8.7 Hz, ArH), 3.95 (s, 3H, OCH3), 2.80 (s, 3H, 
COCH3); MS (ESI): m/z 273.0 [M+Na]+. 
 
Synthesis of reagent tert-butyl methyl oxalate (170). Methyl oxalyl chloride (4.08 
mmol, 0.376 mL) was added drop wise to a mixture of anhydrous pyridine (4.08 mmol, 
194 μL), tert-butanol (2.04 mmol, 0.194 μL) and anhydrous ether (5 mL), and the 
resulting solution stirred at room temperature for 2 h. After the reaction, water was added 
to the mixture followed by a saturated solution of NaHCO3. The reaction mixture was 
thereafter extracted with ethyl acetate and organic layer was concentration to obtain tert-
butyl methyl oxalate (170) which was used without further purification. White liquid; MS 
(ESI): m/z 183.0 [M+Na]+. 
 
 
General procedure for the synthesis of final diketo acid compounds 172-181. 
To a stirred solution of freshly prepared NaOMe (145 mg Na metal in 2 mL methanol) in 
anhydrous THF(15 mL) at rt was added drop wise a mixture of tert-butyl methyl oxalate 
(1 mL) and acetyl phenanthrene intermediates (168a-168j) (0.4 g, 1.57 mmol) in DME 
(15 mL). The resulting red colored mixture was stirred at room temperature for 4 h. After 
the reaction, the mixture was poured into cold water and acidified with dilute HCl. Solid 
ester intermediates were precipitated in quantitative yields and were dried in vacuo and 
taken to the next step without further purification. Aqueous NaOH (5.87 mL, 1M) was 
added to the solution of ester intermediates 171i-171j (0.50 g, 1.47 mmol) in a MeOH-
THF (1:1, 20 mL) mixture.  The resulting solution was stirred at rt for 6 h. After the 
reaction the mixture was poured into cold water and acidified with dilute HCl. The solid 
precipitated was dried in vacuo. The crude was recrystallized with ethanol to give pure 
final products 172-181. 
 
4-(8-fluorophenanthren-3-yl)-2,4-dioxobutanoic acid (172). Yellow solid; yield 89%; 
mp 138-140 °C; 1H NMR (500 MHz, DMSO-d6): ? 9.43 (s, 1H, ArH), 8.91 (d, 1H, J = 
8.0 Hz, ArH), 8.27 (d, 1H, J = 9.0 Hz, ArH), 8.10-8.30 (m, 3H, ArH, enolic CH), 8.05 (d, 
1H, J = 9.0 Hz, ArH), 7.75-7.80 (m, 1H, ArH), 7.56 (t, 1H, J = 9.0 Hz, ArH); MS (ESI): 
m/z 308.8 [M?H]?. 
 
4-(8-fluorophenanthren-2-yl)-2,4-dioxobutanoic acid (173). Yellow solid; yield 92%; 
mp 205-206 °C; 1H NMR (300 MHz, DMSO-d6): ? 9.0 (d, 1H, J = 8.7 Hz, ArH), 8.89 (s, 
1H, ArH), 8.76 (d, 1H, J = 8.4 Hz, ArH), 8.30 (d, 1H, J = 8.7 Hz, ArH), 8.18 (d, 1H, J = 
8.7 Hz, ArH), 8.10 (d, 1H, J = 9.0 Hz, ArH), 7.57-7.78 (m, 2H, ArH), 7.35 (s, 1H, enolic 
CH); MS (ESI): m/z 308.8 [M?H]?. 
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4-(4-fluorophenanthren-3-yl)-2,4-dioxobutanoic acid (174). Dark yellow solid; yield 
87%; mp 226-227 °C; 1H NMR (300 MHz, DMSO-d6): ? 10.03 (d, 1H, J = 7.2 Hz, ArH), 
8.12-8.20 (m, 3H, ArH), 7.99-8.07 (m, 2H, ArH), 7.74-7.80 (m, 2H, ArH), 7.10 (s, 1H, 
enolic CH); m/z 288.7 [M?HF]?; HPLC: tR 4.11 min, purity 97.5%. 
 
4-(4,6-difluorophenanthren-3-yl)-2,4-dioxobutanoic acid (175). Yellow solid; yield 
81%; mp >250 °C dec; 1H NMR (300 MHz, DMSO-d6): ? 9.63 (d, 1H, J = 13.8 Hz, 
ArH), 8.09-8.17 (m, 3H, ArH), 7.97 (d, 1H, J = 7.8 Hz, ArH), 7.89 (d, 1H, J = 8.7 Hz, 
ArH), 7.62 (t, 1H, J = 8.4 Hz, ArH), 7.05 (s, 1H, enolic CH); m/z 306.8 [M?HF]?; HPLC: 
tR 4.11 min, purity 98.4%. 
 
4-(7-chlorophenanthren-2-yl)-2,4-dioxobutanoic acid (176). Yellow solid; yield 93%; 
mp 220-222 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.96 (d, 1H, J = 9.0 Hz, ArH), 8.92 
(d, 1H, J = 9.0 Hz, ArH), 8.84 (d, 1H, J = 1.7 Hz, ArH), 8.27 (dd, 1H, J1 = 8.7 Hz, J2 = 
1.8 Hz, ArH), 8.18 (d, 1H, J = 2.1 Hz, ArH), 8.15 (d, 1H, J = 9.0 Hz, ArH), 7.95 (d, 1H,  
J = 9.0 Hz, ArH), 7.75 (dd, 1H, J1 = 9.0 Hz, J2 = 2.1 Hz, ArH), 7.32 (s, 1H, enolic CH); 
m/z 325.0 [M?H]?. 
 
3-(6-chlorophenanthren-2-yl)-3-oxopropanoic acid (177). Yellow solid; yield 78%; mp 
213-215 °C; 1H NMR (300 MHz, DMSO-d6): ? 9.02 (d, 1H, J = 9.0 Hz, ArH), 8.97 (s, 
1H, ArH), 8.82 (s, 1H, ArH), 8.24 (d, 1H, J = 8.7 Hz, ArH), 8.08 (d, 2H, J = 8.4 Hz, 
ArH), 7.97 (d, 1H, J = 9.0 Hz, ArH), 7.77 (d, 1H, J = 8.7 Hz, ArH), 7.28 (s, 1H, enolic 
CH); m/z 325.0 [M?H]?. 
 
4-(8-chlorophenanthren-2-yl)-2,4-dioxobutanoic acid (178). Yellow solid; yield 86%; 
mp 204-206 °C; 1H NMR (300 MHz, DMSO-d6): ? 9.0 (d, 1H, J = 8.1 Hz, ArH), 8.92 (d, 
1H, J = 7.8 Hz, ArH), 8.87 (s,1H, ArH), 8.28 (d, 1H, J = 8.7 Hz, ArH), 8.23 (d, 2H, J = 
1.2 Hz, ArH), 7.90 (d, 1H, J = 6.3 Hz, ArH), 7.74 (t, 1H, J = 7.5 Hz, ArH), 7.31 (s, 1H, 
enolic CH); m/z 325.0 [M?H]?. 
 
4-(8-chlorophenanthren-3-yl)-2,4-dioxobutanoic acid (179). Yellow solid; yield 83%; 
mp >235 °C dec; 1H NMR (300 MHz, DMSO-d6): ? 9.34 (s, 1H, ArH), 9.02 (d, 1H, J = 
8.1 Hz, ArH), 8.00-8.26 (m, 5H, ArH, enolic CH), 7.85 (d, 1H, J = 7.5 Hz, ArH), 7.74 (t, 
1H, J = 7.8 Hz, ArH); m/z 325.0 [M?H]?. 
 
4-(8-fluoro-2-methoxyphenanthren-9-yl)-2,4-dioxobutanoic acid (180). Yellow solid; 
yield 91%; mp 211-213 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.80 (d, 1H, J = 9.0 Hz, 
ArH), 8.70 (d, 1H, J = 8.1 Hz, ArH), 8.02 (s, 1H, ArH), 7.75 (t, 1H, J = 8.1 Hz), 7.66 (d, 
1H, J = 2.1 Hz, ArH), 7.43-7.51 (m, 2H, ArH), 6.58 (s, 1H, enolic CH), 3.95 (s, 3H, 
OCH3); MS (ESI): m/z 338.9 [M?H]?. 
 
4-(2-methoxyphenanthren-9-yl)-2,4-dioxobutanoic acid (181). Orange solid; yield 
88%; mp 198-200 °C; 1H NMR (300 MHz, DMSO-d6): ? 8.82 (d, 1H, J = 9.0 Hz, ArH), 
8.79 (d, 1H, J = 9.3 Hz, ArH), 8.50 (d, 1H, J = 8.1 Hz, ArH), 8.41 (s, 1H, ArH), 7.74 (s, 
1H, ArH), 7.72 (t, 1H, J = 8.1 Hz, ArH), 7.64 (t, 1H, J = 8.1 Hz, ArH), 7.45 (dd, 1H, J1 = 
9.0 Hz, J2 = 2.7 Hz, ArH), 6.98 (s, 1H, enolic CH), 3.94 (s, 3H, ArH); MS (ESI): m/z  
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320.9 [M?H]?. 
 
 
Biological Assays 
 
 
Materials, chemicals, and enzymes. All compounds were dissolved in DMSO 
and the stock solutions were stored at -20 °C. ?[32P]-ATP was purchased from either 
Amersham Biosciences or ICN. The expression systems for wild-type IN were a 
generous gift from Dr. Robert Craigie, Laboratory of Molecular Biology, NIDDK, NIH, 
Bethesda, MD. Cell lines were obtained from American Type Culture Collection (ATCC, 
Rockville, MD). 
 
 
Preparation of oligonucleotide substrates. The oligonucleotides 21top, 5?-
GTGTGGAAAATCTCTAGCAGT-3?, and 21bot, 5?-ACTGCTAGAGATTTTCCACAC-
3?, were purchased from the Norris Cancer Center Microsequencing Core Facility 
(University of Southern California) and purified by UV shadowing on polyacrylamide 
gel. To analyze the extent of 3?-P  and ST using 5?-end labeled substrates, 21top was 5?-
end labeled using T4 polynucleotide kinase (Epicentre, Madison, WI) and ?[32P]-ATP 
(Amersham Biosciences or ICN). The kinase was heat-inactivated and 21-bot was added 
in 1.5M excess. The mixture was heated at 95 °C, allowed to cool slowly to rt, and run 
through a G25 mini spin column (USA Scientific) to separate double-stranded 
oligonucleotide from unincorporated material. 
 
 
Integrase assays. To determine the extent of 3?-P and ST, wild-type IN was 
preincubated at a final concentration of 200 nM with the inhibitor in reaction buffer (50 
mM NaCl, 1 mM HEPES, pH 7.5, 50 μM EDTA, 50 μM dithiothreitol, 10% glycerol 
(w/v), 7.5 mM MnCl2, 0.1 mg/mL bovine serum albumin, 10 mM 2-mercaptoethanol, 
10% dimethylsulfoxide, and 25 mM MOPS, pH 7.2) at 30 °C for 30 min. An aliquot 
(5μL) was electrophoresed on a denaturing 20% polyacrylamide gel (0.09 M Tris-borate, 
pH 8.3, 2 mM EDTA, 20% acrylamide, and 8M urea). Gels were dried, exposed in a 
PhosphorImager cassette, and analyzed using a Typhoon 8610 Variable Mode Imager 
(Amersham Biosciences) and quantitated using ImageQuant 5.2. Percent inhibition (%I) 
was calculated using (Equation 3-1). The IC50 values were determined by plotting the 
logarithm of compound concentration versus percent inhibition to obtain the 
concentration that produced 50% inhibition. 
 
 
Anti-HIV-1 activity assay. The testing of the ability of potent compounds to 
inhibit HIV replication in cell culture was done according to a previously reported 
procedure.182 PBMC (107 cells/T25flask) were stimulated with phytohemagglutinin for 3 
days and infected with a wild-type HIV-1 strain (strain LAI) at 100 50% tissue culture 
infective doses, as described previously.182 The cultures were kept for 5 days in the 
presence of test compounds at serial 1-log dilutions. Subsequently, human PBMC were 
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removed from the culture supernatant by centrifugation (400g, 10 min, 4 °C). This 
clarified supernatant was tested by a reverse transcriptase assay. 
 
 
Cytotoxicity assays. The cytotoxicity of compounds was evaluated using 
uninfected PBMC and CEM leukemia cells according to a previous method.183 PBMC 
were obtained from whole blood of healthy individuals, while CEM were obtained from 
the ATCC (Rockville, MD). The PBMC and CEM cells were cultured in the presence or 
absence of compound for 6 days. After this time period, cells were stained with Trypan 
blue dye, and counted for cell proliferation and viability according to the previously 
reported procedure.184  
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CHAPTER 6.   COMPUTATIONAL STUDIES ON HIV-1 INTEGRASE 
INHIBITORS* 
 
 
Introduction 
 
 The absence of a complete DNA-bound HIV IN crystal structure has presented a 
significant challenge for the structure-based design of potent IN inhibitors. Although X-
ray structures of individual human HIV domains and their combinations (core domain 
and N terminal domain; core domain and C terminal domain; and core domain with an 
inhibitor (5-CITEP)) have been reported,62-76 most of these structures have an unresolved 
flexible loop. Moreover, there are differences in conformations of the active site residues 
in the two structures that show a completely resolved flexible loop (chain B of 1BIS and 
chain C of 1BL3).66,67 The absence of a 3D structure of IN and viral DNA along with the 
two-divalent metals bound in the active site makes the structural information hitherto 
available limited and may be far from reality. 
 
In the first part of this chapter, three dimensional structure-activity relationship 
(3D-QSAR) studies were conducted to gain insights into the binding of chalcone IN 
inhibitors (described in Chapter 3) at the IN active site.  CoMFA and CoMSIA 3D-QSAR 
models were derived to study the influence of stereoelectronic, hydrophobic and 
hydrogen bonding interactions on activity; and to establish predictive tools for design of 
novel inhibitors. In the absence of the complete HIV-DNA crystal structure, ligand-based 
pharmacophore alignments were used to develop the 3D-QSAR models. The resulting 
models showed moderate statistical significance and limited predictive ability. 
 
With an aim to develop improved QSAR models, in the next part of this chapter, a 
homology model of full length IN-DNA-Raltegravir complex developed by our 
collaborator at the Oak Ridge National Laboratory, was used to perform the docking-
based QSAR studies. The models developed demonstrated significant improvement in 
terms of statistical significance and predictive ability over the previous ligand-based 
models. Prospective compounds predicted by the models were synthesized and tested for 
HIV-1 IN inhibitory activities. 
 
The third part of this chapter describes docking studies and exploration of binding 
modes of the substituted phenanthrene ?-diketo acids synthesized in Chapter 5. These 
studies have provided insights into designing further modifications to improve their HIV-
1 IN inhibitory activities. 
 
In last part of this chapter, I have attempted structure-based design to modify our 
synthesized amide derivatives as well as performed in silico screening to discover new  
 
* Portions of this chapter adapted with permission. Sharma, H.; Patil, S.; Sanchez, T. W.; 
Neamati, N.; Schinazi, R. F.; Buolamwini, J. K. Synthesis, biological evaluation and 3D-
QSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1 
integrase inhibitors. Bioorg. Med. Chem. 2011, 19, 2030-2045.179  
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hits for inhibition of HIV-1 IN. The 3D-database searches have resulted in the discovery 
of a hit, displaying ST inhibitory activity of 9 μM, that could be developed as a novel 
class of HIV-1 IN inhibitor.   
 
 
Ligand-Based Modeling Studies 
 
 
Generation of a Pharmacophore Model Using the PHASE Program 
 
Knowledge of the structure of target protein inhibitor interations is limited as no 
crystal structure of human integrase-ligand-DNA complex is available. Therefore, to 
explore the bioactive conformation of these novel IN inhibitors, the PHASE200 (v3.0) 
pharmacophore mapping program implemented in Maestro modeling program package 
(v8.5; Shrodinger Inc.) was used. The 3D structures of molecules were constructed in and 
imported from the SYBYL modeling program (v8.3, Tripos). Conformers of each 
molecule were generated using the OPLS_2005 force field in the macromodel 
conformational analysis program of PHASE. A set of pharmacophoric sites based on 
features defined in PHASE were assigned to the molecules. These included H-bond 
acceptor (A), H-bond donor (D), hydrophobic group (H), negatively charged group (N) 
and aromatic ring (R). The three most potent compounds of the chalcone series, 
compound 86, 88 and 96 were selected as actives for use in identifying a common 
pharmacophore hypothesis using a tree-based partitioning technique of PHASE. The 
resulting pharmacophores were then scored and ranked. The top twenty pharmacophore 
hypotheses were analyzed and validated by partial least square (PLS) regression-based 
PHASE 3D-QSAR. Random external test sets were generated automatically to determine 
the predictive ability of the models. The hypothesis that afforded the best PLS statistics 
(Table 6-1) and the highest predicted ability consisted of six features viz., two H-bond 
acceptors, two hydrophobic groups, a negative group and one aromatic ring (Figure 6-1). 
Two H-bond acceptor features mapped onto the oxygen of the hydroxyl and the 3-keto 
moiety and negative feature mapped onto the carboxylate group of the salicylic acid 
pharmacophore. The two hydrophobic features mapped to the halogen substituent of ring 
A and the para substituted halogen in aryl ring B. The aromatic pharmacophoric feature 
mapped onto aromatic ring A. Residuals of the training and the test set are listed in 
Tables 6-2 and 6-3, respectively. The prediction curve for the test set is shown in Figure 
6-2. As can be seen, the hypothesis gave a good predictive model with a predictive r2 of 
0.57 for an external test set of ten compounds. It was also able to distinguish active and 
inactive compounds, with the latter group not aligning well to the features (Figure 6-3 
and Figure 6-4). 
 
 
Ligand-Based 3D-QSAR Analysis 
 
 
CoMFA and CoMSIA 3D-QSAR models. Statistical analysis by PLS201,202 was 
done using CoMFA and CoMSIA descriptors as independent variables and biological  
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Table 6-1. Residuals of training set by PHASE 3D-QSAR 
 
Cpd. Actual ST pIC50 Predicted ST pIC50 Residuals 
81 4.60 4.85 -0.25 
82 4.85 4.59 0.26 
83 4.49 4.53 -0.04 
85 4.92 4.84 0.08 
86 5.30 4.94 0.36 
87 4.45 4.85 -0.40 
88 5.15 5.02 0.13 
89 4.72 4.66 0.06 
90 4.46 4.59 -0.13 
91 4.29 4.29 0.00 
92 4.74 4.87 -0.13 
93 4.79 4.83 -0.04 
95 4.88 4.82 0.06 
96 5.40 5.40 0.00 
97 4.27 4.49 -0.22 
98 4.00 4.21 -0.21 
99 4.03 4.48 -0.45 
103 4.39 4.44 -0.05 
104 4.76 4.63 0.13 
105 4.62 4.33 0.29 
106 4.52 4.44 0.08 
107 4.54 4.63 -0.09 
108 4.82 4.59 0.23 
110 4.23 4.42 -0.19 
111 4.12 3.94 0.18 
112 4.12 4.15 -0.03 
113 5.04 4.99 0.05 
114 4.74 4.79 -0.05 
115 4.79 4.79 0.00 
116 4.74 4.85 -0.11 
117 4.26 4.32 -0.06 
118 4.33 4.16 0.17 
119 4.26 4.28 -0.02 
120 4.96 4.86 0.10 
124 4.49 4.46 0.03 
125 4.74 4.60 0.14 
126 4.23 4.32 -0.09 
127 4.40 4.24 0.16 
128 4.30 4.37 -0.07 
129 4.16 4.10 0.06 
130 4.68 4.80 -0.12 
149 4.82 4.83 -0.01 
153 4.00 4.26 -0.26 
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Figure 6-1. The best pharmacophore hypothesis (AAHHNR) mapped on 
compound 88 
 
 
 
Table 6-2. PLS statistics of PHASE 3D-QSAR model 
 
PLS statistics Results 
q2 0.57 
r2 0.74 
SD 0.17 
F 28.30 
PLS factors 4.00 
Pearson r 0.75 
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Table 6-3. Residuals of test set by PHASE 3D-QSAR 
 
Cpd. Actual ST 
 pIC50 
Predicted 
ST pIC50 
Residuals 
84 5.04 4.86 0.18 
94 4.85 4.78 0.07 
100 4.60 4.71 -0.11 
101 4.77 4.63 0.14 
102 4.52 4.25 0.27 
109 4.41 4.28 0.13 
121 4.80 4.91 -0.11 
122 4.20 4.51 -0.31 
123 4.28 4.46 -0.18 
154 4.00 4.35 -0.35 
 
 
 
 
 
 
Figure 6-2. PHASE 3D-QSAR predictions of the test set 
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Figure 6-3. Alignment of active compounds by PHASE 
 
 
 
 
 
 
Figure 6-4. Alignment of inactive compounds by PHASE 
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activity in the form of pIC50 values as dependent variable. The molecular alignment used 
for CoMFA and CoMSIA 3D-QSAR modeling was derived from PHASE pharmacophore 
mapping (Schrödinger, Inc.). PHASE derived pharmacaphore hypotheses have been 
successfully used to derive “bioactive conformations” for 3D-QSAR modeling in 
previous work from our laboratory203 and elsewhere (Telvekar et al.).204 Thus, “bioactive 
conformations” of all the molecules from PHASE conformational analysis were 
superimposed using the MATCH alignment tool in SYBYL (Figure 6-5). Fifty three (53) 
synthesized target compounds were used for the 3D-QSAR analyses. The Leave-One-Out 
(LOO) method of cross validation was used for initial assessment of the predictive 
abilities of the models with the training sets. The optimal number of components used in 
the final QSAR models was that which gave the smallest standard error of prediction.  
Reliability of the models was tested by prediction of 10 compounds selected as an 
external test set using factor analysis. The PLS analysis results from both the CoMFA 
and CoMSIA models are summarized in Table 6-4. Cross-validated q2 values of 0.43 and 
0.54 were obtained for CoMFA and CoMSIA, respectively. Results of rigorous statistical 
testing using group cross-validation (20 groups), bootstrapping and randomization of 
activity data demonstrated the robustness of the QSAR models. Both CoMSIA and 
CoMFA identified six outliers, which were excluded on the basis of their extreme 
residual values (Table 6-5). Out of these, five outliers were common to both CoMFA and 
CoMSIA. These were compounds 87, 98, 99, 126 and 128. The reasons for compound 
126 being an outlier are not apparent. With compound 87 (iodo substituted) and 
compound 128 (X = CH3), their outlier status may stem from structural uniqueness, 
whereas the outlier status of compounds 98 and 99 (least active analogs, X = Cl) may 
drive from different binding modes. The CoMFA and CoMSIA predictions for the 
training and the test sets are shown in Figures 6-6 and 6-7, respectively. The CoMFA 
and CoMSIA residual values for the training set are given in Table 6-5 and the 
corresponding values for the test set in Table 6-6. In concordance with the higher q2 
value, the CoMSIA model performed better than CoMFA model, and predicted all test set 
compounds within 0.56 log unit of the actual pIC50 values. 
 
 
CoMFA and CoMSIA contour maps. Steric CoMFA maps (Figure 6-8) show 
green contours around the ortho and para positions on aryl ring B indicating that bulky 
groups are favored at these positions. This is validated by the fact that a benzyl group 
substitution at the ortho-position resulted in higher activity (compound 113). Compounds 
115 and 120, which have a bulky chloro phenoxy and thiophene groups around the green 
contour at the para-position also displayed better inhibitory activities. A large yellow 
contour surrounds a small green contour at the meta position on aryl ring B suggesting 
that only a limited bulk is favorable for activity. This is apparent by the loss of inhibitory 
activity observed with compound 117, the bulky cyclopentyl ring of which occupies the 
sterically disfavored yellow contour region. There is also a green contour evident at the 
R1 position on the aromatic ring A. This may be the reason why among the three 
halogens at that position, bromine, which is the bulkiest, afforded the highest activity. At 
the aryl ring B, CoMFA electrostatic map reveals a red contour at the 3?-position 
suggesting that electronegative groups could increase activity at this position. This is 
most exemplified by the 3?-Cl substitution in compound 84 which had an IC50  
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Figure 6-5. Alignment of dataset for 3D-QSAR 
 
 
 
Table 6-4. PLS statistics of CoMFA and CoMSIA 3D-QSAR 
 
PLS statistics CoMFA CoMSIA 
q2 0.43 0.54 
r2 0.94 0.94 
S 0.09 0.09 
F 78.32 78.69 
PLS components 6.0 6.00 
Field contribution   
Steric 0.474 0.100 
Electrostatic 0.526 0.428 
Hydrophobic  0.283 
Donor  0.146 
Acceptor  0.044 
Bootstrapping r2 (20 runs) 0.96 ± 0.01 0.96 ± 
0.01 
Randomization r2 (20 runs) 0.33 0.39 
Cross-validation q2 (20 runs) 0.44 0.50 
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Table 6-5. Residuals of training set of CoMFA and CoMSIA models 
 
Cpd. Actual ST pIC50   CoMFA Res.        CoMSIA Res. 
81 4.60 -0.13 -0.12 
82 4.85 0.12 0.12 
83 4.49 -0.18 -0.19 
84 5.04 0.05 0.03 
85 4.92 -0.15 -0.08 
86 5.30 0.16 0.11 
87 4.45 -0.62 -0.96 
88 5.15 0.21 0.19 
89 4.72 0.10 -0.07 
90 4.46 0.06 -0.04 
91 4.29 0.05 -0.003 
92 4.74 0.01 0.04 
93 4.79 -0.03 -0.03 
94 4.85 -0.13 -0.03 
95 4.88 0.07 0.11 
96 5.40 -0.05 -0.05 
97 4.27 -0.02 0.09 
98 4.00 -0.62 -0.89 
99 4.03 -0.79 -0.74 
100 4.60 0.02 0.005 
101 4.77 0.01 0.11 
102 4.52 0.03 0.06 
104 4.76 -0.009 0.04 
105 4.62 -0.02 -0.13 
106 4.52 -0.03 -0.12 
107 4.54 0.06 0.04 
109 4.41 -0.001 -0.04 
110 4.23 -0.05 -0.05 
111 4.12 -0.02 -0.02 
114 4.74 -0.07 -0.01 
115 4.79 -0.07 0.56 
117 4.26 -0.03 0.00 
118 4.33 0.07 0.09 
119 4.26 0.002 -0.03 
120 4.96 0.10 0.04 
122 4.20 0.01 -0.07 
123 4.28 -0.84 -0.09 
126 4.23 -0.41 -0.31 
127 4.35 -0.05 -0.01 
128 4.30 -1.03 -1.03 
129 4.16 -0.01 0.11 
153 4.00 -0.047 -0.05 
154 4.00 0.07 0.04 
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Figure 6-6. Predictions of ST activities of the training and the test set compounds 
by CoMFA 
 
Training and the test sets are represented by blue diamonds and red triangles, 
respectively. 
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Figure 6-7. Predictions of ST activities of the training and the test set compounds 
by CoMSIA 
 
Training and the test sets are represented by blue diamonds and red triangles, 
respectively. 
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Table 6-6. Residuals of the test set predictions given by CoMSIA and CoMSIA 
models 
 
Cpd. Actual ST pIC50 CoMFA Res.       CoMSIA Res. 
103 4.39 -0.41 -0.28 
108 4.82 0.35 0.30 
112 4.12 -1.00 -0.32 
113 5.04 0.25 0.35 
116 4.74 0.14 0.37 
121 4.79 0.09 0.09 
124 4.49 -0.10 0.22 
125 4.74 0.19 0.05 
130 4.67 0.11 0.56 
149 4.82 0.76 0.40 
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Figure 6-8. CoMFA steric and electrostatic contour plots of ligand-based model 
 
Green and yellow contours illustrate regions where steric bulk has favorable and 
unfavorable effects on activity, respectively. Blue and red isopleths indicate regions 
where an increase of positive and negative charge is required for activity.   
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value of 9 μM. However, for compound 126, a decrease in activity was observed. Red 
contours are also present at the 5?- and the 6?-positions. The dichloro-substituted 
compounds 92 and 93 having Cl at the 5?- and 6?-positions showed improved activities. 
There are also distant blue contours around aryl ring B, which predicts that 
electropositive groups should increase activity at these positions. Electronegative oxygen 
atom of the methoxy substituents in compounds 91, 111 and 112 points towards the blue 
contours and thus may explain the loss of activity observed by the presence of methoxy 
groups in these compounds. The red contours around the salicylic acid moiety in aryl ring 
A suggest that a negative charge is important for activity in this region, possibly for 
chelation with the active site Mg2+ ions. This is in agreement with the proposed 
mechanism of action of these compounds as HIV-1 integrase inhibitors. There is a red 
contour around the 4?-position and both blue and red contours at the 5?-position (R1). This 
suggests that polarizability effect might be important at R1 and could explain the 
increased activity conferred by bromine substitution over other halogens and the similar-
sized hydrophobic methyl group at this position.  
 
The CoMSIA steric contour map shown in Figure 6-9 reveals a large green 
contour around aryl ring B. Like in the CoMFA, the electrostatic contours of CoMSIA 
also show red contours at the 3? and the 4?-positions on ring B, and at the 5?-position (R1) 
on ring A. There is a blue contour located at the position of the hydrogen atom of the 
hydroxyl group of the salicylic acid moiety. The hydrophobic, H-bond donor and 
acceptor contours are shown in Figure 6-10. There is a white contour located near the R1 
substituent position which suggests hydrophophilic groups increase activity at this region. 
This might be the reason why compound 128 which has a hydrophobic methyl group was 
less active than the fluorine (compound 109) and chlorine substituted analogs (compound 
102) at the R1 position. Furthermore, compound 128 resulted in 13 times reduction of 
activity when compared to bromine at this position. The improved activity observed with 
bromine at R1 position may result because of its polarization effect. White contours are 
also evident at the 2? and the 5?-positions on ring B indicating that hydrophilic groups are 
favored for activity. This was confirmed with the loss of potency of compounds 90 and 
110 which have hydrophobic methoxy and methyl groups at these regions. There is 
another white region observed over the 3-keto oxygen again signifying the presence of 
hydrophilic groups at this position. There is a yellow contour close to the 4?-positions on 
ring B. A hydrophobic group at the 4?-position is expected to increase activity, as 
bromine substituent does in compound 86 and chlorine substituent in compound 85. The 
3?-keto functionality perfectly fit the magenta contour within their vicinity indicating that 
they may act as H-bond acceptors. The cyan contour which appears to have merged into 
the magenta contour might result from the hydrogen of the hydroxyl moiety. It indicates 
its role as H-bond donor and may involve in H-bonding interactions with the acceptor 
residues (acidic catalytic triad) of the receptor active site. The good congruence of 
CoMFA and CoMSIA contour maps with the observed biological activity suggests these 
models could aid the design of more active compounds. 
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Figure 6-9. CoMSIA steric and electrostatic contour plots of ligand-based model 
 
Green contour illustrates region where steric bulk has favorable effect on activity.  Blue 
and red isopleths indicate regions where an increase of positive and negative charge is 
required for activity. 
 
 
 
 
 
 
Figure 6-10. CoMSIA hydrophobic, H-bond donor and H-bond acceptor contour 
plots of ligand-based model 
 
White contours indicate regions where hydrophilic groups increase activity, whereas 
yellow contours indicate regions where hydrophobic groups increase activity, cyan 
indicates region where H-donors increase activity and magenta contour indicate region 
where H-bond acceptor groups increase activity. 
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Homology Model-Guided Computational Studies on HIV-1 IN Inhibitors 
 
Later, in order to improve the statistical significance and predictive power of our 
developed 3D-QSAR models, a structure-based approach was followed. Furthermore, a 
different strategy was used to obtain new composite 3D-QSAR models by incorporating 
important physico-chemical parameters from potent IN inhibitory compounds to guide 
our lead optimization efforts on a novel series of 3-keto salicylic acid IN inhibitors 
synthesized in Chapter 4. The approved raltegravir,51 which belongs to the class of N-
methyl-4-hydroxypyrimidinone carboxamides,134,135 diketotriazole S-1360125 and 
naphthyridine carboxamide L-870,812127 all have three metal-chelating groups in a 
coplanar conformation mimicking the ?-diketo acid motif. Promising IN inhibitors were 
thus designed as bioisosteres of the diketo acid functionality. However, the advent of 
mono-keto quinolone HIV-1 IN inhibitors143,205 showed that the presence of even two 
coplanar chelating moieties, represented by the ?-ketone and a carboxylic acid in 
elvitegravir is sufficient for potent clinically relevant IN inhibition. Although it is 
established that potent IN inhibitors have two common structural features viz., a 
hydrophobic benzyl group and a chelating motif capable of binding two Mg2+ ions, a 
detailed understanding of the structural features essential for HIV-IN inhibitory activity 
still evades researchers. Therefore, it is important to develop quantitative structure-
activity relationships (QSARs) that combine the most advanced first and second-
generation inhibitors to arrive at a comprehensive and more unified model for IN 
inhibition. Although QSAR studies on IN inhibitors have been reported,206-210 there is 
none combining the two classes viz., the N-methyl-4-hydroxypyrimidinone-carboxamide 
and 4-quinolone-3-carboxylic acid as represented by the approved raltegravir, the 
clinically advanced elvitegravir and their analogs. 
  
 The absence of a 3D structure of IN and viral DNA along with the two-divalent 
metals bound in the active site makes the structural information hitherto available limited 
and may be far from reality. As shown in the Figure 6-11, the inhibitor binding site is 
located at the interface between catalytic core domain (CCD) and C-terminal domain 
(CTD), and involving contacts with the 3? terminus of the viral DNA. Therefore, the 
correct binding mode of drug molecules could not have been predicted based on previous 
partial IN structures. It has been shown that the full-length IN-DNA-inhibitor complex 
model would be required to gain a better understanding of how the inhibitors act against 
IN.  
 
Thus to achieve our objective, we first developed a new homology model of HIV-
1 IN in complex with DNA and inhibitors, based on the recently published crystal 
structure of the foamy virus IN-DNA complex (PDB 3L2T and 3L2U)93 for use in 
structure-based 3D-QSAR studies. Although homology models using the foamy virus  
IN-DNA complex as template were reported by Tang211 and Krishnan  et al.,95  they were 
not without shortcomings. The model developed by Tang et al. consisted of only the 
CCD-DNA complex and may not be a true representation considering the absence of 
CTD and NTD, both of which have been implicated in viral DNA binding. Although, the 
model reported by Krishnan et al. involved all the three domains and the viral DNA, no 
direct contacts of raltegravir with mutant residues Gln148 and Asn155 that are involved  
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Figure 6-11. PFV IN active site  
 
Protein is shown in cartoon representation (green); inhibitor RLT is shown in licorice 
representation; DNA is shown in ribbon representation (purple); two magnesium ions are 
shown as mauve spheres; the residues within 6 Å of RLT are shown as orange lines. Only 
one protein chain is shown for clarity. 
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in viral resistance, are observed. Thus, first a homolog model of a full-length HIV-1 IN-
DNA- inhibitor complex was constructed by our collaborator at the Oak Ridge National 
Laboratory. The sequence alignment of HIV-1 and foamy IN, which are about 20% 
identical, is shown in Figure 6-12. The homology model was then used for docking 
simulations to explore binding interactions of inhibitors with the DNA-bound HIV IN. A 
data set of 103 compounds including our synthesized IN inhibitors described in Chapters  
3 and 4 together with raltegravir and elvitegravir and their analogs reported in the 
literature134,135,143,205 were used for docking and 3D-QSAR studies. Because determining 
the bioactive conformation is critical to developing a successful QSAR model, 
alignments obtained from docking on the homology model were used for the study and 
compared with the usual atom-by atom alignments. 3D-QSAR coefficient contour maps 
were superimposed over the IN active site to visualize and advance our understanding of 
the ligand-receptor interactions. 
 
 
Homology Model: Analysis of Binding Sites 
 
 
 Interactions of the substituted benzyl group. Binding mode and interactions of 
raltegravir are shown in Figure 6-13 and Figure 6-14; and those of elvitegravir in Figure 
6-15 and Figure 6-16, respectively. The docking indicated that the para-fluoro benzyl 
ring of raltegravir is nicely inserted into the cavity (Figure 6-13) that is formed by 
displacement of the 3?-adenosine the when viral DNA associates with integrase in a pre-
integration complex. This unpairing of the terminal 3?-adenosine of the donor DNA 
duplex is essential to unmask the scissile phosphodiester bond for 3?-P and subsequent ST 
reactions. Thus, the interactions of viral DNA with the IN and subsequent unpairing of its 
3?-adenosine result in a cavity being formed at the DNA-protein interface. The 3-chloro-
2-fluorobenzyl ring of elvitegravir also occupied the same cavity (Figure 6-15) formed 
by the DNA-protein interface as the para-fluoro benzyl ring of raltegravir, but is oriented 
slightly upwards at about 45° angle within the cavity relative to raltegravir. The phenyl 
rings of both raltegravir and elvitegravir are involved in ?-? interaction with the cytosine 
base of the viral DNA (see Figure 6-14 and Figure 6-16). While, the phenyl ring of 
raltegravir interacts with the adenine and guanine bases, it is the methoxy and meta-
chlorine substituents in elvitegravir that make contacts with the adenine and guanine 
bases of the viral DNA, respectively. Furthermore, the para-fluorine substituent in 
raltegravir and the ortho-fluorine substituent in elvitegravir engaged in electrostatic 
interactions with the 4-amino group of the cytosine of the donor DNA. The phenyl rings 
of both compounds interact with Glu152. Gln148 appears within 4Å radius of raltegravir 
and elvitegravir, in our homology models. Thus, our homology models suggest physical 
contacts between raltegravir and elvitegravir with Gln148, which is in agreement with the 
observation that mutation of this residue results in resistance to these drugs. We should 
note that in the crystal structure of foamy virus IN–DNA in complex with raltegravir or 
elvitegravir, there appeared to be no physical contact between both drugs and the 
equivalent residue Ser217.93 The p-fluoro phenyl ring of raltegravir also makes extensive 
vdW with the side chain methylenes, and electrostatic contacts with the amino group of 
Gln146. In contrast, while the vdW contact with Gln146 is maintained, there is no  
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Figure 6-12. Amino acid sequence alignment of PFV and HIV-1 IN 
 
Residues are colored according to the clustal color scheme. 
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Figure 6-13. Binding mode of raltegravir within the active site of IN-DNA 
homology model 
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Figure 6-14. Binding interactions of raltegravir 
 
Mg2+ ions are represented by purple spheres. Active site residues is represented by tubes 
and colored by element. Raltegravir is represented in tubes and highlighted with yellow 
carbons. Other atoms in ligand are colored as follows: O, red; N, blue; F, bright green. 
Hydrogens are omitted for clarity. 
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Figure 6-15. Binding mode of elvitegravir within the active site of IN-DNA 
homology model 
 
 
 
 
 
 
Figure 6-16. Binding interactions of elvitegravir 
 
Mg2+ ions are represented by purple spheres. Active site residues are represented by tubes 
and colored by element. Elvitegravir is represented in tubes and highlighted with yellow 
carbons. Other atoms in the ligand are colored as follows: O, red; N, blue; F, bright 
green; Cl, dark green. Hydrogens are omitted for clarity. 
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apparent electrostatic interaction with this residue in the case of elvitegravir, which on the  
other hand appears to be directed more towards Gln152.  
 
 
Interactions of metal-chelating motif. The three-metal chelating groups in 
raltegravir are involved in coordination with the two metal atoms (Mg2+) in the IN 
active site. The pyrimidinone oxo and the acidic hydroxyl oxygen coordinate in a bi-
dentate manner with the Mg2+ between Asp116 and Asp64. Likewise, the keto oxygen of 
the carboxamide moiety and the acidic hydroxyl oxygen are chelated with the second 
Mg2+ between Asp64 and Glu152. This hydroxyl moiety may also engage in H-bonding 
interaction with Gln148, Asp64 and Asp116. The binding pose of elvitegravir shows that 
it’s two chelating pharmacophore namely, the 4-keto group and the carboxylate 
coordinates the two Mg2+ ions in the integrase active site. 
 
 
Interactions of side chain. The gem-dimethyl oxadiazole carboxamide moiety in 
raltegravir is inserted into the cleft formed by Asp116, Asn117 and loop residues Pro142, 
Tyr143, Asn144 and Pro145. One of the methyl groups of the gem-dimethyl moiety 
interacts with Pro145. The oxadiazole ring is involved in ?-stacking interaction with the 
phenyl ring of Tyr143. The methyl on the oxadiazole is engaged in vdW interactions with 
the side chain methylene of Asn117. Site 3 binding region in elvitegravir has a 
hydroxyalkyl chain which in our model is also directed towards this cleft. One of the two 
methyl groups of the isopropyl substituents makes hydrophobic contacts with Tyr143, 
while the other makes contact with Pro145. The binding interactions revealed by the 
model are in accordance with those seen with the foamy virus crystal structure complex 
with these inhibitors, and confirm the importance of this side chain in the binding of 
raltegravir and elvitegravir. Tyr143 is a conserved residue among all the classes of 
polynucleotidyl transferases212 and is proposed to be important for viral DNA binding. 
Another key residue to target is Asn117 which is implicated in binding of the host 
DNA213 and may thus be important for potent strand transfer (ST) inhibitory activity. Our 
homology model has also revealed Arg263 and Lys264 as important residues close to the 
active site that are involved in viral DNA binding. 
 
 
Docking Studies 
 
For prediction of bioactive conformation and binding modes of our synthesized 
chalcone and amide compounds, we conducted docking simulations using the GLIDE 
(v5.7) program from Schrödinger Inc. (Portland, Oregon, USA).214 Both standard-
precision (SP) and extra-precision (XP) modes of GLIDE were evaluated using a flexible 
ligand and rigid receptor routine. Twenty docking poses were obtained for each molecule, 
the docking being terminated if two consecutive solutions were within a rmsd of 5 Å. 
Overlay of the X-ray derived conformation of raltegravir (Figure 6-17) over the docked 
(SP) conformation resulted in a lower rmsd of 0.60 between all heavy atoms as compared 
with an rmsd of 0.64 obtained with GLIDE XP. The SP option was therefore selected for 
subsequent docking studies, moreover, in addition to slightly better in reproducing the  
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Figure 6-17. Overlay of the crystal structure, homology model, and docked 
conformations of raltegravir  
 
Crystal structure derived conformation of raltegravir is colored green and represented by 
ball and stick; the homology model derived conformation is colored in element and 
represented by tubes; and the GLIDE docking (SP) derived pose is colored by orange 
carbons and shown in tubes. The homology model is shown in ribbons and Mg2+ is 
shown by purple sphere. Hydrogens are omitted for clarity. 
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crystal structure conformation it is computationally less expensive. To test the ranking 
accuracy of GLIDE (SP), the docked poses of raltegravir and elvitegravir were analyzed, 
and it was found that the poses of elvitegravir have better G-scores and E-model energies 
and were ranked higher than those of raltegravir. This reflected the enzyme inhibitory 
activities of the two compounds, with elvitegravir being more potent than raltegravir. The 
best pose of the two most active compounds (86 and 96) selected on the basis of glide 
score are shown in Figure 6-18. The topmost pose of compound 86 showed that its para-
bromobenzyl group is inserted into the cavity formed by the DNA-protein interface 
(Figure 6-18). The phenyl ring interacts with the cytosine and adenine bases of the viral 
DNA and also makes favorable vdW contacts with Gln146 and Pro145 (Figure 6-19). 
Furthermore, the para-bromo substituent interacted with amino group of Gln146.  The 3-
keto and the carboxylate group chelated the two divalent (Mg2+) ions in accordance with 
the proposed mechanism of action of ST inhibitors. The hydroxyl group also weakly 
coordinated with Mg2+ and makes H-bonding contact with the carboxylate of Asp116. 
The docking pose of compound 96 revealed that the 2,3,6-trichloro-substituted phenyl 
ring does not dock into the cavity formed by the DNA-protein interface, but was placed 
rather on the opposite (180°) side exposed to solvent. In this orientation, the 
trichlorophenyl group interacted with Pro142, the methylene of Ser119 and the methine 
of Gly118 (Figure 6-20). The salicylic acid motif coordinates with the two Mg2+ ions, 
and the hydroxyl group H-bonds to the carboxylate of Asp116. The bromine substituent 
on the salicylic acid appears to weakly interact with Tyr143 and Pro145. The docking 
poses thus suggest the presence of multiple binding modes for the chalcones. Their 
smaller size gives them the flexibility to adopt different poses within the IN active site as 
opposed to the relatively bulky elvitegravir and raltegravir which preferentially docked in 
their respective ‘bioactive conformations’. 
 
The amide derivative (compound 149) docked into the IN active site as shown in 
Figure 6-21 and Figure 6-22.  Similar to the p-fluorobenzyl group in raltegravir, the p-
fluorobenzyl group of compound 149 also fitted well into the cavity formed at the IN-
DNA interface, and make contacts with Pro145 and Glu152. The phenyl ring ?-stacks 
with the pyrimidinone ring of cytosine, as well as interact with the adenine base of the 
viral DNA. The F atom makes vdW contacts with side chain methylenes of Gln146 and 
may be involved in H-bonding with the amino group of the cytosine. The 3-keto salicylic 
acid motif coordinates with the two metals in the IN active site. Furthermore, the 2-
hydroxyl group forms H-bond with Glu152. Notably, no interactions with Tyr143 and 
Asn117 were observed. These compounds could be optimized to interact extensively with 
these residues to improve their inhibitory activities. The models developed could thus 
serve as a surrogate platform for structure-based design of potent IN inhibitors.  
 
With a further objective of using the docked conformations to build a docking-
based QSAR model all 103 IN inhibitors of the dataset were docked on the IN active site 
and 20 poses for each compound were generated. These include 3-keto salicylic acid 
chalcones (Table 3-1) and amide derivatives (Table 4-1), synthesized in previous 
chapters. The data set also included reported N-methyl-4-hydroxypyrimidinone 
carboxamides (Tables 6-7 to 6-12 ) and 4-quinolone-3-carboxylic acid and analogs 
(Tables 6-13 and 6-14). Top-most (based on the glide score) pose of 85 compounds  
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Figure 6-18. Comparison of the docked poses of compounds 86 and 96 
 
Compound 86 is colored by yellow carbons and compound 96 colored by orange carbons. 
Mg2+ ions are shown by purple spheres. 
 
 
 
 
 
 
Figure 6-19. Binding interactions of compound 86 in the IN active site 
 
Compound 86 is colored by yellow carbons. Other atoms in the ligand are colored as 
follows: O, red; Br, dark red. Amino acid residues are colored in element; Mg2+ ions are 
shown by purple spheres.   
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Figure 6-20. Binding interactions of chalcone derivative 96 in the IN active site 
 
Compound 96 is colored by orange carbons. Other atoms in ligand are colored as follows: 
O, red; Br, dark red; Cl, dark green. Amino acid residues are colored in element; and 
Mg2+ ions are shown by purple spheres.   
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Figure 6-21. Binding mode of amide derivative 149 in the IN active site 
 
 
 
 
 
 
Figure 6-22. Binding interactions of compound 149 within IN-DNA homology 
model  
 
Compound 149 is colored by yellow carbons. Other atoms in the ligand are colored as 
follows: O, red; Br, dark red; F, bright green. Mg2+ ions are represented by purple 
spheres. IN-DNA complex is colored by element and represented in tubes. Hydrogens are 
omitted for clarity. 
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Table 6-7. Structure and HIV-1 IN inhibitory activities of N-methyl-4-
hydroxypyrimidinone-carboxamides (scaffold 1) used in 3D-QSAR study 
 
 
 
Cpd. R1 R2 STa IC50 (?M) 
183 
 
 
H 
 
0.010 
 
184 
 
H 0.015 
185  
186 
OH 
 
H 
CH3 
0.004 
0.015 
187 
 
H 0.020 
188 
 
H 
 
0.026 
 
a ST represents strand transfer. 
 
(Table adapted with permission from: Summa, V.; Petrocchi, A.; Bonelli, F.; Crescenzi, 
B.; Donghi, M.; Ferrara, M.; Fiore, F.; Gardelli, C.; Gonzalez Paz, O.; Hazuda, D. J.; 
Jones, P.; Kinzel, O.; Laufer, R.; Monteagudo, E.; Muraglia, E.; Nizi, E.; Orvieto, F.; 
Pace, P.; Pescatore, G.; Scarpelli, R.; Stillmock, K.; Witmer, M. V.; Rowley, M. 
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor 
for the treatment of HIV-AIDS infection. J. Med. Chem. 2008, 51, 5843-5855.)134 
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Table 6-8. Structure and HIV-1 IN inhibitory activities of N-methyl-4-
hydroxypyrimidinone-carboxamides (scaffold 2) used in 3D-QSAR study 
 
 
 
Cpd. R STa IC50 (?M) 
189 Me >5.0 
 
190 
 
 
0.021 
191 
 
0.004 
192 
 
0.009 
 
a ST represents strand transfer. 
 
(Table adapted with permission from: Summa, V.; Petrocchi, A.; Bonelli, F.; Crescenzi, 
B.; Donghi, M.; Ferrara, M.; Fiore, F.; Gardelli, C.; Gonzalez Paz, O.; Hazuda, D. J.; 
Jones, P.; Kinzel, O.; Laufer, R.; Monteagudo, E.; Muraglia, E.; Nizi, E.; Orvieto, F.; 
Pace, P.; Pescatore, G.; Scarpelli, R.; Stillmock, K.; Witmer, M. V.; Rowley, M. 
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor 
for the treatment of HIV-AIDS infection. J. Med. Chem. 2008, 51, 5843-5855.)134 
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Table 6-9. Structure and HIV-1 IN inhibitory activities of N-methyl-4-
hydroxypyrimidinone-carboxamides (scaffold 3) used in 3D-QSAR study 
 
 
 
Cpd. R STa IC50 (?M) 
193b 
 
0.015 
194 
 
0.012 
195 
 
0.015 
 
a ST represents strand transfer; b structure of raltegravir. 
 
(Table adapted with permission from: Summa, V.; Petrocchi, A.; Bonelli, F.; Crescenzi, 
B.; Donghi, M.; Ferrara, M.; Fiore, F.; Gardelli, C.; Gonzalez Paz, O.; Hazuda, D. J.; 
Jones, P.; Kinzel, O.; Laufer, R.; Monteagudo, E.; Muraglia, E.; Nizi, E.; Orvieto, F.; 
Pace, P.; Pescatore, G.; Scarpelli, R.; Stillmock, K.; Witmer, M. V.; Rowley, M. 
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor 
for the treatment of HIV-AIDS infection. J. Med. Chem. 2008, 51, 5843-5855.)134 
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Table 6-10. Structure and HIV-1 IN inhibitory activities of N-methyl-4-
hydroxypyrimidinone-carboxamides (scaffold 4) used in 3D-QSAR study 
 
 
 
Cpd. n STa IC50 (?M) 
196 1 0.12 
197 2 0.22 
 
a ST represents strand transfer.  
 
(Table adapted with permission from: Gardelli, C.; Nizi, E.; Muraglia, E.; Crescenzi, B.; 
Ferrara, M.; Orvieto, F.; Pace, P.; Pescatore, G.; Poma, M.; Ferreira Mdel, R.; Scarpelli, 
R.; Homnick, C. F.; Ikemoto, N.; Alfieri, A.; Verdirame, M.; Bonelli, F.; Paz, O. G.; 
Taliani, M.; Monteagudo, E.; Pesci, S.; Laufer, R.; Felock, P.; Stillmock, K. A.; Hazuda, 
D.; Rowley, M.; Summa, V. Discovery and synthesis of HIV integrase inhibitors: 
development of potent and orally bioavailable N-methyl pyrimidones. J. Med. Chem. 
2007, 50, 4953-4975.)135  
 137 
Table 6-11. Structure and HIV-1 IN inhibitory activities of N-methyl-4-
hydroxypyrimidinone-carboxamides (scaffold 5) used in 3D-QSAR study 
 
 
 
Cpd. R STa IC50 (?M) 
198 
 
0.062 
199 
 
0.69 
200  
 
0.14 
201 
 
0.10 
202 
 
0.20 
203 
 
 
 
 
 
0.25 
204 
 
0.13 
205 
 
4.00 
 
a ST represents strand transfer. 
 
(Table adapted with permission from: Gardelli, C.; Nizi, E.; Muraglia, E.; Crescenzi, B.; 
Ferrara, M.; Orvieto, F.; Pace, P.; Pescatore, G.; Poma, M.; Ferreira Mdel, R.; Scarpelli, 
R.; Homnick, C. F.; Ikemoto, N.; Alfieri, A.; Verdirame, M.; Bonelli, F.; Paz, O. G.; 
Taliani, M.; Monteagudo, E.; Pesci, S.; Laufer, R.; Felock, P.; Stillmock, K. A.; Hazuda, 
D.; Rowley, M.; Summa, V. Discovery and synthesis of HIV integrase inhibitors: 
development of potent and orally bioavailable N-methyl pyrimidones. J. Med. Chem. 
2007, 50, 4953-4975.)135 
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Table 6-12. Structure and HIV-1 IN inhibitory activities of N-methyl-4-
hydroxypyrimidinone-carboxamides (scaffold 6) used in 3D-QSAR study 
 
 
 
Cpd. R1 R2 R3 n STa IC50 (?M) 
206   H H Me 1 >5 
207 2-F H H 1 0.175 
208 3-Cl H H 1 0.062 
209 3-Br H H 1 0.019 
210 3-OMe H H 1 0.140 
 
a ST represents strand transfer. 
  
(Table adapted with permission from: Gardelli, C.; Nizi, E.; Muraglia, E.; Crescenzi, B.; 
Ferrara, M.; Orvieto, F.; Pace, P.; Pescatore, G.; Poma, M.; Ferreira Mdel, R.; Scarpelli, 
R.; Homnick, C. F.; Ikemoto, N.; Alfieri, A.; Verdirame, M.; Bonelli, F.; Paz, O. G.; 
Taliani, M.; Monteagudo, E.; Pesci, S.; Laufer, R.; Felock, P.; Stillmock, K. A.; Hazuda, 
D.; Rowley, M.; Summa, V. Discovery and synthesis of HIV integrase inhibitors: 
development of potent and orally bioavailable N-methyl pyrimidones. J. Med. Chem. 
2007, 50, 4953-4975.)135 
 
 
  
 139 
Table 6-13. Structure and HIV-1 IN inhibitory activities of 4-quinolone-3-
carboxylic acid-carboxamides (scaffold 1) used in 3D-QSAR study 
 
 
 
Cpd. R1 R2 R3 STa IC50 (?M) 
211 
 
H H 1.6 ± 0.300 
212 
 
H H 0.043 ± 0.008 
213  
 
 
H 0.024 ± 0.011 
214 
 
 
OCH3 0.009 ± 0.002  
215 
 
 
H 0.008 ± 0.001  
216b 
  
OCH3 0.007 ± 0.002 
 
a ST represents strand transfer; b structure of elvitegravir.  
 
(Table adapted with permission from: Sato, M.; Motomura, T.; Aramaki, H.; Matsuda, T.; 
Yamashita, M.; Ito, Y.; Kawakami, H.; Matsuzaki, Y.; Watanabe, W.; Yamataka, K.; 
Ikeda, S.; Kodama, E.; Matsuoka, M.; Shinkai, H. Novel HIV-1 integrase inhibitors 
derived from quinolone antibiotics. J. Med. Chem. 2006, 49, 1506-1508.)143  
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Table 6-14. Structure and HIV-1 IN inhibitory activities of 4-quinolone-3-
carboxylic acid-carboxamides (scaffold 2) used in 3D-QSAR study 
 
 
 
Cpd. X R1 R2 R3 R4 STa  IC50 (?M) 
217 O F Cl H (CH2)2OH >100 
218 S H H H (CH2)2OH 18.5 ± 3.7 
219  CH2 Cl H Cl (CH2)2OH 0.2 ± 0.0 
220 CH2 Cl H Cl (CH2)3OH 1.3 ± 0.1 
221 CH2 Cl H Cl (CH2)4OH 0.6 ± 0.3 
222 CH2 Cl H Cl (CH2)2N(CH3)2 24.1 ± 5.9 
223 CH2 Cl H Cl (CH2)2OCH3 16.5 ± 0.7 
224 CO Cl H Cl (CH2)2OH >100 
225 CO Cl H Cl (CH2)3OH >100 
226 CO Cl H Cl (CH2)4OH >100 
227 CHCH H H H (CH2)2OH >100 
228 CONH H H H (CH2)2OH >100 
229 NHCO H H H (CH2)2OH >100 
230 NH H Cl F (CH2)2OH >100 
231 NH H Cl F CH2CH3 >100 
 
a ST represents strand transfer.  
 
(Table adapted with permission from: Pasquini, S.; Mugnaini, C.; Tintori, C.; Botta, M.; 
Trejos, A.; Arvela, R. K.; Larhed, M.; Witvrouw, M.; Michiels, M.; Christ, F.; Debyser, 
Z.; Corelli, F. Investigations on the 4-quinolone-3-carboxylic acid motif. 1. Synthesis and 
structure-activity relationship of a class of human immunodeficiency virus type 1 
integrase inhibitors. J. Med. Chem. 2008, 51, 5125-5129.)205 
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found to have identical binding modes. The other poses for the remaining compounds 
were then studied and 13 more compounds were identified to share similar binding 
modes. Markedly different poses were obtained for compounds 191, 214, 217, 220, and 
223. These compounds may have different binding mode or require an induced fit. 
Although it is well established that the GLIDE docking is successful in giving the best 
ligand poses, it fails to rank-order compounds on the basis of their binding affinities. We 
observed that Glide score showed no correlation (r2 = 0.05) with the ST inhibitory 
activities for the 98 similar binding compounds. Thus to further validate their “bioactive 
conformations” a post-docking MM-GBSA rescoring was performed. 
 
 
MM-GBSA Results 
 
The docked poses of the pruned dataset were subjected to Molecular 
Mechanics/Generalized Born Surface Area (MM-GBSA)215 free energy calculations with 
PRIME (v) of the Schrödinger package. The calculated ?Gbind along with vdW 
contributions to binding free energy are listed in Table 6-15. Analysis of the MM-GBSA 
calculations revealed an improved correlation, with r2 = 0.34, between the binding free 
energies (?Gbind) and the ST inhibitory activities (Figure 6-23). A low, albeit better, 
correlation might be a result of a large and diverse set of chemical structures included in 
the analysis and a poor estimation of electrostatic binding energies. However, the vdW 
contribution to the MM-GBSA binding free energy correlated best with the activities with 
an r2 value of 0.57 (Figure 6-24), which went up to 0.62 with the removal of one outlier 
(compound 113). A better correlation with the vdW energy term is significant since 
hydrophobic interactions are one of the most important contributors to IN inhibitory 
activity, and all potent IN inhibitors have a common hydrophobic halogenated benzyl 
ring system as a pharmacophoric feature. Another important contribution to the IN 
inhibitory activity comes from the electrostatic interactions, notably the coordination of 
the metal-chelating heteroatoms in an IN inhibitor with Mg2+ in the IN active site. The 
electrostatic contributions to the binding free energy are however not well predicted (data 
not shown). Previous studies216, 217 have shown that electrostatic energies are difficult to 
estimate particularly when the dataset have both charged and neutral molecules as is the 
case with the present study. Moreover, the negatively charged residues, Asp64, Asp116, 
Glu152 and the two Mg2+ ions are involved in important interactions with inhibitors in 
the IN active site. This system warrants further studies to determine the effects of protein 
charge states, electrostatic interactions cut-offs, parameterization of Mg2+ and the effect 
of solute dielectric constant in the calculation of polar solvation energies. Although prime 
MM-GBSA did not predict accurate binding affinities, it was successful in discriminating 
the data set into active and inactive compounds and validated the docking derived 
‘bioactive conformations’ for 3D-QSAR studies.  
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Table 6-15. Results of free energy calculations by Prime MM-GBSA 
 
Cpd. STa pIC50 ?EvdWb ?Gbindc Cpd. STa pIC50 ?EvdWb   ?Gbindc 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
91 
92 
93 
94 
95 
96 
97 
98 
99 
100 
101 
102 
103 
104 
105 
106 
107 
108 
109 
110 
111 
112 
113 
114 
115 
116 
117 
118 
119 
120 
121 
122 
123 
4.60 
4.85 
4.49 
5.04 
4.92 
5.30 
4.45 
5.13 
4.72 
4.46 
4.29 
4.74 
4.79 
4.85 
4.88 
5.43 
4.27 
4.00 
4.03 
4.60 
4.76 
4.52 
4.38 
4.76 
4.61 
4.52 
4.53 
4.82 
4.40 
4.23 
4.11 
4.11 
5.04 
4.74 
4.79 
4.74 
4.25 
4.33 
4.25 
4.95 
4.79 
4.20 
4.28 
-37.70 
-35.39 
-39.00 
-25.46 
-26.84 
-28.39 
-28.98 
-28.63 
-39.03 
-28.17 
-31.13 
-35.34 
-34.29 
-26.66 
-28.61 
-30.41 
-25.25 
-28.93 
-38.10 
-34.37 
-27.73 
-29.64 
-25.87 
-23.73 
-25.95 
-30.02 
 -27.90 
-25.39 
 -27.36 
-29.06 
-32.14 
-28.81 
-55.14 
-42.70 
-43.87 
-25.41 
-32.82 
-28.20 
-35.18 
-27.33 
-32.29 
-28.55 
-26.55 
 -6.33 
 -19.30 
 -11.52 
 -11.41 
-1.60 
 -4.79 
 3.77 
 -24.25 
 -20.05 
-10.75 
-14.47 
-15.91 
-19.40 
 -16.78 
-23.72 
-25.26 
-12.55 
0.27 
-20.39 
-15.78 
-23.46 
-24.89 
-16.25 
-8.31 
-17.72 
-19.88 
 -16.80 
-14.12 
-20.57 
-0.58 
0.30 
-17.90 
-8.66 
-8.18 
-15.13 
-10.32 
-12.33 
-2.46 
7.00 
-12.42 
-20.32 
-19.60 
-9.40 
130 
149 
153 
154 
155 
183 
184 
185 
186 
187 
188 
189 
190 
192 
193 
194 
195 
196 
197 
198 
199 
200 
201 
202 
203 
204 
205 
206 
207 
208 
209 
210 
211 
212 
213 
215 
216 
218 
219 
221 
222 
224 
225 
4.67 
4.82 
4.00 
4.00 
4.88 
8.00 
7.82 
8.39 
7.82 
7.69 
7.58 
5.30 
7.67 
8.04 
7.82 
7.92 
7.82 
6.92 
6.65 
7.00 
6.16 
6.85 
7.00 
6.69 
6.60 
6.88 
5.39 
5.30 
6.75 
7.20 
7.72 
6.85 
5.79 
7.36 
7.61 
8.08 
8.14 
4.74 
6.69 
6.22 
4.61 
4.00 
4.00 
-29.98 
-36.94 
-34.56 
-33.07 
-34.30 
-49.16 
-47.31 
-46.12 
-49.23 
-53.89 
-49.50 
-39.23 
-45.10 
 -50.90  
-53.16 
-48.03 
-54.68 
-38.24 
-36.54 
-41.86 
-42.60 
-41.47 
-42.29 
-42.38 
-43.74 
-45.00 
-44.73 
-41.10 
-42.57 
-43.18 
-38.83 
-43.05 
-36.08 
-37.86 
-41.43 
 -46.00 
-46.90 
 -42.09 
 -29.96 
 -32.79 
 -29.89 
  -29.53 
-38.45 
-13.63 
-6.32 
-3.41 
-0.85 
-14.90 
-25.99 
-23.00 
-33.17 
-26.32 
-14.50 
-18.62 
-11.15 
-17.67 
-28.62   
-36.04 
-17.85 
-15.89 
-13.52 
-11.69 
-15.60 
-22.80 
-17.45 
-18.98 
-19.51 
-26.00 
-27.90 
-17.11 
-17.03 
-18.06 
-20.70 
-19.28 
-14.69 
-13.24 
-18.06 
-14.66 
 -23.88 
-26.64 
-19.74 
 -33.75 
 -21.98 
 -9.10 
-12.84 
    1.80 
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Table 6-15. (Continued) 
 
Cpd. STa pIC50  ?EvdWb ?Gbindc Cpd. STa pIC50 ?EvdWb ?Gbindc 
124 
125 
126 
127 
128 
129 
4.49 
4.74 
4.22 
4.35 
4.30 
4.16 
-25.68 
-25.25 
-36.65 
-28.73 
-28.85 
-27.15 
 -9.55 
-9.30 
-6.59 
-4.40 
-22.05 
-3.69 
226 
227 
228 
229 
230 
231 
4.00 
4.00 
4.00 
4.00 
4.00 
4.00 
-29.02 
-29.57 
-30.55 
-29.68 
-31.40 
-24.93 
-4.09 
-5.34 
-4.21 
-10.79 
-14.31 
-4.49 
 
a ST represents strand transfer; b represents van der Waals energy; c represents binding 
free energy. 
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Figure 6-23. Correlation between the MM-GBSA ?Gbind and the ST inhibitory 
activities (pIC50s) 
 
 
 
 
 
Figure 6-24. Correlation between the MM-GBSA ?GvdW energies and the ST 
inhibitory activities (pIC50s) 
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Homology Model-Guided 3D-QSAR Studies 
 
 
Molecular data set. A total of 103 compounds were used for the 3D-QSAR 
studies. Although the data set represented several different compound classes, they all 
share a somewhat similar structural core. These compounds have common mechanism of 
action (chelation of the divalent metal and inhibition of ST) and cover a wide range of 
IC50 values spanning over 5 log units, thus constitute a suitable set of compounds for 
QSAR studies. The dataset was also evenly distributed with regard to activity, comprising  
potent IN inhibitors having IC50s of 7-8 nM, moderately active 3-keto salicylic acid 
derivatives with IC50s of 4-5 μM and inactive compounds with IC50s of 100 μM. To 
evaluate the predictive ability of models, the dataset was divided into a training set of 90 
compounds and an external validation test set of 13 compounds. The test set was selected 
randomly using factor analysis in the SYBYL package (vX1.1, Tripos Associates Inc. St. 
Louis, MO) and contained compounds representing all the four different potency 
categories. 
 
 
Conformation and alignment of the data set. For 3D-QSAR studies we 
compared two atom-fit alignment rules (models 1 and 2), with the docking alignment 
(model 3). Determination of the “bioactive conformation” is of utmost importance for the 
development of a successful 3D-QSAR model of the CoMFA and CoMSIA type. To this 
end, the developed raltegravir-IN-DNA homology model was used to extract the 
conformation of raltegravir (compound 193). This conformation of raltegravir obtained 
from our homology model perfectly superimposed over its reported X-ray conformation 
in the PDB 3L2T complex. This conformation of raltegravir was used as a template for 
alignment and as a conformational template to build the remaining N-methyl-4-
hydroxypyrimidinone carboxamides. Similarly, the homology model derived 
conformation of elvitegravir (compound 216) was used to build the remaining 4-
quinolone-3-carboxylic acid analogs. The topmost pose of the amide derivative 149 
obtained from the docking simulations was used as a template to build the other amide 
derivatives. As discussed in the docking studies, chalcones appear to have multiple 
binding modes. The highest-ranked poses of the two most active compounds 86 and 96 
were each used as a bioactive conformation template to build the remaining chalcones of 
the series. To take into account the conformations of the two most active chalcone 
derivatives, two different alignments rules, alignment I (model 1) and alignment II 
(model 2), were generated. It was primarily aimed to assess their effect on the overall 
unified 3D-QSAR model for IN inhibition. However, the conformations of the N-methyl-
4-hydroxypyrimidinone carboxamides, 4-quinolone-3-carboxylic acids and 3-keto 
salicylic acid amides remained identical in both alignments. 
 
Alignment I. For alignment I, the atom-fit alignment function in SYBYL was  
used for a pair-wise alignment of elvitegravir, chalcone and amide derivatives with 
raltegravir as a template. The conformations of these compounds were judiciously 
aligned over raltegravir template taking into consideration their interactions with the IN 
active site, and with atomic coordinates adjusted to provide the maximum overlap of the 
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molecules in the dataset. All the compounds were then partially energy minimized by the 
Simplex procedure to relieve excessive strain. The bound X-ray and homology model-
derived conformations revealed partial overlap of the pyrimidinone and quinolone 
moieties of raltegravir and elvitegravir, respectively. The carboxylate of elvitegravir and 
the 6-oxo group of raltegravir chelate the same Mg2+ ion (between Asp116 and Asp64). 
Therefore, for alignment, the pyridone ring of elvitegravir was superimposed over the 
pyrimidinone ring of raltegravir such that the 3?-carbon of the quinolone system was 
superimposed over the 6?-carbon of the pyrimidinone ring of raltegravir. In this 
orientation, the C?-5 carbon of the quinolone ring in elvitegravir superimposed over the 
carbonyl carbon of the carboxamide moiety in raltegravir. This alignment rule resulted in 
a good overlap of the six-membered rings and matched the crucial metal-chelating 
pharmacophoric groups. Other pharmacophoric features as represented by their 
halogenated phenyl rings, which inserted into a cavity as shown in the homology models 
aligned well. The docked conformation of the topmost poses of the amide analog 149 and 
chalcone derivative 86, revealed that their salicylic acid groups mimicked the 
pyrimidinone ring of raltegravir. The docking also suggested that the 3-keto oxygen of 
reference compounds 149 and 86, and the carbonyl oxygen of the carboxamide of 
raltegravir interacted with the same Mg2+ ion (between Asp64 and Glu152). Likewise, the 
carboxylate groups of compounds 149 and 86 and the pyrimidinone oxo of raltegravir 
coordinated with the Mg2+ between Asp64 and Asp116. Thus, for alignment of the amide 
and chalcone derivatives, the salicylic acid rings of compounds 149 and 86 were aligned 
over the pyrimidinone ring of raltegravir such that 1?-carbon atoms of compounds 149 
and 86 were superimposed over the 6?-carbon of the pyrimidinone ring of raltegravir. 
Furthermore, the carbonyl carbons of compounds 149 and 86 were superimposed over the 
carbonyl carbon of the carboxamide moiety of raltegravir. This alignment rightly 
positioned their halogenated phenyl rings into the hydrophobic cavity as depicted in the 
docking studies. The superimposition of the data set using alignment I is shown in Figure 
6-25. 
 
Alignment II. The pyridone ring of elvitegravir and the salicylic acid group of 
compound 149 were superimposed (atom-fit) over the pyrimidinone ring of raltegravir 
similar to alignment I. However, the docked pose of compound 96 was used as the 
bioactive conformation for the chalcone derivatives. As discussed in the docking section, 
the halogenated phenyl ring of compound 96 was placed in the opposite (180°) direction. 
In this orientation, the carboxylate of compound 96 is directed towards the carbonyl 
oxygen of the benzyl carboxamide moiety of raltegravir and both functionalities interact 
with the Mg2+ between Asp64 and Glu152. Thus for this alignment, the salicylic acid 
group and the carboxylate carbon of compound 96 were respectively superimposed over  
the pyrimidinone ring  and the carbonyl carbon of the carboxamide moiety of raltegravir. 
The superimposition of the dataset using alignment II is shown in Figure 6-26. 
 
Alignment III. Theoretically, overlaying the poses of the compounds docked at the 
IN active site should provide a better bioactive conformational alignment than the atom-
fitting alignments I and II. Thus, to derive a truly docking based 3D-QSAR, all the 103 
compounds were docked and their binding poses analyzed. The poses of 98 compounds 
that bound similarly were validated by MM-GBSA rescoring which gave better  
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Figure 6-25. Superimposition of the data set by alignment I 
 
 
 
 
 
 
Figure 6-26. Superimposition of the data set by alignment II 
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correlations (?Gbind r2 = 0.34; ?EvdW r2 = 0.57) with ST inhibitory activities. These 
conformations were then overlayed, to produce an alignment III, which was in effect a 
combination of alignments I and II. Alignment III is depicted in Figure 6-27 was used to 
build a docking-based 3D-QSAR, model 3. 
 
 
PLS Results 
 
PLS analysis using the leave-one-out (LOO) cross-validation method was used to 
determine predictive ability (using the cross-validated coefficient q2) and the number of 
components to use in the final regression models. The optimal number of components  
used (5 for both models 1 and 2) was determined by the number of components that 
yielded the smallest standard error of prediction. Atom-fit alignments I and II were used  
to develop two 3D-QSAR models; model 1 and model 2, respectively. Alignment I may 
be more plausible since placement of the hydrophobic phenyl rings of the chalcones into 
the cavity should have more contact of the inhibitors with IN than alignment II in which 
part of the phenyl ring of the inhibitor is solvent-exposed. However, significant q2 and r2 
values were obtained for CoMFA and CoMSIA 3D-QSARs of both models 1 and 2 
(Table 6-16). In terms of PLS statistics, the CoMFA of both models performed better 
than their CoMSIA counterparts. The CoMFA 3D-QSAR model 1 performed slightly 
better than the CoMFA model 2, with q2 and r2 values of 0.82 and 0.94, respectively, 
compared to q2 of 0.79 and r2 of 0.93 for CoMFA model 2.  Similar q2 values around 0.71 
were obtained for both CoMSIA models 1 and 2. On the basis of its extreme residual 
value, compound 189 was identified as an outlier in model 1. It was the only compound 
in the series which did not have a hydrophobic p-fluoro benzyl ring and thus its structural 
uniqueness might be a factor for it being an outlier. 
 
To test the robustness of the predictive capabilities of the models, they were used 
to predict the activity of an external test set of 13 compounds which were excluded from 
the training set. The residuals of the training and test set predictions for model 1 are listed 
in Tables 6-17 and 6-18, respectively.  The corresponding residual values for model 2 are 
given in Tables 6-19 and 6-20. For model 1, the CoMFA prediction curves for the 
training and the test set are shown in Figure 6-28 and the corresponding CoMSIA 
predictions in Figure 6-29. The corresponding CoMFA and CoMSIA predictions for 
model 2 are shown in Figure 6-30 and Figure 6-31, respectively. As is evident, the 
present study gave high correlations between actual and predicted values for the external 
test set. CoMFA and CoMSIA gave comparable predictive r2 values of 0.93 and 0.83 for 
model 1 and corresponding predictions of 0.90 and 0.82 for model 2. In addition, more 
stringent group cross-validation (20 times) was applied to further test the reliability of 
models. As shown in Table 6-16, r2cv values of 0.82 was obtained for CoMFA and 0.71 
for CoMSIA of model 1. The corresponding values for model 2 were 0.78 and 0.69 for 
CoMFA and CoMSIA, respectively. These results demonstrate that both models are 
stable and statistically robust. Moreover, low CoMFA and CoMSIA scrambling average 
q2 values of 0.17 and 0.18, respectively for model 1 and 0.31 and 0.25 for model 2 also 
validate the models’ statistical significance, showing they were not obtained by chance 
correlation. The result of bootstrapping further corroborates the robustness of the derived  
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Figure 6-27. Docked conformations of the data set compounds used as alignment 
III 
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Table 6-16. PLS statistics of 3D-QSAR models 
 
PLS Statistics Model 1  Model 2  Model 3 
CoMFA           CoMSIA CoMFA        CoMSIA  CoMFA         CoMSIA 
q2 0.82 0.71 0.79 0.71 0.61 0.60 
r2 0.94 0.93 0.93 0.94 0.93 0.94 
S  0.34 0.36 0.38 0.35 0.36 0.33 
F 284.69 240.51 222.65 261.51 221.03 263.92 
PLS Component 5 5 5 5 3 3 
Field 
Contribution 
      
Steric 0.526 0.105 0.528 0.107 0.453 0.122 
Electrostatic 0.474 0.288 0.472 0.292 0.547 0.242 
Hydrophobic   0.242  0.223  0.193 
H-Donor  0.224  0.214  0.232 
H-Acceptor  0.141  0.164  0.211 
Bootstrapping 
 r2 (20 runs) 
0.94 ± 0.012 0.95 ± 0.016 0.90 ± 
0.01 
0.95 ± 
0.01 
0.95 ± 
0.011 
0.96 ± .009
Cross-validation  
q2 (20 runs) 
0.82 0.71 0.78 0.69 0.60 0.59 
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Table 6-17. Residuals of predictions of the training set by CoMFA and CoMSIA 
of model 1 
 
Cpd. Actual 
STa  pIC50 
          Residuals  Cpd. Actual  
STa IC50 
        Residuals 
 CoMFA    CoMSIA  CoMFA   CoMSIA
81 
82 
83 
85 
86 
87 
88 
89 
90 
92 
93 
94 
95 
97 
98 
99 
100 
101 
102 
103 
105 
106 
107 
108 
109 
110 
111 
112 
113 
114 
115 
116 
117 
119 
120 
121 
122 
123 
124 
125 
126 
4.60 
4.85 
4.49 
4.92 
5.30 
4.45 
5.13 
4.72 
4.46 
4.74 
4.79 
4.85 
4.88 
4.27 
4.00 
4.03 
4.60 
4.76 
4.52 
4.38 
4.61 
4.52 
4.53 
4.82 
4.40 
4.23 
4.11 
4.11 
5.04 
4.74 
4.79 
4.74 
4.25 
4.25 
4.95 
4.79 
4.20 
4.28 
4.49 
4.74 
4.22 
0.20 
0.17 
-0.07 
0.22 
0.74 
0.09 
0.64 
0.12 
0.23 
0.09 
0.18 
0.24 
0.29 
-0.36 
-0.35 
-0.55 
-0.06 
0.13 
-0.04 
-0.23 
-0.09 
-0.09 
-0.14 
0.19 
-0.23 
-0.41 
-0.17 
-0.18 
0.13 
0.15 
-0.01 
0.07 
0.01 
-0.25 
0.26 
0.08 
-0.35 
-0.10 
-0.06 
0.14 
-0.40 
0.48 
0.27 
-0.39 
0.26 
0.21 
-0.26 
0.18 
0.15 
0.11 
0.20 
0.38 
0.26 
0.32 
-0.34 
-0.19 
-0.59 
0.02 
0.11 
0.01 
-0.26 
-0.12 
-0.12 
-0.08 
0.18 
-0.16 
-0.20 
-0.31 
-0.15 
0.44 
0.26 
0.03 
0.30 
-0.03 
-0.23 
0.10 
0.42 
-0.03 
-0.17 
0.00 
0.00 
-0.52 
149 
153 
154 
155 
183 
185 
186 
187 
188 
189* 
190 
191 
193 
195 
196 
197 
201 
202 
203 
204 
205 
206 
207 
208 
209 
210 
212 
213 
214 
215 
216 
217 
218 
219 
220 
222 
223 
224 
225 
226 
227 
4.82 
4.00 
4.00 
4.88 
8.00 
8.39 
7.82 
7.69 
7.58 
5.30 
7.67 
8.39 
7.82 
7.82 
6.92 
6.65 
7.00 
6.69 
6.60 
6.88 
5.39 
5.30 
6.75 
7.20 
7.72 
6.85 
7.36 
7.61 
8.04 
8.08 
8.14 
4.00 
4.74 
6.69 
5.88 
4.61 
4.79 
4.00 
4.00 
4.00 
4.00 
0.44 
-0.43 
-0.35 
0.51 
-0.26 
0.54 
-0.03 
-0.37 
-0.39 
-2.64 
-0.40 
0.26 
-0.05 
-0.25 
-0.01 
0.19 
0.54 
0.04 
0.04 
0.32 
-0.79 
-1.08 
0.14 
0.14 
0.62 
0.06 
0.78 
-0.22 
0.01 
0.20 
0.20 
-1.41 
-0.43 
1.17 
0.47 
-0.73 
-0.45 
0.01 
0.16 
-0.04 
-0.16 
0.42 
-0.34 
-0.28 
0.12 
-0.21 
-0.07 
0.40 
-0.60 
-0.12 
-3.16 
0.35 
-0.25 
-0.19 
0.01 
0.27 
0.25 
0.66 
0.01 
-0.01 
0.31 
-0.82 
-0.66 
0.15 
0.00 
0.46 
-0.01 
-0.05 
-0.30 
0.28 
0.92 
0.30 
-1.61 
-1.08 
0.82 
0.25 
-0.39 
-0.35 
-0.23 
0.13 
0.49 
-0.47 
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Table 6-17. (Continued) 
 
Cpd. Actual 
STa  pIC50 
          Residuals    Cpd. Actual 
 STa pIC50 
        Residuals 
  CoMFA    CoMSIA CoMFA   CoMSIA
127 
128 
129 
130 
4.35 
4.30 
4.16 
4.67 
-0.16 
-0.39 
-0.38 
0.13 
-0.03 
-0.16 
-0.61 
0.11 
228 
229 
230 
231
4.00 
4.00 
4.00 
4.00 
0.39 
-0.19 
0.01 
-0.05 
0.60 
0.18 
-0.50 
-0.32 
 
a ST represents strand transfer; * represents outlier.  
 
 
 
Table 6-18. Residuals of predictions of the test set by CoMFA and CoMSIA of 
model 1 
 
Cpd. Actual 
STa pIC50 
            Residuals 
 CoMFA        CoMSIA 
84 5.04 0.62 0.21 
91 4.29 0.05 0.08 
96  5.43 0.84 1.11 
204 4.76 0.05 0.14 
118 4.33 -0.03 -0.15 
184 7.82 -0.57 -0.51 
192 8.04 -0.16 -0.18 
194  7.92 -0.42 0.22 
198 7.00 -0.26 0.09 
199 6.16 -0.38 0.31 
200 6.85 -0.61 -0.39 
211 5.79 -0.52 -1.68 
221 6.22 0.76 0.66 
 
a ST represents strand transfer.  
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Table 6-19. Residuals of predictions of the training set by CoMFA and CoMSIA 
of model 2 
 
Cpd. Actual  
STa pIC50 
Residuals  Cpd. Actual  
STa pIC50 
Residuals 
 CoMFA     CoMSIA  CoMFA    CoMSIA 
81 
82 
83 
85 
86 
87 
88 
89 
90 
92 
93 
94 
95 
97 
98 
99 
100 
101 
102 
103 
105 
106 
107 
108 
109 
110 
111 
112 
113 
114 
115 
116 
117 
119 
120 
121 
122 
123 
124 
125 
126 
4.60 
4.85 
4.49 
4.92 
5.30 
4.45 
5.13 
4.72 
4.46 
4.74 
4.79 
4.85 
4.88 
4.27 
4.00 
4.03 
4.60 
4.76 
4.52 
4.38 
4.61 
4.52 
4.53 
4.82 
4.40 
4.23 
4.11 
4.11 
5.04 
4.74 
4.79 
4.74 
4.25 
4.25 
4.95 
4.79 
4.20 
4.28 
4.49 
4.74 
4.22 
0.40 
0.27 
-0.24 
0.36 
0.57 
-0.25 
-0.03 
0.15 
0.11 
0.18 
0.14 
0.26 
0.32 
-0.29 
0.00 
-0.54 
0.05 
0.20 
-0.15 
-0.21 
0.01 
-0.09 
-0.04 
0.23 
-0.27 
-0.27 
-0.22 
-0.19 
0.03 
0.17 
0.01 
0.10 
0.04 
-0.14 
0.42 
0.13 
-0.32 
0.01 
0.08 
0.26 
-0.26 
0.53 
0.30 
-0.53 
0.29 
0.17 
-0.06 
0.17 
0.22 
-0.06 
0.19 
0.25 
0.21 
0.32 
-0.30 
-0.02 
-0.46 
0.08 
0.21 
0.01 
-0.20 
0.08 
0.04 
0.03 
0.30 
0.10 
0.27 
0.17 
0.19 
-0.24 
-0.14 
-0.13 
-0.06 
0.07 
0.19 
-0.12 
0.03 
0.27 
0.24 
0.05 
-0.13 
0.38 
149 
153 
154 
155 
183 
185 
186 
187 
188 
189 
190 
191 
193 
195 
196 
197 
201 
202 
203 
204 
205 
206 
207 
208 
209 
210 
212 
213 
214 
215 
216 
217 
218 
219 
220 
222 
223 
224 
225 
226 
227
4.82 
4.00 
4.00 
4.88 
8.00 
8.39 
7.82 
7.69 
7.58 
5.30 
7.67 
8.39 
7.82 
7.82 
6.92 
6.65 
7.00 
6.69 
6.60 
6.88 
5.39 
5.30 
6.75 
7.20 
7.72 
6.85 
7.36 
7.61 
8.04 
8.08 
8.14 
4.00 
4.74 
6.69 
5.88 
4.61 
4.79 
4.00 
4.00 
4.00 
4.00 
0.10 
-0.57 
-0.44 
0.29 
-0.29 
0.49 
-0.03 
-0.24 
-0.04 
0.28 
-0.81 
0.13 
-0.21 
-0.31 
-0.35 
0.61 
0.84 
-0.05 
0.18 
0.43 
-0.78 
-1.05 
0.24 
0.35 
0.90 
0.04 
0.76 
-0.05 
-0.21 
0.13 
0.15 
-0.05 
-0.44 
1.11 
0.57 
-0.49 
-0.39 
-0.11 
-0.05 
-0.14 
-0.32 
0.07 
-0.62 
-0.46 
-0.30 
0.09 
-0.18 
-0.02 
-0.12 
0.32 
-0.38 
0.50 
-0.32 
-0.57 
-0.19 
-0.38 
0.15 
0.91 
0.22 
0.30 
0.59 
-0.59 
-0.62 
0.20 
0.13 
0.90 
0.07 
0.26 
0.12 
-0.02 
-0.74 
-0.04 
0.66 
0.60 
-0.97 
-0.26 
0.49 
0.14 
0.08 
-0.08 
-0.39 
0.50 
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Table 6-19. (Continued) 
 
Cpd. Actual 
STa pIC50 
Residuals   Cpd. Actual 
STa pIC50 
        Residuals 
CoMFA    CoMSIA CoMFA    CoMSIA
127 
128 
129 
130 
4.35 
4.30 
4.16 
4.67 
-0.24 
-0.47 
-0.37 
0.06 
0.04 
0.23 
0.17 
0.35 
228 
229 
230 
231
4.00 
4.00 
4.00 
4.00 
0.36 
-0.19 
-0.15 
-0.15 
-0.49 
-0.31 
0.14 
0.15 
 
a ST represents strand transfer.  
 
 
 
Table 6-20. Residuals of predictions of the test set by CoMFA and CoMSIA of 
model 2 
 
Cpd. Actual STa 
pIC50 
Residuals 
 CoMFA     CoMSIA 
84 5.04 -0.11 0.11 
91 4.29 -0.07 -0.01 
96  5.43 0.70 1.06 
104 4.76 0.19 0.23 
118 4.33 -0.73 -0.38 
184 7.82 -0.71 -0.79 
192 8.04 -0.20 0.10 
194  7.92 0.18 0.24 
198 7.00 -0.15 0.15 
199 6.16 -0.22 0.00 
200 6.85 -0.43 -0.38 
211 5.79 0.21 -1.57 
221 6.22 0.81 0.67 
 
a ST represents strand transfer.  
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Figure 6-28. Predictions of the training and the test set by CoMFA of model 1 
 
Training and the test sets are represented by blue and red spheres, respectively. 
 
 
 
 
 
 
Figure 6-29. Predictions of the training and the test set by CoMSIA of model 1 
 
Training and the test sets are represented by blue and red spheres, respectively. 
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Figure 6-30. Predictions of the training and the test set by CoMFA of model 2 
 
Training and the test sets are represented by blue and red spheres, respectively. 
 
 
 
 
 
 
Figure 6-31. Predictions of the training and the test set by CoMSIA of model 2 
 
Training and the test sets are represented by blue and red spheres, respectively. 
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models. PLS results of model 3, which was developed using the docking derived 
alignment, III are also shown in Table 6-16. For estimating predictivity, the same 13 
compounds were used as an external test set. The models, which could be developed with 
only 3 components, gave q2 and r2 values of 0.61 and 0.93 for CoMFA and the 
corresponding values of 0.60 and 0.94 for CoMSIA. Both the CoMFA and the CoMSIA 
models gave low standard error of estimate (SEE) and large F values of 0.36, 221.03 and 
0.33, 263.92, respectively. Cross-validation and boot-strapping results indicated that both 
CoMFA and CoMSIA models were statistically robust. The CoMFA model performed 
significantly better in estimating the test set compounds with a predictive r2 value of 0.82 
as compared with a predictive r2 value of 0.62 obtained with the CoMSIA model. The 
residuals of the training and the test set predictions of model 3 are summarized in Table 
6-21 and Table 6-22, respectively. Plots of CoMFA and CoMSIA predictions for the 
training and the test set are shown in Figures 6-32 and 6-33. Comparison of the QSAR 
models suggests that the atom-based alignment models 1 and 2, gave higher q2 values 
when compared with the docking-based alignment model 3. However, models 1 and 2 
were derived using 5 components and the higher q2 values might result from over-fitting 
of the data points because of the higher number of components used. Thus to check for 
any over-fitting, models 1 and 2 were revisited using 3 components. Re-derived model 1 
gave q2 and r2 values of 0.67, 0.85 for CoMFA and 0.60 and 0.84 for CoMSIA, 
respectively. However, the model gave higher SEE and smaller F values (0.54, 173.69 for 
CoMFA and 0.57, 151.09 for CoMSIA) compared to the docking-based model 3. 
CoMFA and CoMSIA 3D-QSARs of model 2 when derived with 3 components gave 
lower q2 and r2 values (q2 = 0.58, r2 = 0.75 for CoMFA; and q2 = 0.55, r2 = 0.76 for 
CoMSIA).  Moreover, these models also resulted in higher SEE and smaller F values 
when compared to model 3. Thus, in terms of robustness and ability to generalize, the 
docking-derived 3D-QSAR models are better than the ligand-based alignments I and II. 
Also, compared to our previous pharmacophore-based CoMFA and CoMSIA 3D-QSAR 
modeling of the salicylic acid derive IN inhibitors, this structure-based and composite 
3D-QSAR approach has generated better models, with best q2 and predictive r2 values of 
0.82 and 0.93, respectively, compared to best q2 and predictive r2 values of 0.54 and 0.57, 
respectively. Taken together, the results suggest that the docking-based composite QSAR 
models are better predictive tools than our previous QSAR models for lead optimization 
of the 3-keto salicylic acid series. 
 
 
Contour Maps 
 
 
Model 1: CoMFA contour maps. The PLS coefficients derived CoMFA steric 
and electrostatic contours mapped around raltegravir are displayed in Figure 6-34 and 
Figure 6-35, respectively. The IN-DNA binding site is represented as Connolly surface 
which was generated by the MOLCAD program in the SYBYL modeling package. There 
are green and yellow contours in the region close to the gem-dimethyl side chain. This is 
the region where substantial modifications were made that eventually led to the optimized 
gem-dimethyl oxadiazole carboxamide moiety. This side chain is positioned such that the 
oxadiazole ring occupies a pocket, which is indicated by a green contour in the cleft  
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Table 6-21. Residuals of predictions of the training set by CoMFA and CoMSIA 
of model 3 
 
Cpd. Actual 
STa pIC50 
Residuals Cpd. Actual 
STa  pIC50 
Residuals 
 CoMFA    CoMSIA  CoMFA   CoMSIA
81 
82 
83 
85 
86 
87 
88 
89 
90 
92 
93 
94 
95 
97 
98 
99 
100 
101 
102 
103 
105 
106 
107 
108 
109 
110 
111 
112 
113 
114 
115 
116 
117 
119 
120 
121 
122 
123 
124 
125 
126 
4.60 
4.85 
4.49 
4.92 
5.30 
4.45 
5.13 
4.72 
4.46 
4.74 
4.79 
4.85 
4.88 
4.27 
4.00 
4.03 
4.60 
4.76 
4.52 
4.38 
4.61 
4.52 
4.53 
4.82 
4.40 
4.23 
4.11 
4.11 
5.04 
4.74 
4.79 
4.74 
4.25 
4.25 
4.95 
4.79 
4.20 
4.28 
4.49 
4.74 
4.22 
0.19 
0.12 
0.06 
0.37 
0.72 
-0.14 
0.46 
-0.01 
-0.003 
0.41 
0.10 
0.06 
0.25 
-0.19 
-0.20 
-0.65 
0.36 
0.22 
0.23 
-0.19 
0.14 
-0.28 
 0.17 
-0.28 
0.52 
-0.60 
-0.18 
-0.52 
0.19 
0.14 
0.20 
0.31 
-0.26 
0.26 
0.04 
0.11 
0.40 
-0.13 
0.07 
0.05 
0.02 
 0.15 
 0.08 
 0.02 
 0.66 
 0.67 
-0.21 
 0.44 
 0.03 
-0.04 
0.30 
-0.05 
 0.16 
0.43 
-0.46 
-0.46 
-0.68 
0.14 
0.29 
0.04 
-0.34 
-0.15 
-0.14 
 0.13 
-0.01 
-0.07 
 0.00 
 0.02 
 -0.21 
 0.20 
 0.20 
 0.40 
 0.04 
-0.09 
-0.12 
 0.15 
 -0.03 
-0.26 
-0.33 
-0.12 
0.07 
-0.10 
149 
153 
154 
155 
183 
185 
186 
187 
188 
189 
190 
191* 
193 
195 
196 
197 
201 
202 
203 
204 
205 
206 
207 
208 
209 
210 
212 
213 
214* 
215 
216 
217* 
218 
219 
220* 
222 
223* 
224 
225 
226 
227 
4.82 
4.00 
4.00 
4.88 
8.00 
8.39 
7.82 
7.69 
7.58 
5.30 
7.67 
8.39 
7.82 
7.82 
6.92 
6.65 
7.00 
6.69 
6.60 
6.88 
5.39 
5.30 
6.75 
7.20 
7.72 
6.85 
7.36 
7.61 
8.04 
8.08 
8.14 
4.00 
4.74 
6.69 
5.88 
4.61 
4.79 
4.00 
4.00 
4.00 
4.00 
0.26 
-0.45 
0.06 
0.08 
-0.41 
-0.03 
-0.53 
0.45 
-0.20 
-0.05 
0.52 
  N/I 
0.40 
0.006 
0.01 
0.54 
-0.08 
0.25 
-0.22 
-0.16 
-0.03 
-0.45 
-0.10 
0.06 
0.69 
-0.06 
0.79 
0.58 
  N/I 
0.25 
-0.22 
  N/I 
-1.42 
-0.02 
  N/I 
-0.55 
  N/I 
-0.32 
-0.14 
-0.49 
-0.003 
-0.16 
0.11 
0.17 
-0.20 
0.61 
-0.03 
0.25 
-0.19 
-0.01 
-1.31 
-0.22 
    N/I 
0.12 
-0.22 
-0.02 
0.43 
0.21 
0.03 
-0.04 
0.13 
0.14 
0.002 
-0.02 
-0.43 
0.44 
0.10 
0.34 
0.39 
    N/I 
0.06 
-0.02 
    N/I 
-0.60 
0.49 
    N/I 
-0.50 
    N/I 
0.40 
-0.78 
0.15 
-0.01 
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Table 6-21. (Continued) 
 
Cpd. Actual 
STa pIC50 
       Residuals   Cpd. Actual 
STa pIC50 
Residuals 
CoMFA  CoMSIA  CoMFA  CoMSIA
127 
128 
129 
130 
4.35 
4.30 
4.16 
4.67 
0.01 
-0.10 
-0.13 
-0.20 
-0.05 
-0.16 
0.20 
0.13 
228 
229 
230 
231
4.00 
4.00 
4.00 
4.00 
-0.02 
-0.26 
0.20 
-0.29 
-0.51 
-0.02 
-0.29 
0.13 
 
* Compounds excluded from the dataset because of the lack of common binding mode, 
N/I represents not included in the data set,  a ST represents strand transfer. 
 
 
 
Table 6-22. Residuals of predictions of the test set by CoMFA and CoMSIA of 
model 3 
 
Cpd. Actual 
STa pIC50 
Residuals 
CoMFA      CoMSIA
84 5.04  0.52 0.46 
91 4.29 -0.29 -0.11 
96  5.43 1.06 0.96 
104 4.76 0.42 0.02 
118 4.33 -0.01 -0.03 
184 7.82 0.58 1.69 
192 8.04 -0.66 0.48 
194  7.92 1.06 1.99 
198 7.00 0.70 0.28 
199 6.16 -0.89 -0.18 
200 6.85 0.37 -0.75 
211 5.79 0.25 -0.77 
221 6.22 0.46 0.50 
 
a ST represents strand transfer.   
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Figure 6-32. Predictions of the training and the test set by CoMFA of model 3 
 
Training and the test sets are represented by blue and red spheres, respectively. 
 
 
 
 
 
 
Figure 6-33. Predictions of the training and the test set by CoMSIA of model 3 
 
Training and the test sets are represented by blue and red spheres, respectively. 
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Figure 6-34. CoMFA steric contour maps of model 1 superimposed on raltegravir 
 
Green and yellow contours illustrate regions where steric bulk has favorable and 
unfavorable effects on activity respectively. 
 
 
 
 
 
 
Figure 6-35. CoMFA electrostatic contour maps of model 1 superimposed on 
raltegravir 
 
Blue and red isopleths indicate regions where an increase of positive and negative charge 
is required for activity. 
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formed by residues Asn117, Pro142, Tyr143, Asn144 and Pro145. The N-hydroxyalkyl 
side chain of the quinolone ring of elvitegravir also occupies the green contour and thus 
shows nearly 6 times improved activity relative to the unsubstituted analog (212 vs 215). 
The two yellow contours above the pyrimidinone ring indicate that steric bulk is 
unfavorable in this region. The N-acetyl substituted piperidine ring of compound 205 fits 
into a yellow contour, which might explain the decrease in activity of this compound and 
other structural analogs of 4-quinolone-3-carboxylic acids with a bulky phenyl ring, such 
as compounds 228 and 229. Moreover, their hydroxyethyl side chains also point towards 
the steric disfavored yellow contour region, further supporting a decrease in activity of 
these analogs. There are several yellow regions around the hydrophobic phenyl ring, 
suggests that steric bulk is not favored at these positions possibly because of clashing 
with the donor DNA. This might be one of the reasons fluorine whose size is similar to 
hydrogen’s is the most optimal substituent on this ring. The electrostatic map of CoMFA 
shows a blue contour close to the pyrimidinone ring, implying that groups that have 
electropositive character are favored for activity. This is supported by the presence of 
electron-deficient nitrogen-containing ring systems in many different classes of IN 
inhibitors including the pyrimidinone ring of raltegravir and the quinolone ring of 
elvitegravir, as well as the acidic phenolic hydrogen in this region. There are three red 
contours close to the metal-chelating pharmacophore of raltegravir indicating that the 
presence of electron rich groups is favored for activity. There is also a red contour at the 
ortho-position on the fluorobenzyl group. This is explained by the contour superimposed 
on elvitegravir which reveals the ortho-fluoro substituent occupying these red contours. 
A distal red contour which is close to the meta-postion on the benzyl group of 
elvitegravir again suggests that negative charge is favorable in this region. This is 
reflected by the presence of an electronegative chlorine substituent at this position in 
elvitegravir and related analogs. 
 
Because the developed QSAR models are developed for potential use in 
optimizing our lead amide derivatives to more potent IN inhibitors, CoMFA contours 
were also mapped over compound 149. The bromine substituent at the para-position of 
the salicylic acid group could be substituted with bulky groups for improvement of 
activity as a green contour resides at this region. The CoMFA contours help explain the 
loss in activity of compounds 117, 118 and 119, which have cyclopentyl and substituted 
polycyclic naphthalene rings placed in steric bulk disfavored yellow-contoured regions. 
 
 
Model 1: CoMSIA contour maps. CoMSIA steric and electrostatic contours 
mapped onto raltegravir are similar to those of the CoMFA model in having two yellow 
contours which result from the steric clash with the amide backbone of Tyr143 and the 
solvent accessible surface. Like in the CoMFA map, there is a green contour which is 
occupied by the carboxamide moiety of the oxadiazole side chain. However, in 
compound 206, the side chain is oriented towards the yellow contours and explains the 
loss in activity. Another steric bulk-favored green region is occupied by the 
p-fluorobenzyl group, which has a positive influence on potency.  This is confirmed by 
the significant loss of activity of compound 189 which lack of a phenyl at this position. 
The green contour is flanked by a large yellow contour suggesting that bulk tolerance 
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within the cavity is quite limited. This could be the reason behind the reduced potency of 
compounds 112 and 117 in the chalcone series whose methoxy and bulky cyclopentyl 
groups fit into the disfavored yellow region. Similarly for compounds 118 and 119, loss 
in activity might result from the naphthyl rings placed in the bulk disallowed yellow 
region. The phenyl ring in compounds 217, 224, and 227-229 fits into the disfavored 
yellow region, and that might account the significant loss in activity of these analogs.  
 
The CoMSIA electrostatic map shows two red contours close together near the 
oxadiazole ring which is involved in ?-stacking interactions with the phenyl ring of the 
Tyr143. Similar to the CoMFA electrostatic contour map, there is a blue contour over the 
hydroxyl group of raltegravir. This possibly reflects the ionizable acidic OH group of 
raltegravir. Lastly, there are two small red contours around the oxygen of the methoxy 
and the hydroxyl groups in elvitegravir, correctly predicting the requirement of electron 
rich groups at this location.   
 
CoMSIA hydrophobic contours superimposed on raltegravir (Figure 6-36) show 
the presence of two large yellow regions indicating that hydrophobic groups at these 
positions are favored for activity. While one of the yellow contours is occupied by the 
phenyl ring in raltegravir, the phenyl ring of elvitegravir is oriented towards the second 
yellow contour. There is also a small yellow region at the para-position on the phenyl 
ring. Indeed, the presence of hydrophobic halogens like bromine in compound 86 or 
chlorine in compound 88 suggest the presence of hydrophobic interactions at this 
position. There is a hydrophilic region that the ribose and the phosphate regions of the 
viral DNA. This voluminous white contour encloses the the carboxamide moiety and 
extends up to the central hydroxyl substituent in the pyrimidinone ring of raltegravir. The 
reduced potency of compound 206 may be explained by having the hydrophobic methyl 
group of its N-methyl carboxamide moiety located in the white region, which is counter 
to the preference of a hydrophilic moiety. A yellow contour fits over the methyl and a 
white contour fits over the carbonyl group of the oxadiazole carboxamide side chain in 
raltegravir in agreement with their hydrophobic and hydrophilic character, respectively. 
The H-bond donor-acceptor contour plots mapped onto raltegravir are shown in Figure 
6-37. The magenta contour signifies that acceptor groups on the inhibitor are favored at 
that location, whereas the red contour encompasses a region where H-bond acceptors are 
disfavored, probably because of the presence of the carbonyl oxygen of the amide 
backbone of Tyr143 in the receptor. Another magenta contour is merged within the 
purple contour suggesting an H-bond acceptor is favored but a donor is disfavored which 
relate to groups that interact with the backbone NH of Pro145. It is close to the 8?-
position of the quinolone ring in elvitegravir indicating that acceptor groups are well 
tolerated at this position. There is another red contour above the phenyl ring at the ortho 
and meta-positions in raltegravir implying that H-bond acceptors are disfavored at these 
positions. One of the purple regions is merged with and complements the magenta 
contour at the 8?-position of the quinolone ring. The other purple region appears to 
complement the presence of the amino group of Gln148 in the receptor site, signifying 
that the presence of H-bond donor at this region is detrimental to activity. Cyan contours 
indicate regions where H-bond donor groups increase activity. One of the cyan contours 
fits the NH group of the pyrimidinone carboxamide functionality in raltegravir while the  
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Figure 6-36. CoMSIA hydrophobic contour maps of model 1 superimposed on 
raltegravir 
 
Yellow and white contours enclose areas favorable for hydrophobic and hydrophilic 
groups respectively. 
 
 
 
 
 
 
Figure 6-37. CoMSIA H-bond contours of model 1 
 
Purple contours indicate regions where H-bond donor decreases activity whereas cyan 
contour illustrates regions where H-bond donor increases activity. Magenta isopleths 
indicate areas where H-bond acceptor increases affinity while red isopleths indicate areas 
where H-bond acceptor decreases affinity. 
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other is located in the region close to the hydroxyl of the alkyl hydroxyl group of 
elvitegravir. 
 
 
Model 2 contour maps. The CoMFA steric (Figure 6-38) and electrostatic 
(Figure 6-39) contours on raltegravir arising from model 2 have similarities to the 
contours obtained in model 1. One green contour again fits into the oxadiazole ring 
suggesting that bulk is favored. Nearby yellow regions similar to those in the CoMFA 
contour of model 1 indicate sterically disallowed regions. Likewise, there are several red 
and one blue contours around the metal-chelating pharmacophore. Similar to the CoMFA 
model 1, the contours also explain the loss of inhibitory activity of compounds 189, 206, 
217, 224 and 225, and 227-229. In addition, the CoMFA contour map further reveals 
green regions around the two meta-positions on the phenyl ring, suggesting that bulky 
groups could be added at these positions. One of the green contours is occupied by the 
methyl of the methoxy group in elvitegravir, corroborating the increase in activity seen 
with the presence of methoxy substituents in compounds 213 vs. 214 and 215 vs. 216. 
The CoMSIA steric and electrostatic contours projected onto raltegravir reveal SAR 
information similar to CoMSIA isopleths of model 1. However, there is a distant yellow 
contour which fits around the phenyl ring of the chalcone derivatives. In alignment II, the 
phenyl rings of the chalcones were oriented in the opposite (180°) direction to those in 
alignment I, and not within the cavity formed by the displacement of 3?-adenosine of the 
viral DNA. The hydrophobic contour of CoMSIA projected on raltegravir (Figure 6-40) 
shows two white regions around the metal-chelating pharmacophore and another similar 
white region below the NH of the carboxamide moiety in raltegravir and oxygen of the 
methoxy substituent in elvitegravir. Again as in model 1, a yellow contour close to the 
gem-dimethyl substituent is observed, suggesting a hydrophobic favored region. The H-
bond donor and acceptor contours (Figure 6-41) show a large cyan isopleth located on 
the hydroxyl group of the hydroxalkyl side chain in elvitegravir. This appears to 
complement the red polyhedra observed in the corresponding contour maps of model 1. 
There are small cyan and magenta contours close to the pyrimidinone ring of raltegravir 
showing the positive role of a H-bond donor. There are two purple contours around the 
benzyl groups of raltegravir and elvitegravir implying that H-bond donors are not 
tolerated on the phenyl ring. One of the purple contours fits over the meta-chloro 
substituent of elvitegravir suggesting the preference for a H-bond acceptor at this 
position. 
  
 
Model 3 contour maps. Contours resulting from docking-based alignment III are 
mostly similar to the contours that resulted from models 1 and 2. Since details of these 
contours have been described above, only the contours that differ markedly are further 
discussed. CoMFA and CoMSIA steric and electrostatic contours are shown in Figure  
6-42 and Figure 6-43, respectively. A large green contour observed in the CoMFA map 
is directed towards the gem-dimethyl substituent indicating the importance of this 
sterically favored group. Large yellow contours near the oxadiazole ring are evident in 
both CoMFA and CoMSIA maps, and may have resulted due to the lack of space beyond 
the oxadiazole shown by the surface protrusion on the right upper side of the oxadiaxole  
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Figure 6-38. CoMFA steric contours of model 2 
 
Green and yellow contours illustrate regions where steric bulk has favorable and 
unfavorable effects on activity respectively. 
 
 
 
 
 
 
Figure 6-39. CoMFA electrostatic contours of model 2 
 
Blue and red isopleths indicate regions where an increase of positive and negative charge 
is required for activity.   
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Figure 6-40. CoMSIA hydrophobic contours of model 2 
 
Yellow and white contours enclose areas favorable for hydrophobic and hydrophilic 
groups respectively. 
 
 
 
 
 
 
Figure 6-41. CoMSIA H-bonding contours of model 2 
 
Purple contours indicate regions where H-bond donor decreases activity whereas cyan 
contour illustrates regions where H-bond donor increases activity. 
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Figure 6-42. CoMFA steric and electrostatic contours of model 3 
 
Green and yellow contours illustrate regions where steric bulk has favorable and 
unfavorable effects on activity respectively; blue and red isopleths indicate regions where 
an increase of positive and negative charge is required for activity.  
 
 
 
 
 
 
Figure 6-43. CoMSIA steric and electrostatic contours of model 3 
 
Green and yellow contours illustrate regions where steric bulk has favorable and 
unfavorable effects on activity respectively; blue and red isopleths indicate regions where 
an increase of positive and negative charge is required for activity.  
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ring of raltegravir. Similarly, a green common contour is mapped onto the phenyl ring 
suggesting that bulk is favored inside the cavity. In the CoMFA map, a yellow contour is 
observed close to the benzyl moiety implying the possibility of steric clash with the 
surrounding DNA. Electrostatic contours show several red contours close to the metal-
chelating oxygen atoms implying that electronegative groups increase activity. A blue 
contour common in both CoMFA and CoMSIA maps is also present near the metal-
chelating pharmacophore. These contours which suggest electropositive or H-donor 
groups are favored for activity resulted from the acidic phenolic OH residues. A large 
blue contour (near the green region) observed in CoMFA is indicative of positive groups 
interacting with the surrounding deoxyribose phosphate backbone in the DNA. Both the 
CoMSIA hydrophobic, H-bond donor and H-bond acceptor contours are shown in Figure 
6-44. There are yellow contours that map onto the hydrophobic phenyl ring and gem-
dimethyl substituent suggesting that hydrophobic groups are favored at these positions. 
There are white hydrophilic regions which map on the carboxamide moiety and on the 
oxadiazole ring. The H-bonding contours show two purple contours close to o-position 
on the phenyl ring and a red contour close to the m-position indicating that H-bond 
donors and acceptors are disfavored at these positions, respectively. There is a purple 
contour close to the metal-chelating atoms implying that H-bond donors are disfavored. 
An overlapping magenta and red contours suggest H-bond acceptor is favored, while 
beside it H-bond donor is disfavored. An overlapping cyan and magenta contours occur 
around the NH of the benzyl carboxamide moiety indicating that NH can act as both a H-
bond donor and acceptor at this position. Thus, the contour maps of model 3 reinforced 
the SAR features explained by contour maps of 3D-QSAR models 1 and 2. This is not 
surprising since the docking-based alignment II, was in a way a composite of alignments 
I and II. 
 
 The two best 3D-QSAR models, 1 and 3, were finally used to predict the amide 
derivatives that, were prospectively synthesized in Chapter 4. Thus, compounds in the 
correct ionization states were assigned MOPAC atomic charges and predicted for their 
ST activities. Comparison of the predicted vs. experimental activities is shown in Table 
6-23. Both CoMFA and CoMSIA of the docking-based QSAR model 3 performed better 
than their model 1 counterparts; as all the predicted compounds were found to be within 1 
log unit of the pIC50 values. Furthermore, the CoMFA, of model 3 predicted three out of 
total five compounds used for validation within 0.50 log units. With reference to related 
amide, compound 149, used in the training set, the CoMFA of model 3 predicted two 
compounds (152, 157) to be more active than the reference compound 149. Upon 
biological testing it was revealed that these two compounds were reasonably predicted. 
Thus, the final performance of the CoMFA of QSAR model 3, which performed the best, 
may be considered acceptable. As the data set used in building the QSAR models 
included only four salicylic acid-3-carboxamides, further studies using greater number of 
salicylic acid-3-carboxamides derivatives in the training set may improve the predictive 
ability of the 3D-QSAR models for the design of related novel 3-keto salicylic acid IN 
inhibitors.  
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Figure 6-44. CoMSIA hydrophobic and H-bonding contours of model 3 
 
Yellow and white contours enclose areas favorable for hydrophobic and hydrophilic 
groups respectively; purple contours indicate regions where H-bond donor decreases 
activity whereas cyan contour illustrates regions where H-bond donor increases activity. 
Magenta isopleths indicate areas where H-bond acceptor increases affinity while red 
isopleths indicate areas where H-bond acceptor decreases affinity. 
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Table 6-23. Comparison of the predicted activities of the 3D-QSAR models guided synthesized compounds 
 
 
 
Cpd. X R1 R2 Actual 
pIC50 
Model 1 predicted pIC50 Model 3 predicted pIC50 
CoMFA (Res.)b   CoMSIA (Res.)b CoMFA(Res.)b   CoMSIA(Res.)b
149a 
150 
COOH 
COOH 
Br 
Br 
4-F 
4-Br 
4.82 
4.16 
4.38 (0.44) 
4.45 (-0.29) 
4.40 (0.42) 
4.39 (-0.23) 
 4.56 (0.26) 
4.65 (-0.49) 
4.98 (-0.16) 
5.11 (-0.95) 
151 COOH Br 2,4-di- 
F-3-Cl 
5.39 4.44 (0.95) 4.43 (0.96)  4.56 (0.83) 5.14 (-0.25) 
152 CONHCH2-4-
F-Ph 
Br 4-F 5.22 4.61 (0.61) 4.34 (0.88)  5.18 (0.04) 5.59 (-0.37) 
157 OH COCHCH-
Ph 
4-F 4.67 5.96 (-1.29) 6.03 (-1.36)  5.12 (-0.45) 5.53 (-0.86) 
158 COCHCH-
2,3,6-tri-Cl-Ph 
Br 4-F 4.00 4.44 (-0.44) 4.16 (-0.16)  4.71 (-0.71) 4.51 (-0.51) 
 
a Reference compound used as training set in 3D-QSAR models 1 and 3; b Represents residual values.
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Linear Interaction Energy Activity Model 
 
To compare the three dimensional (3D) molecular interaction field-based 
(CoMFA) and molecular similarity indices based (CoMSIA) QSAR models with the 
linear interaction approximation218 derived energy parameters, a LIA QSAR model of the 
IN inhibitors was developed. LIA estimates the free energy of binding by deriving 
electrostatics, vdW, and cavity energy terms using a molecular mechanics force field and 
is based on the surface generalized born continuum model of solvation.219 The objective 
of building the LIA QSAR model is to correlate the changes in the free energy of binding 
of the IN inhibitors in our dataset with their experimental IC50 values; and therefore to 
provide a direct estimation of the potencies based on their binding free energies. 
Although, unlike the CoMFA and CoMSIA models, the LIA calculations are not highly 
dependent on the molecular alignments in calculating the binding free energies, their 
accurate estimation is subject to giving a correct binding pose. 
 
 Thus, 98 integrase inhibitors of the dataset which shared similar binding modes, 
as revealed by the docking studies, were used for building the LIA QSAR model. Same 
test set of 13 compounds, docking-based CoMFA and CoMSIA 3D-QSAR models, was 
used for prediction. Correlation coefficient r2 of 0.59 was obtained for the training set 
with an rmsd of 0.88. Group cross-validation (leave-4-out) q2 of 0.54 indicates that model 
can reasonably predict compounds not included in the training set. The model was then 
used to predict the activities for the test set compounds. A plot of training and test set 
predictions is shown in Figure 6-45. Correlation coefficient r2 of 0.79 between the actual 
and predicted activities of the test set indicates that the LIA model has good predictive 
ability. This model could estimate the binding affinities of novel HIV-1 IN inhibitors and 
aid the virtual screening of IN inhibitors for lead discovery and development.  
 
The vdW, electrostatic and cavity energy terms obtained from the LIA 
calculations (Table 6-24) showed correlation of 0.44, 0.09, and 0.44, with the ST IC50s, 
in that order. Liaison did not estimate electrostatics accurately probably because of 
similar reasons mentioned in the MM-GBSA results. Regression coefficients ?, ?, and ?, 
for the vdW, electrostatic and cavity energy terms were found to be 0.087, -0.01, and 
0.11, respectively. This indicates that the cavity and the vdW energy terms contribute 
significantly to activity. The larger value for the cavity term implies that binding of IN 
inhibitors is greatly influenced by placement of the ligand into a binding pocket. This is 
in agreement with one of the most important binding requirements of potent IN 
inhibitors. The crystal structures of the foamy virus IN-DNA complex in the presence of 
IN inhibitors, raltegravir and elvitegravir, have revealed that their halogenated benzyl 
ring is bound in a cavity formed by the IN-DNA interface after the displacement of  3? 
adenosine of the viral DNA. This feature has also been correctly depicted by our 
homology models of HIV-1 IN-DNA-inhibitor complex that were discussed previously. 
Analysis of the energy terms for raltegravir (compound 193) and elvitegravir (compound 
216) explains their similar binding orientation in the IN active site. There is a greater 
desolvation penalty for raltegravir as opposed to a smaller penalty for elvitegravir. 
Although the halogenated benzyl groups of both dock into the cavity, the amide linkage 
gives the benzyl moiety in raltegravir more flexibility to get more deeply buried into the 
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Figure 6-45. Plot of actual and predicted ST inhibitory activities (pIC50s) by the 
LIA model 
 
Training and the test sets are represented by blue and red spheres, respectively. 
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Table 6-24. Average van der Waals (UvdW), electrostatic (Uele) and cavity energy 
(Ucav) terms obtained from the LIA calculations 
 
Cpd. UvdWa   Ucavb Uelec Cpd.  UvdWa   Ucavb   Uelec 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
91 
92 
93 
94 
95 
96 
97 
98 
99 
100 
101 
102 
103 
104 
105 
106 
107 
108 
109 
110 
111 
112 
113 
114 
115 
116 
117 
118 
119 
120 
121 
122 
-3.64 
-3.17 
-3.91 
0.68 
-26.95 
-24.27 
-27.07 
-2.52 
-10.07 
-2.58 
-4.31 
-7.48 
-6.45 
-1.17 
-2.99 
-3.00 
0.50 
-28.18 
-9.72 
-7.40 
-2.05 
-2.28 
-0.52 
2.10 
-0.25 
-6.46 
-3.92 
-0.47 
-0.67 
-20.29 
-30.44 
-2.11 
-43.47 
-43.65 
-39.13 
-0.30 
-5.54 
-21.15 
-33.45 
-1.57 
-10.34 
-3.24 
2.58 
3.22 
2.59 
3.31 
4.09 
3.66 
3.49 
3.45 
3.88 
3.58 
3.88 
3.92 
2.86 
3.19 
3.09 
2.56 
2.85 
3.10 
3.73 
3.83 
2.76 
2.80 
2.79 
2.60 
2.82 
2.70 
2.76 
2.77 
2.42 
4.07 
3.94 
3.69 
4.33 
3.93 
4.61 
3.28 
4.27 
4.48 
4.25 
3.48 
3.51 
3.46 
-168.58 
-134.91 
-170.39 
-188.99 
49.82 
7.71 
17.18 
-189.98 
-131.13 
-206.55 
-205.05 
-137.5 
-140.39 
-192.54 
-212.50 
-211.46 
-189.28 
32.94 
-131.34 
-136.34 
-210.58 
-210.01 
-192.11 
-190.17 
-188.10 
-131.34 
-139.22 
-173.17 
-223.33 
-0.53 
-4.52 
-206.71 
156.91 
65.95 
114.87 
-191.02 
-220.24 
-22.96 
9.11 
-187.59 
-171.10 
-188.87 
130 
149 
153 
154 
155 
183 
184 
185 
186 
187 
188 
189 
190 
192 
193 
194 
195 
196 
197 
198 
199 
200 
201 
202 
203 
204 
205 
206 
207 
208 
209 
210 
211 
212 
213 
215 
216 
218 
219 
221 
222 
224
-27.66 
-13.87 
-36.41 
-30.57 
-21.30 
-46.92 
-38.81 
-32.81 
-39.26 
-48.65 
-36.04 
-34.42 
-53.72 
-51.16 
-42.67 
--38.97 
-50.27 
-20.29 
-18.37 
-33.37 
-32.74 
-28.04 
-32.52 
-30.96 
-34.24 
-35.59 
-33.56 
-37.09 
-32.49 
-35.37 
-35.15 
-34.90 
-19.66 
-19.93 
-31.61 
-30.97 
-28.31 
-24.35 
-10.23 
-22.61 
-19.66 
-10.92 
2.50 
4.41 
4.65 
1.76 
3.23 
8.80 
6.94 
6.60 
7.60 
10.16 
7.92 
8.61 
10.67 
9.62 
8.66 
8.33 
8.64 
6.17 
5.82 
6.07 
6.44 
6.73 
6.53 
5.92 
6.37 
7.18 
7.26 
6.55 
5.31 
6.67 
6.55 
7.01 
2.74 
2.87 
2.90 
3.30 
3.68 
3.40 
3.51 
3.30 
3.80 
3.45 
-70.53 
-38.58 
-7.63 
-14.81 
-95.56 
-82.23 
-59.44 
-114.88 
-58.80 
-34.48 
-77.39 
-96.62 
-72.47 
-84.71 
-60.23 
-64.80 
8.57 
-120.44 
-122.33 
-50.90 
-59.14 
-54.86 
-66.60 
-61.17 
-57.75 
-56.45 
-57.56 
-56.89 
-73.44 
-62.96 
-74.77 
-63.40 
-70.65 
-82.47 
-26.08 
-16.52 
-88.37 
-81.58 
-109.24 
-77.11 
-54.20 
-113.49 
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Table 6-24. (Continued) 
 
Cpd.   UvdWa  Ucavb  Uelec Cpd. UvdWa  Ueleb  Ucavc 
123 
124 
125 
126 
127 
128 
129 
-2.36 
0.47 
0.04 
-3.29 
-20.81 
-1.68 
-30.26 
2.27 
3.17 
3.43 
2.70 
2.68 
2.55 
2.37 
-205.83 
-193.39 
-190.18 
-175.25 
-100.44 
-203.84 
2.51 
225 
226 
227 
228 
229 
230 
231
-34.58 
-3.04 
-7.43 
-7.51 
-6.26 
-7.09 
-6.47 
3.40 
3.74 
4.22 
5.05 
5.70 
5.36 
4.87 
42.80 
-152.21 
-68.26 
-93.39 
-122.54 
-74.82 
-140.74 
 
a Represents van der Waals energy; b represents cavity energy term; c represents 
electrostatic energy.  
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cavity (see Figure 6-13); than that in elvitegravir (see Figure 6-15). This loss of 
desolvation energy is then immediately followed by more favorable electrostatic and 
vdW interactions with IN and viral DNA, contributing to potent inhibitory activities.  The 
electrostatic energy, although not correlated well for the entire data, could be compared 
among raltegravir and elvitegravir given that their crystal structure conformations were 
used in the LIA calculations. Electrostatic terms were observed to be more favorable for 
elvitegravir probably because of the free negatively charged carboxylate that can 
participate in stronger electrostatic interactions with the two Mg2+ ions in the integrase 
active site. The vdW energy term is more favorable for raltegravir which could be due to 
more hydrophobic contacts with residues in the IN active site. Notably, raltegravir has an 
extended gem-dimethyl oxadiazole side chain which is involved in vdW contacts with 
side chain methylene of Asn117, ?-stacking interactions with Tyr143 and vdW contacts 
with Pro142. These interactions on the other hand are not observed with the hydroxyl 
alkyl chain in elvitegravir. Evaluation of the energy terms for the two most active 
chalcone derivatives also gives support to their binding modes. As discussed in the 
docking section, these compounds may have two binding poses (Figure 6-18), one that 
docks their phenyl ring into the cavity (compound 86) and the other (compound 96) 
whose most frequent conformations have their phenyl ring placed away from the cavity, 
exposed to solvent.  The LIA cavity energy term for compound 76 is less than that of 
compound 86, suggesting a binding mode in which their 2,3,6-trichloro-substituted 
phenyl ring is placed outside the cavity and interacts with the methylene of Ser119 and 
the methine of Gly118. The more favorable vdW energy term for compound 86 also 
implies that its halo-phenyl ring docks into the cavity and makes more favorable vdW 
contacts. 
 
 
RACHEL-Guided Design of Compound 137 
  
Receptor-based design was attempted to synthesize amide compound 157. 
Analysis of binding interactions of raltegravir (Figure 6-14) revealed vdW interactions 
between the methyl on the oxadiazole ring and the side chain methylenes of Asn117. 
Moreover, the oxadiazole ring in raltegravir establishes a ?-stacking interaction with the 
phenyl ring of Tyr143. Tyr 143 is a conserved residue among the family of retroviruses 
and literature reports have shown that mutation of this residue (Y143 R/C) decreases viral 
susceptibility to raltegravir.220 The binding interactions of elvitegravir (Figure 6-15) also 
revealed vdW interactions between its isopropyl moiety and the Tyr143 residue. 
Conformation of the most active compound (96) in the chalcone series also showed that 
its halogenated-phenyl ring interacted (Figure 6-20) with Tyr 143, Gly118, and Ser119. 
In contrast, no interactions with Tyr143 or Asn117 were observed in our synthesized 3-
keto salicylic acid amides IN inhibitors. Based on these observations and the sterically 
favorable requirement, suggested by the 3D-QSAR contours, prompted me to append a 
bulky group with an aim of having ? -stacking interactions with Tyr143. Thus, to 
determine the importance of this site in the inhibition of IN, the amide derivative 149, 
was used as a lead to design a compound that could mimic the interactions of the 
oxadiazole ring of raltegravir. Towards this end, RACHEL, a lead optimization 
program221 in the Sybyl molecular modeling package was used. Compound 149 bound to 
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the IN active site (Figure 6-46) suggesting that the bromine at the R1 position could be 
substituted and used as a site for modification. Tyr143 was defined as the target site in 
the receptor for directing the fragments to grow and make contacts with this residue. 
Automated combinatorial optimization was then performed and the compounds were 
conformationally searched and iteratively processed within the IN active site. Only those 
compounds that dock well in the receptor site were retained as hits. To optimize the size 
of the resulting hits, a molecular weight filter (50-200 Da) was applied in the searching 
process. After the analysis, a set of 50 hits were obtained, which were then evaluated. On 
the basis of drug-likeness and synthetic feasibility only 1 hit (232) was considered for 
further evaluation. Compound 232 had a hydrophobic aryl akyl moiety substituted at the 
R1 position. The binding interactions of compound 232 (Figure 6-47) revealed that the 
phenyl ring of the added fragment is involved in the desired pi-stacking interaction with 
Tyr143, and also made vdW contacts with Asn117. Superimposition of the conformations  
of raltegravir by shape complementary (Figure 6-48) supported the synthesis and 
biological testing of the derived compound. 
 
 
Docking Studies of Synthesized Phenanthrene HIV-1 IN Inhibitors 
 
To determine the binding modes of phenanthrene derivatives, synthesized in 
Chapter 5, docking studies were also conducted on a homology model of a complete 
HIV-1-DNA-complex. Docking studies predominantly revealed two distinct binding 
modes for the phenanthrene derivatives. The docked conformations of compound 177 are 
shown in Figure 6-49 and interactions in Figure 6-50 and Figure 6-51, respectively. In 
both orientations, the ?-diketo acid chelating pharmacophore interacted with the two 
Mg2+ ions in the IN active site, thus contributing to IN inhibition in accordance with the 
proposed mechanism of action of ST inhibitors. The phenanthrene ring in one binding 
mode interacted with residues Glu92, Ser119, Asn120, and Phe121, in a novel binding 
region in the IN active site.  In the other mode, the phenanthrene ring made contacts with 
Pro142, Tyr143, and Asn117, and Gly118. It is important to note that because of steric 
bulk, the phenanthrene ring does not dock into the cavity into which the characteristic 
halobenzyl moieties of advanced IN inhibitors, including raltegravir and elvitegravir, are 
inserted.93 The interactions of the halobenzyl groups with DNA bases and IN residues 
that forms this cavity is one of the most important features contributing to potent IN 
strand transfer activities. Structure-based design suggests significant potential for 
improvement of potencies of this series of IN ST inhibitors as a halobenzyl moiety could 
be appended to occupy this vacant cavity. More importantly, docking studies showed no 
significant interactions with Gln148 and Asn155 which are key residues that cause viral 
resistance. Since, compound 174 resulted in a significant loss of activity (ST IC50 of 63 
μM) its binding pose was also evaluated. It was observed that compound 174 
predominantly docked in a different binding mode (Figure 6-52). In this orientation, 
while the phenanthrene ring interacted with Thr66, His67, and Leu68, only the acid and 
the enolic oxygen of the ?-diketo acid motif chelate the two Mg2+ ions. The loss of 
potency may be attributed to a disruption of chelation by an adjacent electron 
withdrawing fluorine substituent. Structurally similar derivative 175 had similar binding 
pose (Figure 6-53) as 174. However, the improved activity of compound 175 might  
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Figure 6-46. RACHEL-based design using compound 149 as lead 
 
 
 
 
 
 
Figure 6-47. Binding interactions of RACHEL derived compound 232 
 
Mg2+ ions are represented by magenta spheres. Active site residues are represented by 
wires. Compound 212 is represented in tubes and shown with grey carbons. Other atoms 
in the ligand are colored as follows: O, red; N, blue; F, bright green. H, white. 
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Figure 6-48. Superimposition of compound 232 over Raltegravir 
 
Mg2+ ions are shown by magenta spheres. Raltegravir is shown in wires and colored by 
element. Compound 232 is shown in tubes and highlighted with green carbons. Other 
atoms in ligands are colored as follows: O, red; N, blue; F, bright green. H, white. 
 
 
 
 
 
 
Figure 6-49. Binding modes of compound 177 in IN active site 
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Figure 6-50. Interactions of compound 177 in one binding mode 
 
Mg2+ ions are represented by purple spheres. Active site residues are represented by tubes 
and colored by element. Compound 177 is represented in tubes and highlighted with 
yellow carbons. Other atoms in the ligand are colored as follows: O, red; Cl, dark green.  
 
 
 
 
 
 
Figure 6-51. Second binding mode of compound 177 
 
Mg2+ ions are represented by purple spheres. Active site residues are represented by tubes 
and colored by element. Compound 177 is represented in tubes and highlighted with 
yellow carbons. Other atoms in the ligand are colored as follows: O, red; Cl, dark green.  
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Figure 6-52. Binding interactions of compound 174 in the IN active site 
 
Mg2+ ions are represented by purple spheres. Active site residues are represented by tubes 
and colored by element. Compound 174 is represented in tubes and highlighted with 
yellow carbons. Other atoms in the ligand are colored as follows: O, red; F, bright green.  
 
 
 
 
 
 
Figure 6-53. Binding interactions of compound 175 in the IN active site 
 
Mg2+ ions are represented by purple spheres. Active site residues are represented by tubes 
and colored by element. Compound 175 is represented in tubes and highlighted with 
yellow carbons. Other atoms in the ligand are colored as follows: O, red; F, bright green. 
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result from favorable hydrophobic contact that the R5 position fluoro makes with the 
alkyl side chains of Leu68. 
 
 
Experimental  
 
 
Docking Simulations 
 
For prediction of bioactive conformation and binding modes of the synthesized 
chalcone and amide compounds; as well as for the QSAR study and the in-silico 
screening, we conducted docking simulations using the GLIDE (v5.7) program from 
Schrödinger Inc. (Portland, Oregon, USA). The protein and preparation wizard of 
Maestro (v9.2) interface in the Schrödinger modeling package was used to prepare the 
protein, applying the OPLS-2005 force-field. Compounds were constructed using the 3D-
sketcher module in Maestro. The carboxylic acid moiety was constructed as a carboxylate 
for docking. The inhibitors were energy minimized using the MacroModel (v9.9) 
molecular mechanics program, and prepared for docking using the LigPrep (v2.5) facility 
in Maestro. Twenty docking poses were obtained for each molecule, the docking being 
terminated if two consecutive solutions were within a rmsd of 5 Å.  
 
 
MM-GBSA Analysis 
 
Computational methods to predict the binding free energy of a ligand to its 
receptor target include rigorous techniques like free energy perturbation (FEP)222 and 
thermodynamic integration (TI)223 methods. These methods are more accurate in 
predicting binding affinities in certain protein-ligand systems than the use of common 
scoring functions, but are computationally intensive and highly time consuming. At the 
next level of approximation, is a semiempirical linear interaction energy (LIE) method. 
Emperical scoring functions used by various docking programs are designed to include 
various approximations in order to determine the binding pose and estimate the binding 
affinities of a large number of molecules in short periods of time. Docking procedures 
treat proteins as rigid, do not consider protein and ligand desolvation, and ignore the 
entropic terms in energy calculations. Although docking algorithms have been highly 
successful in reproducing correct binding poses, the approximate scoring functions often 
fail to rank order compounds on the basis of their binding affinities. Recent advances in 
drug discovery have used a combination of molecular mechanics and continuum 
salvation methods to determine and predict the relative binding free energies with better 
accuracy; these include Molecular Mechanics/Poisson-Boltzmann Surface Area (MM-
PBSA)224 and Molecular Mechanics/Poisson-Generalized Born Surface Area (MM-
GBSA). The MM-GBSA method evaluates binding free energies by minimization and 
MD of the protein-ligand complexes. Equation 6-1, Equation 6-2, and Equation 6-3 
calculates free energy of binding (?Gbind) between a ligand and its receptor as; 
 
 ?Gbind =  ?H ? T?S = ?EMM + ?Gsol ? T?S           (Eq. 6-1) 
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 ?EMM  = ?Einternal + ?Eelectrostatic + ?EvdW (Eq. 6-2) 
 
 ?Gsol = ?GPB/GB + ?GSA (Eq. 6-3) 
 
where ?EMM is the difference between the molecular mechanics energies of protein-
ligand complex and the sum of the molecular mechanics energies of the free ligand and 
the unliganded protein. ?Gsol is the corresponding difference in the solvation energies 
and –T?S is the corresponding differences in conformational entropy upon binding. 
?Einternal, ?Eelectrostatic and ?Evdw are internal (bond length, angle, torsion), electrostatic and 
van der Waals (vdW) energies, respectively. ?GPB/GB and ?GSA are the electrostatic 
(polar) and non electrostatic (nonpolar) solvation energies, respectively.  
 
The docking-derived conformations of 98 compounds, which have common 
binding modes and were used to build 3D-QSAR model 3, were first subjected to energy 
minimization by the local optimization module in the Prime package (v3.0 from 
Schrödinger Inc.) and binding free energies were calculated using the OPLS-2005 force 
field and the GBSA continuum model. All residues were kept frozen in the Prime 
calculations. The entropy penalty upon ligand binding was ignored in estimating the 
binding free energies which is calculated in prime-MM-GBSA using Equation 6-4; 
 
 ?Gbind = ?EMM + ?GGB + ?GSA (Eq. 6-4) 
 
 
3D-QSAR Studies 
 
3D-QSAR methods like comparative molecular field analysis (CoMFA)225 and 
comparative molecular similarity analysis (CoMSIA)226 are widely used to guide the 
synthesis of novel compounds by identifying the physiochemical properties that are 
important for activity, as well as an activity  prediction tool. 3D structure building and 
CoMFA and CoMSIA studies were performed using the SYBYL program (version X1.1) 
on a Dell computer workstation with the Red Hat Linux operating system. All the 
molecules were assigned MOPAC partial atomic charges. The CoMFA descriptors, steric 
(Lennard-Jones 6-12 potential) and electrostatic (Coulombic potential) field energies, 
were calculated using Tripos force field with a distance-dependent dielectric constant, 
using the SYBYL default parameters: 2 Å grid points spacing, an sp3 carbon probe atom 
with +1 charge, vdW radius of 1.52 Å, and energy cut-off of 30 kcal/mol. The five 
similarity indices in CoMSIA, namely, steric, electrostatic, hydrophobic, H-bond donor 
and H-bond acceptor descriptors, were calculated using a C1+ probe atom with a radius of 
1.0 Å placed at regular grid spacing of 2 Å. A Gaussian-type distance dependence was 
used between grid point q and each atom i of the molecule. The default value of 0.3 was 
used as the attenuation factor (R). Column filtering was set to 2.0 kcal/mol. CoMSIA 
steric indices are related to the third power of the atomic radii, electrostatic descriptors 
are derived from atomic partial charges, hydrophobic fields are derived from atom-based 
parameters, and H-bond donor and acceptor indices are based on experimental results 
(SYBYL program). 
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Partial Least Squares Analysis 
 
Partial least square (PLS) regression analysis is widely used to correlate important 
structural features with biological activity, and derives a mathematical relationship 
between dependent and independent variables, particularly when the number of 
descriptors outnumber the number of compounds.227 For the present study, CoMFA and 
CoMSIA descriptors were used as independent variables and ST pIC50 (biological 
activity) values were used as dependent variable. The predictive value of the models was 
evaluated by leave-one-out (LOO) cross-validation. The cross-validated coefficient, q2, 
was calculated using Equation 6-5 
 
 
?
?
(Ypredicted 
_Yactual)
2
(Yactual 
_Ymean)
2
1 _q2 =
 (Eq. 6-5) 
 
where Ypredicted, Yactual, and Ymean are predicted, actual and mean values of the target 
property (pIC50), respectively. ?(Ypredicted – Yactual)2 is the predictive sum of squares 
(PRESS). Conventional correlation coefficient r2 and its standard error, s, were also 
computed for the final PLS models. CoMFA and CoMSIA coefficient maps were 
generated by interpolation of the pair wise products between the PLS coefficients and the 
standard deviations of the corresponding CoMFA or CoMSIA descriptor values. External 
validation of the developed models was performed by determining the predictive r2 of the 
test set compounds using Equation 6-6 
  
 r2 = (SD – PRESS) ? SD (Eq. 6-6) 
 
where SD is the sum of the squared deviations between the biological activity of the 
molecules in the test set and the mean biological activity of the training set. 
 
Linear Interaction Approximation (LIA) Calculations 
 
LIA parameters were also used to develop a QSAR model for the IN inhibitors in 
the dataset. The docked conformations of 98 compounds having similar binding modes 
were separately subjected to binding affinity calculations in the Liaison module (v 5.7) 
from Schrödinger Inc. For the LIA calculations active-site residues surrounding the 
ligand were considered flexible. The LIA method uses a Surface Generalized Born (SGB) 
continuum solvation model to determine the binding free energy as a linear function of 
hydrophobic, electrostatic and cavity energy terms, which are calculated using the 
molecular mechanics force field, using Equation 6-7 
 
?G = ? ( <UbvdW > ? < UfvdW>) + ? (<Ubelec > ? < Ufelec>) 
 + ? (<Ubcav > ? < Ufcav>) (Eq. 6-7) 
 
where < > represents the ensemble average; b means the ligand in the bound form while f 
means the ligand in the free form. ?, ?, and ? are the coefficients. The vdW, electrostatic 
and cavity energy terms are represented by UvdW, Uele, and Ucav.  Energy minimization 
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sampling using a conjugated gradient technique was used for minimization, with an rmsd 
of 0.01 for convergence and a maximum of 1000 steps. 
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CHAPTER 7.   CONCLUSIONS 
 
 
In summary, I have synthesized and evaluated the HIV-1 integrase inhibitory 
activities of a series of chalcones and related amides harboring a 3-keto salicylic acid 
moiety as a ?-diketo acid bioisostere. Consistent with the DKA class of IN inhibitors, 
these series of compounds were also generally selective against the IN strand transfer 
step. Most of the potent compounds of the series also inhibited HIV replication in cell 
culture with moderate antiviral activities, which supports further development of the 
series. Following are the three modifications, I believe could be attempted to improve the 
activities to submicro and nanomolar levels. 
 
(1) The 3-keto salicylic acid ring may be modified in that the 3-keto group could 
be incorporated into a ring system (Figure 7-1) to design bicyclic compounds. As 
discussed in the introduction chapter, one of the key features in the development of 
potent IN inhibitors is the requirement of coplanar chelating moieties. The 3-keto oxygen 
had an angle relative to the core salicylic acid ring. Incorporating it into a ring system 
may make the chelating moieties more coplanar and result in a conformation that may 
chelate more effectively with the two Mg2+ in the IN active site. 
 
(2) All advanced IN inhibitors have a heterocyclic structural core. Future efforts 
could be directed at incorporating a heteroatom, preferentially nitrogen into the ring 
system (Figure 7-2).  
 
(3) Position R1 (see Figure 7-1) could be thoroughly investigated. This is the site 
where the gem-dimethyl oxadiazole carboxamide group of raltegravir and the isopropyl 
hydroxyl substituent in elvitegravir reside. Structure-based design could be used to 
improve the HIV-1 integrase inhibitory activity of this series of compounds. Targeting 
Tyr143 and Pro145 by putting other groups at the R1 position may improve IN inhibitory 
activity. A series of compounds, with amines replacing the bromine at the R1 position, 
have been designed and docked in the IN active site. Docking results (Figure 7-3) 
revealed that the amino substituents are positioned into a new region making contacts 
with Arg263 and Lys264. These amino acids appear to interact with viral DNA and could 
be targeted to explore their effect on IN inhibition. 
 
I have also synthesized electronegative groups containing phenanthrene ?-diketo 
acids as HIV-1 integrase inhibitors. Docking studies suggest that the compounds have 
different binding modes than raltegravir and, do not significantly interact with residues 
involved in viral resistance (Asn 155, Gln 148). Thus, this series of compounds could be 
investigated to circumvent viral resistance associated with current clinically used 
integrase inhibitors. However, efforts are needed to prevent their cellular toxicities and to 
improve their anti-viral activities. The phenanthrene could be modified to a structurally 
related stilbenes that may prevent their intercalation with DNA and thus, may reduce 
their toxicities. Docking studies have also revealed that the cavity occupied by the 
halobenzyl group in raltegravir and elvitegravir is vacant (see Figure 6-46). Further 
optimization could be attempted to append a halo benzyl moiety that could occupy the  
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Figure 7-1. Optimization of 3-keto salicylic acid to a related bicyclic compound 
 
 
 
 
 
 
Figure 7-2. Optimization of 3-keto salicylic acid to a 4-carboxamide-3-hydroxy 
picolinic acid 
 
 
 
 
 
 
Figure 7-3. Design of new 3-carboxamide salicylic acid IN inhibitors 
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vacant cavity. 
 
In computational studies, I have explored the binding modes of potent HIV IN 
inhibitors by docking and 3D-QSAR studies using a homology model of HIV IN-DNA 
complex. The binding mode of raltegravir and elvitegravir are in accordance with the 
foamy virus structure revealing interactions important for inhibitor-IN binding. The para-
fluorobenzyl group in raltegravir and the halogen-substituted benzyl ring of elvitegravir 
insert into the cavity formed by displacement of the 3?-end of the viral DNA and engage 
in strong electrostatic and vdW interactions with the DNA-IN interface. The metal-
chelating pharmacophore of raltegravir and elvitegravir interacted with the two metal 
ions (Mg2+) in the IN active site. The models showed the binding contributions of the 
gem-dimethyloxadiazole carboxamide moiety in raltegravir and the N-alkyl hydroxyl side 
chain in elvitegravir and identified Tyr143 as key residues interacting with IN inhibitors. 
 
To improve our knowledge of the stereoelectronic, hydrophobicity and hydrogen 
bonding requirements for IN inhibition, extensive 3D-QSAR studies were conducted 
using both the PHASE derived ligand-based and the homology model-guided structure-
based molecular alignments. Homology model guided composite 3D-QSAR study, 
performed by combining four different classes of IN inhibitors, yielded significantly 
improved statistical results than the ligand-based 3D-QSAR study; which was conducted 
on synthesized chalcone and amide derivatives. Thus, integration of different scaffolds 
proved advantageous in arriving at a single 3D-QSAR model capable of accommodating 
diverse IN inhibitors without any bias for a particular functionality. The QSAR model 
developed using the docking-based and MM-GBSA validated alignments performed the 
best.  Both CoMFA and CoMSIA of the docking-based model showed good predictive 
ability when evaluated on prospectively synthesized compounds. The CoMFA of 
docking-based model 3 has performed the best, and could be further developed by 
incorporating more of the synthesized amide derivatives in the training set and then 
predicting novel related IN inhibitors. 
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